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ABSTRACT

Acceptability of a Vaginal Ring to Prevent HIV and Pregnancy:
Integrating Multiple Qualitative Methods
by
Dana Watnick, MPH, MSSW

Advisor: Diana Romero, PhD, MA

Heterosexual vaginal sex can simultaneously put women at risk for unintended pregnancy
and sexually transmitted infections, such as HIV, disproportionately impacting poor women
around the world. Both unintended pregnancy and HIV are persistent public health concerns
associated with negative outcomes for mothers, families and communities. The current mix of
prevention tools available to women to protect against unintended pregnancy and HIV is
limited. Multipurpose Prevention Technologies (MPTs) are innovative products that
simultaneously offer protection against pregnancy and HIV. However, MPTs will only be
effective in reducing unintended pregnancy and incident HIV if women are willing to use
them. With an understanding that product use relies on some level of product acceptability,
I designed my dissertation study to produce a conceptual model of women’s acceptability
of an MPT intravaginal ring (IVR).
Toward this end, I used grounded theory methodology and multiple qualitative methods
(in-depth interviews, focus group discussions and card sort data) with 18-45 year old women in
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the US, in the context of a Phase 1 trial of an antiretroviral IVR, to explore acceptability of an
MPT in vaginal ring form. Concurrent to the conceptual analysis necessary for model
development, I conducted a methodological assessment of the three forms of data to increase
overall validity and complexity of findings in the new model. I integrated conceptual findings
generated from the interviews, card sorts and focus groups with insights generated from
evaluation of features inherent to each method.
The emergent model “Dynamic Considerations for Acceptability and Likely Use of an
MPT Ring” identified a narrative of acceptability and use that includes three main constructs.
The first construct related to product acceptability was “Episodic Factors”, which includes MPT
product, use, and sexual encounter attributes that women consider per life episode (e.g. a sexual
encounter). A second construct is “The Priority Triad”, which is a core process within the model
that drives both women’s acceptability and commitment to use an IVR MPT. This triad describes
how women (re)prioritize, (re)shift and (re)balance their acceptability of an IVR MPT based on
the dynamic needs of relationships, partners and the self. A third construct describes the
“Rationale for Need” of an MPT, based on women’s perceived risk of HIV and/or fertility
desires. Women who determine there is no rationale for needing an MPT will be unlikely to use
one, regardless of triadic priorities or episodic considerations. The conceptual components of this
newly developed model were generally comparable across all three data collection methods, and
data triangulation efforts demonstrated strong complementary results.
The new model elucidates the complexity of women’s acceptability and expected use of a
vaginal ring for simultaneous prevention of HIV and pregnancy. The integration of multiple
qualitative methods adds validity, depth and further insight into this model. Results from this
study can inform clinicians and clinical guidelines for improving decision-making about
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prevention methods that is woman-centered but also partner- and relationship-aware. Product
developers should not develop a ‘best’ product, but rather a suite of MPTs that can fit a woman’s
needs at different moments in her life. New MPT study designs should consider involvement of
both partners; assessment of use during menstruation and sex; and should include women in
different types of relationships, with varied perceptions of HIV risk and fertility desires. Study
designs that incorporate multiple or mixed methods should embrace the inherent benefits of the
respective data collection methods for deeper contextualization and meaning-making of
conceptual findings. Future research efforts should test, augment and clarify this new model
conceptually, as more MPTs are developed and evaluated and in different populations.
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SECTION 1: BACKGROUND AND SIGNIFICANCE
Introduction
Unprotected heterosexual intercourse simultaneously puts women at risk for unintended
pregnancyi and HIV, disproportionately impacting poor women around the world. Multipurpose
Prevention Technologies (MPTs) are products that can be used to simultaneously prevent HIV
and pregnancyii and are in early stages of biomedical development, a process that typically
neglects user perspectives on product acceptability. This qualitative dissertation is one of the first
studies to include women’s perspectives concurrent to vaginal ring use during the course of a
clinical trial.
Although many multi-level factors contribute to contraceptive and microbicide
acceptability, to date there is no conceptual framework that incorporates individual, relationship
and social level factors. This dissertation research therefore addresses a critical gap in
understanding the multi-level factors that influence women’s acceptability and likely use of
vaginal ring MPTs. Further, this dissertation systematically identifies the way in which we know
what we know through a methodological assessment of data collection methods, which will
allow us to identify useful methodological approaches for future research on product
acceptability.

‘Unintended pregnancy’ is typically a composite measure of mistimed or unwanted births,
induced abortions, and miscarriages from unintended pregnancies.1 Further discussion of this
measure can be found in this dissertation in Section 1: “Women and Unintended pregnancy”.
ii
Multipurpose prevention technologies (MPTs) are designed to prevent two or more sexual and
reproductive health (SRH) issues at once; for example, preventing Herpes and HIV, or
pregnancy and HIV. For the purposes of my research, however, I limited the focus to MPTs that
are designed to explicitly prevent HIV and pregnancy, although other SRH issues, though not
targeted, may be concurrently prevented as well.360
i

1

The dissertation is organized into 4 sections. Section 1 provides the rationale for this
study, including relevant literature, along with background information about the study. Section
2 describes the study design and introduces the methodological approaches to data production
and analysis and introduces the ways in which grounded theory methodology informed the study
overall. Section 3 first provides an overview of the substantive grounded theory developed from
the data; then describes each component of the theory in-depth; and, finally, explores how
specific features of each data collection method added to the overall understanding of
acceptability and likely use of a vaginal ring MPT. Section 4 contextualizes the contribution of
this research in relation to other knowledge informing the development of acceptable
HIV/pregnancy prevention products for women and presents conclusions and implications for
product development as well as the research process. A discussion of Study Limitations is also
included as well as steps taken to minimize potential negative effects on study validity and
overall findings.
Sexual and reproductive health prevention needs of women

Over the sexual and reproductive life course, women are faced with many challenges
associated with pregnancy prevention and prevention of sexually transmitted infections,
including

HIV.

The

bodies

of

literature

regarding

these

prevention

methods

(contraception/family planning and HIV prophylaxes) are vast, yet insufficient attention has been
paid to the overlapping imperatives of these two needs. For those women with intersecting risk
for pregnancy and HIV infection, the availability of MPTs adds an important option to their
contraception and disease prevention method mix that is crucial for supporting overall sexual and
reproductive health.
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During this early stage in MPT development efforts, it is important to identify subpopulations of women at greatest risk for HIV or unintended pregnancy for whom the impact of
multipurpose prevention might be greatest. Although interest in MPT development has been
growing substantially over the past decade, financial resources have been limited, making it
especially important to identify sub-populations who would benefit most from an MPT.
However, identifying these sub-populations is difficult as surveillance data are not typically
aggregated by overlapping risk for HIV and unintended pregnancy. Therefore, in the following
review of the literature, I identify sub-populations that can be reasonably projected to be at
highest need for an MPT based on risk for HIV and risk for unintended pregnancy separately and
together. Within these sub-populations of women at risk, I call attention to specific demographic
factors such as geographic region and age, as well as individual and couple-level characteristics
such as occupation and relationship status.
Women and unintended pregnancy
Worldwide, 40% of pregnancies are ‘unintended’, defined as mistimed or unwanted
births, induced abortions, and miscarriages from unintended pregnancies.1 Women in
heterosexual relationships who use traditional contraceptive methods (defined as rhythm method
or withdrawal) or no method at all have a higher likelihood of unintended pregnancy than
women who use a modern method of contraception (such as barrier methods, pills or devices).2
Unintended pregnancy is a persistent public health concern associated with negative outcomes
for mothers, families, and children including unsafe abortion, increased maternal substance abuse
and depression, relationship instability between parents, inadequate prenatal care, and increased
infant morbidity and mortality in children who were unintended.3–10 Sequelae from the 85
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million unintended pregnancies in 2012 included 42 million abortions, many of which are unsafe
in the developing world , 11 million miscarriages, and 32 million unwanted or mistimed births.1
The direct causal association between unintended pregnancy and these negative outcomes
is difficult to tease apart, as maternal social and economic disadvantage is correlated with both
pregnancy intendedness and poor health.7,11 Further, unintended pregnancy is itself a
complicated construct to measure, as it does not capture the complexities involved with the
phenomenon of getting pregnant, which may not always fit with a cognitive intentionality,12–14
and it presents difficulties in collecting valid retrospective data.13,15–18 Thus, global family
planning interventionists frequently use a proxy indicator to identify those at greatest risk for
poor pregnancy outcomes, called ‘unmet need for modern contraception’ (UNMC).1,19,20 This
metric captures women (15-49 yrs) who are sexually active, capable of pregnancy, and say they
want to stop or delay childbearing for two or more years, but nevertheless are not using any form
of modern contraception.21 Women who are classified as having an UNMC make up a large
share of those experiencing unintended pregnancies, accounting for 79% of all unintended
pregnancies.22,23
Unintended pregnancy rates and UNMC are not uniform for all sub-groups of women,
however, with large disparities existing across region, age, and relationship status. The global
unintended pregnancy rate in 2012 was 53 per 1000 women with higher rates in developing (54
per 1000 women) vs. developed regions (44 per 1000 women).1 Further, proportions of total
pregnancies that were unintended vary dramatically by region, with the highest in the Caribbean
(64%), South America (62%) and Southern Africa (55%), and the lowest in Western Africa
(26%), Northern Africa (29%), and Western Europe (34%).1 In 2010, UNMC among married or
cohabiting women was lowest in the North America region (under 10%) and highest in North
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Africa (approximately 15%) and sub-Saharan Africa (over 25%) with Asia, Europe, Latin
America & the Caribbean and North America around 10%.20 It is important to note that low
rates of unintended pregnancy (and associated low UNMC) do not necessarily equate to high
rates of contraceptive use or prevalence, evidenced by high overall fertility in North and West
Africa where large family size is desired and low overall fertility in Western Europe where
family size is small.
In a 2016 analysis, scientists from The Guttmacher Institute evaluated UNMC in
developing countries, using demographic and health surveys data.24 In general, women with less
education, experiencing deeper levels of poverty, and those living in rural areas had higher rates
of UNMC than their counterparts with more education, relatively less poverty, and urban living
environs.

24

Although the United States is a high income country, we see similar patterns of

unintended pregnancy being disproportionately higher among Black and Latina women and girls
who have overall lower socioeconomic status than white women and girls.25
Reasons for contraceptive non-use in those with UNMC include side effect concerns and
long-term health impact; perception of not being at-risk for pregnancy because of not having
experienced a pregnancy in the past thus assuming infertility;26 low frequency of sex;
amenorrhea due to breastfeeding, or being post-partum; and conceptual disapproval of family
planning.27 Although these themes appear frequently for women across the globe, there are
important variations. For example, 46% of all married women cite sexual inactivity because their
husband ‘was away or staying elsewhere’ as a reason for contraceptive non-use. If we examine
differences by country—e.g., Tanzania (16%) vs. Haiti (79%)—women’s sexual inactivity may
reflect larger demographic factors such as male migration for work.24
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Another example of differences in contraceptive non-use exists by age. Younger women
cite being ‘not married’ almost three times as often as older women, possibly indicating sporadic
relationships or the stigma that would come with admitting to sexual activity outside marriage. In
the United States, married women had the lowest rate of unintended pregnancy in 2011
compared to cohabiting women who had more than four times that rate (141/1000 vs. 29/1000
women and girls, 15-44 years old).25
Unintended pregnancy among adolescent girls (typically defined as 15-19 years old) is of
special concern because of the high risks associated with pregnancy, clandestine and unsafe
abortion, and childbirth in girls and young women.28–30 Adolescent pregnancies ae projected to
increase by 1.5-1.8 million per year in Eastern, Western, Central, and Southern Africa over the
next decade, where currently one-third of adolescent pregnancies are unintended.31,32 About half
of adolescent pregnancies (in women 15-19 years old) are unintended in developing countries,
and half of those are estimated to end in unsafe abortions.33 There are approximately 38 million
adolescent girls in developing countries who are sexually active, and 23 million of them have a
UNMC putting them at risk for unintended pregnancies, unsafe abortions, and increased
morbidity and mortality associated with adolescent pregnancy.33 Lack of knowledge and access
to contraception, increased intimate partner violence and lack of control over contraceptive use
and timing of first birth (married girls are often expected to reproduce soon after marriage) are
all reasons why adolescent girls are especially vulnerable to increased fertility and unintended
pregnancy compared to older women.23,24
Women and HIV
HIV

transmission

during

heterosexual

sex

persists

as

a

global

problem,

disproportionately affecting poor, young women. UNAIDS estimates 2.1 million individuals

6

acquired HIV in 2015 and, in sub-Saharan Africa, incidence is more than twice as high for young
women than young men (15-24).34,35 Prevalence of HIV infection in women has remained
stable, at approximately half of all cases globally. However, when these data are disaggregated
by region it is clear that there is a disproportionate HIV burden on women living in regions with
high community viral loads, especially sub-Saharan Africa and the Caribbean, where 58% and
61% of HIV cases, respectively, are among women.36 Other sub-groups of women at relatively
higher risk for HIV include sex workers,37 young women,38–40

and women in HIV sero-

discordant relationships.41 In the United States, HIV incidence among women was small (19% in
2014) compared to men, yet 87% of those infections were attributable to heterosexual sex.42
Compared to men and boys in heterosexual relationships, women and girls are at
increased risk overall for HIV. It is well-established that HIV is transmitted more easily from a
man to a woman than the reverse during condomless vaginal sex because of increased HIV
susceptibility in the cervicovaginal area compared to the penis.43 However, physiological
differences are merely one component of a much larger framework involving extensive
sociopolitical and gender-based inequality between women and men. Social and cultural norms
around masculinity, femininity, and sexuality and power dynamics between men and women
often limit women’s ability to access healthcare, education, and employment, or to negotiate
condom or microbicide use with male partners.44,45
The intersection of gender, power, and poverty creates a system in which many women
are at disproportionately increased risk for HIV. For example, male-to-female intimate partner
violence is one manifestation of gender inequality that is indicative of increased HIV infection in
women, with violent male partners more likely to have multiple partners than men who are not
violent toward their partners.46,47 A lack of prioritizing education for girls and women may also
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increase HIV risk. In a review of school dropout internationally, many households had genderbased preferences to educate boys instead of girls in resource-constrained contexts resulting in
increased school dropout for girls.48 One study found that, compared to women with at least 6
years of schooling, under-educated women are doubly likely to acquire HIV.46
For poor women, maintaining financial security for themselves and their children often
means that women are beholden to their male partners’ wishes, including sexual activity, that
puts them at increased HIV risk including sex without a condom or partaking in intravaginal
practices such as ‘dry sex’ which creates increased HIV vulnerability through increased vaginal
abrasions.44,49 Regional increases in poverty have forced both men and women into migrant labor
increasing women’s HIV risk in two ways: male migrants who travel to cities with
disproportionate HIV prevalence have a greatly increased likelihood of bringing infection home
to their female partners, and female migrant workers are often greatly limited in their labor
options, and therefore often end up doing high-risk sex work to feed their families and
contracting HIV themselves.50–52
Young women and girls (typically 15-24 yrs old 34) are a sub-group of particular concern
because they are vulnerable to all of the above risks for HIV at a younger age, meaning a lifetime
of disease management and potential transmission to others. Young women account for 20% of
all new HIV infections globally, despite making up only 11% of the adult population and are
mainly acquiring HIV from heterosexual sex.34 In 2013 nearly 60% of incident cases of HIV
among 15-24 year olds occurred in girls and young women. Of all the 15-24 year old girls and
women living with HIV globally, 80% of them live in sub-Saharan Africa where 450,000 new
infections occurred in this age and gender group in 2015.53,54
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Young women face particular risks due to physiology as well as social factors. Biological
researchers are investigating whether girls’ potential for increased susceptibility to HIV is due to
increased likelihood of mucosal injury in the immature female genital tract potentially as a result
of sexual violence.55 In recent studies of young South African women in 2015 and 2016,
scientists have also discovered the effects of vaginal bacteria that can protect or disrupt the
protective properties in the vaginal microbiome as well as bacteria that nullify or “gobble up” the
microbicide tenofovir in young women.56,57 In addition to young women’s increased
physiological susceptibility to HIV infection, the interaction with gender inequalities such as
vulnerability to rape and having an older partner further increase their risk.38,39
HIV infections vary by relationship status and region. For example, South African
married partners have lower rates of infection than unpartnered individuals, or women in new or
non-marital relationships. Yet, in Kenya, girls in early marriages (ages 14-19) have higher HIV
risk than girls in out-of-marriage relationships.58,59 More research is needed to understand the
different risk levels relationship status may confer in regions with different background HIV
prevalence, and norms related to age at marriage. One review explained the compelling forces
driving poor, young girls to transactional sex with older partners as payment for basic needs,
increased social status, and confirmation of a partner’s love and commitment.60 Regardless of the
underlying causes, however, tracking the effect of relationship status on HIV risk is critical to
understanding HIV prophylaxis in women across sub-groups, and for understanding the
markedly increased risk that young women face.
In a 50-country systematic review of the literature, female sex workers were found to
have 13.5 times the prevalence of HIV than the general population of women 15-49 yrs, and
prevalence estimates from 2013 demonstrate that 11.8% of sex workers were HIV positive
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globally.37 HIV prevalence in sex workers varies regionally; the highest pooled prevalence is in
sub-Saharan Africa estimated at 36.9% compared to 1.7% in the Middle East and North Africa.
Despite this extraordinarily high prevalence of HIV in sex workers, and risk of transmission,
HIV preventive services reach less than 50% of this target population.37 Although sex workers
are one of the highest prevalence sub-groups impacted by HIV, they are also one of the most
likely to respond to HIV prevention programs given their motivation to preserve their health and
ability to maintain a living.61 In some cases, sex workers are prohibited or dissuaded from using
condoms for financial benefit and face violence if they refuse.62 However, a female-controlled
prophylactic device that does not require negotiation with a male client (such as a vaginal ring)
could be one way for sex workers to protect themselves, their partners and their clients.
HIV-negative women in a serodiscordant relationship have increased risk of HIV via
sexual transmission from their partner. A ‘heterosexual serodiscordant’ couple is typically
defined as a couple that is married, co-habiting, co-parenting or in a longer-term relationship
length (>3-6 months) wherein one partner is HIV negative and the other is HIV positive.63
Serodiscordance in heterosexual couples can translate into substantial reproduction of disease
and disease burden within a population. For example, estimates from high prevalence settings
show that approximately half of HIV positive people have an HIV negative partner, and in low
prevalence settings up to 75% of HIV positive people are in a serodiscordant relationship. A
2013 study that mathematically modeled HIV infection rates among serodiscordant couples in
sub-Saharan Africa found that 29% (ranging from 10-52%) of new infections would occur
among serodiscordant couples.41 In these relationships, recommendations include antiretroviral
medication (ARVs) for the HIV positive partner to reduce viral load, as undetected viral load
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prevents transmission, and PrEP for the HIV negative partner (where available) to prevent
infection.64,65
The belief that monogamy can reduce HIV risk does not hold true in serodiscordant
relationships, whether status is known or unknown. Rather, for women, the likelihood of
infection increases the longer an HIV negative woman remains in a sexual relationship with her
positive male partner. One study that modeled HIV transmission among serodiscordant couples
demonstrated that over one year, women’s risk of contracting HIV (from a male partner living
with HIV) ranged from 0.05% to 20%, but over the course of 10 years women’s risk increased,
ranging from 0.5% to 89%.66
Consistent use of

PrEP or a condom, with or without the male partner’s use of

antiretroviral medication, decreases a woman’s risk of acquiring HIV to 2% or less at the oneyear mark.66 In a 2016 study in South Africa, however, it was found that incidence of HIV
infection was lower in serodiscordant married couples where spouses cohabited than in other
serodiscordant marriages or in unmarried cohabiting serodiscordant couples (which had the
highest incidence). Thus, the type of relationship also matters for likelihood of transmission
within serodiscordant couples.67,68 The difference in infection for these different relationship
types may reveal important vulnerabilities to HIV risk such as lower level of commitment or
concurrent partnerships.68 The label ‘serodiscordant’ necessitates that the status of both partners
is known and shared. However, there is likely a large number of couples for whom the HIV+
partner’s status is unknown or undisclosed, and therefore those couples are not classified as
serodiscordant and thus cannot be targeted for intervention. The risk of disease transmission may
be underestimated for this subpopulation because the size of this group itself is likely
underestimated.

11

Women at the intersection of risk for HIV and Unintended Pregnancy
There are many countries in which rates of HIV, unmet need for contraception and
unintended pregnancies are similarly high. In a 2016 mapping study of countries with
overlapping high rates of UNMC and HIV, Schelar et al. used three different analytic techniques
(principle component analysis, additive prevalence, and graphical overlap) to determine the
composite burden of HIV and UNMC in countries or regions around the world, to demonstrate
places where MPTs could have the greatest impact21 (Appendix A). Their triangulated analyses
used multiple sources of country-level demographic data and showed that countries within subSaharan Africa exhibited the highest prevalence of composite burden of HIV and UNMC.
Unsurprisingly, many of the countries with relatively higher levels of gender-based inequality
and poverty were among the countries with high composite levels of HIV and UNMC (e.g.,
Albania, Kenya, Tanzania, Zambia) of HIV and UNMC.
Although women can be at risk for HIV and unintended pregnancy from an unprotected
sex act, there is also the potential that pregnancy risk and/or HIV risk can increase because of an
interactive effect between the two risk factors.69 A handful of researchers have demonstrated a
risk association between pregnancy and HIV acquisition, where HIV infection doubled70 or
tripled71 during pregnancy, and demonstrated a four-fold increase in HIV incidence among
pregnant vs. non-pregnant women.72 These increases in risk have been attributed both to
physiological changes occurring during pregnancy putting a woman’s body at increased risk of
disease acquisition as well as behavioral changes including partner infidelity and HIVunprotected sex.70,73 Babies are also greatly impacted by the intersection of HIV and unintended
pregnancy in mothers. In one South African study (n= 10,178), babies who were exposed to HIV
in-utero were more likely to have been unintended than babies of HIV negative mothers; among
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babies exposed in-utero to HIV, 61% were unintended as compared with 39% who were not
exposed to HIV in-utero.74
Epidemiologically, we are able to identify sub-populations of women at increased risk for
HIV and unintended pregnancy. However, this does not always translate into perceived risk for
either of these outcomes. Although many studies document an association between low
perceived risk (despite actual risk) for pregnancy and contraceptive use,75–77 little is yet known
about how HIV risk perception impacts uptake of preventive devices like PrEP, microbicides or
MPTs.
MPTs for Dual Prevention of HIV and unintended pregnancy
The emergence of MPTs to bridge historical silos of family planning and STI/HIV prevention
The emerging field of MPT research and development has built upon two historically
siloed fields of health services and research mainly in Low and middle income countries, but also
in high income countries: 1) Family planning (FP)/reproductive health, and 2) HIV
treatment/prevention.78–82 Despite calls made by international health bodies for bidirectional
integration (HIV into FP and FP into HIV), this goal has faced many challenges at multiple
levels.80,83–85 Some of the main challenges have included funding shifts like restrictions on US
family planning services and increases in international HIV aid; service delivery problems
related to provider training and keeping supplies stocked at ‘brick and mortar’ clinics; and
patient fear of stigma for accessing contraceptive or HIV services.80,86
As researchers, organizations and government bodies persist in trying to meet integration
goals, one concrete approach to deconstructing the silos is the development of an integrated
product that can simultaneously prevent HIV and pregnancy. In 2009 an international
collaborative, the Initiative for Multipurpose Prevention Technologies (IMPT), was launched to
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bring together autonomous disciplines of HIV/STIs and contraceptive research to collaborate and
advance the science around biomedical MPT research and development.87 The IMPT is a
“product-neutral collaboration” of members (researchers, product developers, funders,
policymakers and advocates) from multiple disciplines who work together toward development
of impactful MPTs. This unique approach to product development is responsive to the historical
divisions between disciplines and market competitors, among others.

87

The IMPT also

recognizes that the success of new MPTs will rely on a deep understanding of the lessons learned
from the currently available MPTs.
Lessons learned from currently available MPTs: male and female condoms
Currently, the only two MPTs available to guard against pregnancy and HIV
simultaneously are male and female condoms. Most of the behavioral research around both types
of condoms has examined attributes of one condom type or the other, although some studies have
actually compared acceptability of male vs. female condoms, generally finding greater overall
acceptability and use of male condoms among both men and women.

88–90

Male condoms have

had a longer history of use globally, having been marketed first as a contraceptive device and
more recently to stop the spread of STIs/HIV, as more effective methods of contraception have
been developed and the threat and severity of STIs/HIV have become more pressing. With
perfect use, male condoms have a high rate of efficacy for pregnancy prevention, with only a 2%
failure rate.91,92 A recent estimate taken by global modeling analysis demonstrated that condoms
have averted approximately 50 million HIV infections since the epidemic began.93
Female condoms emerged more recently in the 1980s as a ‘female-initiated’ option for
contraception and STI/HIV prevention. Female condoms have a slightly higher pregnancy failure
rate than male condoms with perfect use (5% vs. 2%), or typical use (21% vs. 14%) and have an
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STI failure rate of 3-6% with correct and consistent use.92,94,95 Studies of women in stable
relationships showed that female condoms were somewhat acceptable to both female and male
partners, with acceptability increasing with continued use, and product failure decreasing over
time.90,96 Women report feeling safer and more capable of protecting themselves, having better
lubrication and even heightened sexual pleasure from the outer female condom ring when
compared to the male condom.97–99 However, significant drawbacks to female condoms have
been highlighted including difficulty with insertion, foreign sensation, messiness, and noisiness
(with the original FC1);90,97 thus, initial bad impressions of its use as an MPT have dissuaded
further product use.94,96 Price is often cited as a barrier to female condom accessibility and
uptake (the unit cost is higher than male condoms; in 2008 the UNFPA was paying 29 times the
price for a female condom than male condom for country-wide distribution),94 making female
condoms more difficult to access than male condoms, especially for poor women. The cost
differential, however, has been cited as a function of initial price monopoly and supply failure
rather than a true failure of user demand based on acceptability.94
Despite the potential effectiveness of both male and female condoms to prevent
pregnancy and HIV, most people do not or cannot always use either type correctly or
consistently.100,101 There are multiple reasons cited for incorrect or inconsistent use including a
variety of individual-level factors such as low risk-perception, interrupting the momentum of sex
and decreased sensitivity.

102,103

Couple-level factors include expectations of monogamy

precluding need for a condom for disease prevention, concerns over partner trust, relationship
saliency and positive fertility desires.104 Provider-level factors have been cited such as lack of
training, lack of available pelvic demonstration models, or providers’ own discomfort with
sexuality. 105,106 Social or community-level factors include stigmatization of sexual behavior and
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STIs, gendered power dynamics that dictate men to carry and approve of use of condoms and
women to comply.

107–109

Finally, problems with low government-level prioritization, under-

investment in research and development of the female condom, supply chains and distribution
have been cited as reasons for low uptake.94,105 Lessons learned about acceptability and use from
current barrier-method MPTs thus include a variety of factors at multiple levels of potential
intervention.
MPT product development: lessons learned from contraceptives and PrEP
Although male and female condoms have benefits of lower cost, lack of side effects and
availability, (among others), they also have a host of issues that make them undesirable for
women and men, especially in the context of a committed or long-term relationship. Thus,
developers of new MPTs are aiming to address some of the problems associated with condom
use in order to make the next generation of MPTs more acceptable to potential users. The
approach to this work requires integration of lessons learned from both previous contraceptive
research and the relatively new knowledge around adherence and acceptability learned from
microbicide and other PrEP trials.110 Because the only MPTs currently available to the public are
barrier methods (male and female condoms), evaluation of user preferences for drug-based
MPTs in a real world setting is not yet possible.111 To proxy for this gap in product availability, I
will present information from three separate literatures that can contribute to our understanding
of MPT acceptability: 1) contraceptives; 2) Pre-Exposure Prophylaxis (PrEP)/microbicides and
trials; and 3) hypothetical MPTs and MPTs in early development stages.
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Lessons from contraceptives
Contraceptive methods to control fertility in women include birth control pills; patches;
vaginal rings; long-acting injectables; cervical caps; diaphragms; IUDs; implants; emergency
contraception; spermicides; and male and female condoms (also MPTs). It has been shown
through an analysis of data from 80 countries, that improving access to a wide range of
contraceptive options is associated with higher rates of contraceptive use.112 Some of these
existing forms of contraceptive devices are also being considered for use as microbicide and
MPT delivery systems, thus only those forms will be discussed here further: a pill, vaginal gels,
vaginal rings and diaphragms. The oral contraceptive pill has been available in the US since it
was FDA-approved in 1960, and since then approximately 82% of US women have reported
using it at some point during their reproductive lives.113 Although the pill has a possible
effectiveness of over 99%, the typical failure rate is 8%91, which is attributed to adherence issues
such as forgetting or having logistical barriers to taking a daily pill (e.g. refilling prescriptions on
time) and decreased acceptability from hormonal side effects such as weight gain, headaches,
change in mood and decreased libido.114
In a study to understand a spermicide in gel vs. vaginal film form of contraception,
women liked the ease of gel use but disliked the messiness. In response, women would use less
product to decrease messiness, decreasing product efficacy.

115

The film was much harder to

insert and caused dryness. Across different sites, however, the ‘wet’ or ‘dry’ attribute was
preferred differently as related to regional cultural norms about preferences for wet or dry sex,
which has been seen in other contexts testing microbicide products.115,116
Contraceptive research with vaginal rings demonstrated that overall, rings have been
acceptable to most users, especially the monthly ring which is controlled by the woman,
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providing hormonal drug for three weeks of wear and one week out for withdrawal bleeding,
which many women like because users are reassured they are not pregnant.117,118 Although there
are higher than expected ring removals partly due to hormonal side effects, other reasons such as
discomfort with vaginal touching, expulsions during toileting, and objections to a partner feeling
the ring during sex have been attributed to non-acceptability of the device itself.117
Diaphragms with spermicidal jelly are used as contraceptive barrier methods, and are
available in a provider-fitted style as well as a single-size option. Diaphragms are less effective
at pregnancy prevention than condoms, with a failure rate of 6% with perfect use but a similar
failure rate as condoms with typical use of approximately 20%.95 In one study comparing the
fitted and single-size diaphragm failure rates were found to be similar at approximately 11% for
both.119 One large qualitative study of women in seven countries showed a broad range of
acceptability of the diaphragm varying across regions, cultures, socioeconomic status and
relationship status.120 American women, who had the most experience with diaphragms, had
different levels of acceptability based on suburban vs inner-city profiles: suburban women
appreciated using a non-hormonal contraceptive device, yet disliked the messiness vs. inner-city
women disapproved of touching themselves for insertion and were worried about inconvenient
clinic visits for fittings. Cambodian, Peruvian, Mexican and Pakistani women were unfamiliar
with diaphragms but expressed hypothetical concerns including cost, dirtiness associated with reuse, lack of time to plan for insertion and lack of privacy for insertion in shared sleeping
quarters. 120
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Lessons from PrEP/microbicide clinical trials:
As of 2016, the one method of PrEP that has been approved for use by the US FDA is
oral Truvada (a combination of tenofovir disoproxil fumarate (TDF)+ emtricitabine (FTC)).121
Although Truvada has been approved for use as PrEP since 2012, many women have been
reluctant to take it prophylactically, so there are little data of female PrEP use. 122 In contrast to
the way we can understand contraceptive acceptability in real-world users, we can only study
issues around acceptability and uptake of PrEP more generally, by examining participant
experiences in the large clinical trials that evaluate(d) safety, pharmacokinetics, efficacy,
acceptability

and adherence of microbicide-based drugs and other forms of PrEP in

development.
Trials of both oral Truvada and oral TDF have demonstrated reduction of relative risk of
acquiring HIV ranging from 44-86% with high-risk populations, with questions remaining about
the impact of low adherence on risk reduction. These include the iPrEx, IPERGAY and PROUD
studies with men (and transgender women) who have sex with men;123–125 the Partner’s PrEP
study with serodiscordant couples;126 the TDF2 trial with heterosexual men and women in high
prevalence regions;127 and, the Bangkok Study with injecting drug users.128 However, two
additional efficacy trials of oral Truvada (FemPrEP129 and VOICE130) with heterosexual women
failed to show efficacy of oral dosing due to widespread product non-adherence and
subsequently ended prematurely. One study with heterosexual women (CAPRISA-004131)
demonstrated efficacy with an overall 39% HIV risk reduction and by 54% in women who used
it consistently. It involved pericoital use of tenofovir-based intravaginal gel applied within 12
hours before and 12 hours after sex (with no more than 2 doses in 24 hours). However, a
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subsequent study (FACTS 001 trial)132 utilizing 1% tenofovir vaginal gel found no such efficacy
with daily130 or pericoital gel use, also citing product adherence as a barrier to efficacy.
Reasons for non-adherence in the three failed trials (FemPrEP, VOICE and FACTS) were
complex and are important to understand if the microbicide and MPT fields are to advance.
Compared to trials with MSM or serodiscordant couples where HIV risk is understood and
acknowledged more openly, heterosexual women in these 3 failed trials had a lower perception
of risk. For example, in the Partners PrEP study, HIV negative partners had nearly 100%
adherence, citing that taking the study product decreased their anxiety about contracting HIV,
compared to 70% of women in FemPrEP reporting they were at low risk for contracting HIV.133–
135

Risk perception was measured among all women in FemPrEP, four weeks prior to testing.

Among women who seroconverted during FemPrEP, when asked about risk perception four
weeks before HIV diagnosis, they justified their low risk perception as related to prior noninfection, trusting their partner not to infect them and sometimes an inability to protect
themselves despite perceived risk.136
In addition to risk perception, there have been significant barriers to user acceptability
and product adherence in oral and vaginal gel PrEP trials. Investigational gels have been noted
for their messiness, leaking137 and dosing schedules that require a high level of planning that is
incongruous with sexual activity in most couples.138 (It bears noting that gels have also been
discussed positively as providing lubrication during sex.139) In a qualitative sub-study to evaluate
non-adherence in the VOICE trial of daily oral pills and vaginal gel, African women associated
taking the daily ARV with stigmatized treatment instead of prevention for HIV.140 Because of
this women were secretive about taking their daily pill or using a vaginal gel, often hiding it from
other members in the household and their partners. Trials have shown that partner support or
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disapproval also heavily influenced overall product acceptability and adherence to a trial or
regimen. 140–143
Because of the significant adherence challenges with FemPrEP, VOICE and FACTS 001,
scientists and product developers have expanded the repertoire of medication type and delivery
systems for PrEP use by women. Other PrEP medications are in development and are currently
being tested for efficacy in a variety of delivery systems. These include maraviroc as a daily pill
and vaginal ring144; rilpivirine and cabotegravir as an injectable145,146; dapivirine in a vaginal
ring144,147; and tenofovir or TDF as a vaginal gel, vaginal ring or a rectal gel.148 For women
engaging in penile-vaginal sex, the use of vaginally localized microbicides (eg. ring, gel or film)
over oral administration has benefits of higher drug concentrations in the cervicovaginal area and
resulting in greater HIV protection.149–151 Also, adherence to PrEP and its delivery system
remains a crucial and relatively new area of inquiry as efficacy of ARV-based PrEP appears to
be highly dependent on adherence. 152–155
In response to the trial failures of pills and vaginal gels in women, biobehavioral
scientists are beginning to emphasize the need for developing additional medications and devices
for HIV prevention, particularly ones that do not require daily or peri-coital-dependent use, and
that are acceptable to women, their partners and communities. Most of these newly designed
devices are female-initiated, in response to gender norms that allow for a man to override a
female partner’s agency over protection from HIV and unintended pregnancy.156,157 Longeracting approaches, such as sustained delivery of ARVs from an intravaginal ring (IVR) or longacting injectables, may overcome some of the acceptability and adherence challenges observed
in previous PrEP trials given the higher acceptability of these methods for pregnancy prevention.
158,159

Although research has been conducted on acceptability of ARV-containing IVRs, there is a
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dearth of behavioral research to understand the breadth of issues for potential users, their
partners and communities. 153,160–163
Since the failures associated with microbicide gels have been reported, scientists have
begun to favor the development of intravaginal rings to deliver PrEP drugs. Recent studies with
women in sub-Saharan Africa showed microbicide IVRs to be very tolerable and comfortable
during everyday use as well as during sex. 153,160,161 In the two most advanced clinical trials of
dapivirine rings (the ASPIRE trial and Ring Study), microbicide rings reduced HIV acquisition
by 27-31% in the overall study samples. However, in girls 18-21 years of age, no significant HIV
protection was conferred, potentially indicating differences in young peoples’ acceptability of
IVRs and/or a biological difference in the cervicovaginal area that makes young women more
susceptible to infection than older women. 164,165
Studies of acceptability of dapivirine and placebo IVRs in African and US women
demonstrated that the rings were comfortable, not noticeable during daily activities, but
approximately 10-20% expressed a preference not to wear the ring during menses.

152,161,163,166

When a dapivirine IVR was tested in post-menopausal US women, over 90% of women reported
liking the ring after 12 weeks of wear.167 Social and cultural level issues including gender-based
violence, intravaginal practices, menstrual practices and sexual pleasure have also been noted in
trials as key factors for microbicide user acceptability.168–172
A rationale for developing an IVR for both pregnancy and HIV prevention is that it is a
female-initiated method. Because it is worn internally and is not used episodically, women do
not need to negotiate or even disclose ring use to male partners, as they might with condoms or
vaginal gels.156,157 However, previous microbicide gel research showed that covert use was not a
concern in most serious or monogamous relationships.173–177 Therefore, more research is needed
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to develop a product that can properly address individual and relationship needs to guide
responsive product development.
Early stage development of MPTs
Unlike contraceptive or microbicide devices in development, MPTs are in an earlier stage
of development and so there is no published literature on effectiveness of these products, and
limited information on efficacy is based on current trials.

87,178

The MPTs currently in pre-

clinical or clinical development are IVRs, gels, suppositories, films, oral tablets, intrauterine
reservoirs and a diaphragm (a modified, silicone, one-size-fits-most “SILCS” diaphragm179
releasing a microbicide). According to the IMPT database tracking MPT technology in
development, as of July 2019 there are five vaginal ring MPTs in preclinical trials and two that
are in Phase 1 clinical trials. Four of the five rings are a combination of a previously tested
microbicide + hormonal contraceptive, and one is a microbicide + nonhormonal contraceptive.87
The vaginal rings are being developed to range in duration of use from 28 to 90 days, with some
question about if and when menses will occur in relation to ring exchange. The modified SILCs
diaphragm could be designed for use over the course of a year and the gels are being designed to
be long-acting and coitus-independent.179 From a historical perspective, we can surmise that
these products arose in response to acceptability knowledge accrued from microbicide trials that
1) developed products localized to the cervicovaginal area for women because of behavioral
barriers to oral daily dosing and pharmacological problems with sufficient drug levels at the
exposure sight, 2) a range of pericoital and coitus-independent products, and 3) hormonal and
non-hormonal products.
Only one study to date reports on primary data regarding MPT-specific concerns and
preferences from a hypothetical MPT. In this study, the data were collected from participants
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who had participated in two microbicide trials using candidate gel or gel + diaphragm in Malawi
and Zimbabwe.180 Women, their partners, healthcare providers and community stakeholders
were asked about hypothetical acceptability of a gel MPT. Some of the advantages named of an
MPT were the health protection provided for multiple indications at once, specifically protecting
women from compounded health challenges related to being HIV+ and pregnant; the ability to
hide or downplay importance of either drug component (microbicide or contraception) to a
partner; and an (incorrect) assumption that a combined product had fewer drugs and subsequent
side effects than contraceptive + microbicide separately.

180

There was also a division among

women: some prioritized HIV-only prevention, some prioritized pregnancy-only prevention and
others HIV and pregnancy prevention, potentially indicative of women in different life contexts
and reproductive stages perceiving needing protection from different things.
What is still not known about MPTs is women’s preferences for MPTs wear duration,
interaction with menstruation, partner concerns and coitus dependence. While we can conjecture
about these preferences by cobbling together what we know from women’s PrEP and
contraceptive preferences separately, it is time that we prioritize and explore this construct in the
context of actual product development efforts. Until recently, research for microbicide and MPT
development has excluded user experience and acceptability, and reasons for non-adherence are
discovered much later in the product development pipeline (after Phase 1 clinical trials, often
when products are more difficult to modify). Acceptability research on long-acting approaches to
prevent HIV and unintended pregnancy is critical early in product development, however, so that
user and partners’ perceptions, concerns, and preferences can be identified and incorporated into
subsequent design iterations. Incorporating user preferences in early phase clinical trials may
shorten the product development timeline, prevent costly large-scale clinical trials that fail due to
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participant non-adherence, and improve likelihood of product adoption once developed.181
MPTs, are still in the early development stage, and are already following a similar trajectory of
clinical testing as microbicides; it is crucial that user perspective is incorporated early for these
same reasons.
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Study Purpose and Specific Aims
The purpose of this research is to develop a theory of MPT vaginal ring acceptability.
Toward this end, I use multiple qualitative methods (in-depth interviews, focus group discussions
and card sort data) from US women 18-45 years old in the context of a Phase 1 trial of an
antiretroviral IVR to explore acceptability of an MPT in vaginal ring form. My dissertation:

1. Uses grounded theory methodology to explore multiple levels of influence
(individual, couple, social) on acceptability of an IVR MPT and identify thematic
differences by experimental group (ex. side effects) and by potential theoretically
emergent factors (ex. relationship status).
a. Implements in-depth interviews to understand women’s individual and
relationship contexts, perceptions and attitudes about an IVR MPT.
b. Implements a card sort activity to identify relative value of identified
acceptability factors and to provide insight into the way women group, sort
and describe components of IVR MPT acceptability.
c. Implements focus groups to further examine emergent factors found in 1a and
1b, and to understand socio-cultural factors related to IVR MPT acceptability.
2. Conducts a methodologic assessment of the comparability and complementarity of
acceptability findings across the three different data collection techniques employed
to inform both the validity of the findings as well as potential differences attributable
to the method.
3. Develops a conceptual model for IVR MPT acceptability among women in the US,
based on the findings from Specific Aims 1 and 2.
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Significance
Understanding women’s need for sexual and reproductive health products for prevention,
and specifically MPTs, requires an understanding of both single and combined risk factors for
HIV and unintended pregnancy. Eventual MPTs offer a positive addition to women’s options for
supporting and protecting their sexual and reproductive health. By targeting both kinds of risks
with the same preventive device, health workers and advocates may redouble the positive impact
of their work by offering a product responsive to the needs of some women.
New MPT products present challenges related to combining drugs and device technology,
highlighting the need for scientists to ‘cross the aisle’ between the family planning and HIV
prevention fields in order to make effective and acceptable products that serve women’s varying
needs for contraception and disease prevention. There is international commitment from these
two disciplines to pursue a collaborative model to MPT development. Incorporating user input
into early phase clinical trials may shorten the product development timeline, prevent costly
large-scale clinical trials that fail due to participant non-adherence, and improve likelihood of
product adoption once developed.181
In order to best understand the parameters of MPT acceptability it is essential to speak
directly to women to learn how potential users define components of acceptability as they relate
to the context of their own lives including their sexual relationships, families and communities.
Since our understanding of MPT acceptability is minimal, and limited to barrier methods only,
qualitative inquiry is the appropriate methodological choice to explore the breadth and depth of
‘acceptability’ as a construct and how this construct applies to women and their partners at
multiple levels of influence. Using multiple qualitative methods adds strength and allows for
exploration of multiple levels of influence on women’s MPT acceptability, ultimately leading to
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a new theoretical model grounded in the data. The development of a new model of MPT
acceptability will help guide future inquiry into MPT product acceptability and development.
Further, an evaluation of the methodological contributions to this model will be helpful to future
study design choices of other MPTs.
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SECTION 2: GUIDING FRAMEWORKS and METHODOLOGY
In this chapter I describe the approach and present the rationale for using grounded theory
methodology to explore and develop an integrated theory of women’s acceptability of
technology to prevent HIV and pregnancy. Grounded theory offers an approach to both gathering
and interpreting data to inform this acceptability construct, and consequently develop an
empirically based theory, where currently none exists.
Using Grounded Theory to understand acceptability of MPTs
In their seminal work on the method, Glaser and Strauss (1967) broadly defined grounded
theory as, “the discovery of theory from data systematically obtained and analyzed in social
research”182 (p. 1). It is a systematic and inductive approach to conducting data collection and
analysis that aims to clarify concepts and conceptual relationships within the data for the purpose
of ‘grounding’ theory from those data.183 Grounded theory has been heralded as both a
methodology—indicating presence of an overall research strategy and its underlying
epistemology—and a method—focusing solely on specific techniques and procedures for data
collection and analysis.184,185

Contemporary grounded theory scholars typically align this

methodology with appropriately chosen qualitative methods to generate findings that are
‘grounded’ in the data.185,186 My dissertation research follows in this tradition of incorporating
grounded theory methodology with concrete qualitative methods to ultimately develop a theory
of MPT vaginal ring acceptability. Specifically, my dissertation research takes a grounded
theory approach to overall study design, guiding participant recruitment, data collection, analysis
and theory/conceptual framework generation.186–188
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There are many examples of qualitative studies exploring acceptability of sexual and
reproductive health products using grounded theory.

189–196

However, reports of using grounded

theory in this growing field are nearly always restricted to specific data analysis techniques
focusing on the coding process; 189–191,193,196–198 approaches to thematic analysis that use constant
comparison;196,197,199 and, the incorporation of inductive and deductive thinking.

189,196,197,199,200

Only one of the previously reviewed studies report the development of theory from analysis, and
the same study was the only one reporting the use of theoretical sampling.197 This gap in applied
methodological approaches to acceptability of MPTs is one that my dissertation aims to fill, both
in terms of breadth and complexity.
Grounded Theory and multiple qualitative methods
The general purpose of grounded theory is to help the researcher find a more complete
understanding of a phenomenon at hand through various techniques in order to generate new
theory. According to leaders in the grounded theory movement, these various techniques include
four broad components considered as its ‘foundational pillars’:
1) All is data
2) Emergence (of categories, relationships, theory and research design)
3) Constant comparative analysis
4) Theoretical sampling 201
With these pillars in mind, one of the basic applications of grounded theory is to move
from one stage of understanding into another, which often requires further data collection to
explore emergent findings. These iterative data collection efforts are not prescriptively
qualitative or quantitative but are more so responsive to the emergent and developing pathway of
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understanding. Hence, using more than one type of data is a sensible process for developing a
grounded theory.
Mixed methods and multiple methods research strategies are often logically indicated in
the process of doing grounded theory. While the definitions of mixed and multiple methods are
the center of ongoing methodological debates, the main distinction of importance to this
dissertation is that mixed methods research typically includes at least one quantitative
component, and multiple methods research offers a broader array of possible methods used
within one larger project that can be all qualitative if indicated.202 The overarching strategy for
answering a research question using multiple methods is to “attack [it] with an arsenal of
methods that have non-overlapping weaknesses in addition to their complementary strengths”203
(p. 6). Thus, the process of doing grounded theory offers a theoretically congruent approach to
the use of multiple qualitative methods by its inductive nature.

This dissertation research

attempts to add methodological insight into ways in which multiple qualitative methods can be
effectively triangulated to best inform grounded theory development. The choice of which
qualitative methods were used and their timing in this study is discussed later in this Section.
Guiding conceptual frameworks
In current clinical trials for microbicides, product acceptability is of interest because of
its potential to explain product use or adherence both in the context of a trial and in daily life of
potential users. The acceptability construct, however, has been difficult for researchers to define,
and consensus has not been reached by either the HIV prevention or family planning fields.168,204
Research on acceptability has been guided by an array of social and behavioral theory that has
been applied to contraceptive and microbicide products, and, in this study, was extended to MPT
Rings. 154,205–207
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Two prominent conceptual frameworks of microbicide acceptability guided my research
questions and implementation. The first was The Holistic Model of Microbicide Acceptability
originally developed by Woodsong et al. to clarify key factors relevant to willingness to use a
microbicide gel and diaphragm product pair.208 It was built in response to a union of relatively
linear, individual-level theories that have been used to guide behavior change research on HIV
prevention.209–212 While Woodsong’s model acknowledges individual levels of influence on
microbicide acceptability, it also takes into account socio-cultural and relationship factors that
can influence an individual’s acceptance of a product. Woodsong’s Holistic Model has guided
studies of microbicide acceptability and is a flexible conceptual framework that could feasibly
include elements related to pregnancy prevention.154,161,213 Thus, it was initially adapted for use
in this dissertation (adaptations indicated in italics) to guide initial understanding about the
multiple and interacting levels of influence on MPT IVR acceptability (Figure I).
The model identifies three domains within microbicide acceptability: Product Attributes
(such as sensory experience, side effects or interruption of fertility); Relationship Attributes (e.g.,
how the product impacts relationship trust or partner approval); and Sexual Experience
Attributes (such as impact on sexual pleasure or interruption of the sex act). These domains are
believed to interact with an individual woman’s situation, her perceptions of partner preferences
and socio-cultural norms that, when considered together, may contribute to a robust
understanding of microbicide acceptability. The model appearing in Figure I is an adaptation of
the Holistic Model of microbicide Acceptability, with additional factors related to pregnancy
prevention and fertility that have been found to be important to contraceptive acceptability (e.g.,
changes in menstruation, fertility intentions, experiences and concerns). 209,214,215
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It is worth acknowledging that this conceptual framework as applied to MPT
acceptability also reflects a feminist epistemology, which prioritizes women’s voices and genderaware perspectives in the scientific process to produce MPTs that can be responsive to women’s
needs. Specifically, the framework accommodates the complex interplay between device
technology, a woman, and her contextual environment such that MPT acceptability must be
conceptualized as “relative, conditional and user-driven.”207
Figure I: Conceptual framework for acceptability of an intravaginal ring for multipurpose
prevention of HIV and pregnancy

SOURCE: Adapted from Woodsong C and Alleman P. Sexual pleasure, gender
power and microbicide acceptability in Zimbabwe and Malawi. AIDS Education
and Prevention, 2008 Apr;20(2):171-87. 213
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Study Design
My dissertation research was designed as an integrated multimethod,202,216 qualitative
sub-study implemented within a larger parent study: a first-in-human Phase 1 randomized
placebo-controlled trial to assess the safety of a polyurethane reservoir tenofovir disoproxil
fumarate (TDF) intravaginal ring (IVR) in US women.148 The parent study was conducted in
New York City with 30 healthy, HIV-negative women who were using low-dose combined oral
contraceptives.148 The control arm wore a placebo polyurethane reservoir sodium chloride IVR.
Both the TDF and placebo IVRs resembled the NuvaRing in outer and cross-sectional diameters
of 55 and 5.5 mm, respectively.148 Eligible participants to the parent study were randomized 1:1
to receive either a TDF or placebo IVR for 14 days of continuous use, which was inserted and
removed by a study clinician to ensure proper placement and participant blinding. Participants
were instructed not to remove the IVR, to refrain from oral, anal or vaginal sex, and not to insert
any objects into the vagina.148 The two weeks of continuous ring use occurred when women were
not menstruating.
The objectives of the parent study were to assess the safety of the TDF and placebo IVRs,
and to examine the systemic and genital tract pharmacokinetics of TDF and its metabolites.iii The
objective of my sub-study, by contrast, was to understand how user experiences, beliefs, attitudes
and preferences could shape acceptability of a TDF-based IVR that would prevent both
pregnancy and HIV if it also had contraceptive properties (Aim 1). It is important to note that the
TDF IVR used by the participants in the parent trial did not include any form of contraception, so

iii

Unfortunately, a second Phase 1 trial of the TDF IVR ended early due to adverse physical
events in participants, and thus further investigation of a TDF-only ring has been delayed along
with further development of a TDF-based MPT ring.361
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participants in my study were asked to explore some issues hypothetically (contraceptive and
fertility-related) and others answered based on their lived experience with a TDF-only IVR from
the parent trial (drug or ring-related). Some results from this ongoing research have been
published elsewhere in a paper titled "Acceptability of a tenofovir disoproxil fumarate vaginal
ring for HIV prevention among women in New York City". Those findings will be incorporated
into this dissertation without further regard to citation.166
Recruitment
The parent study recruited 30 female participants from the gynecology and medicine
practices at Montefiore Medical Center (MMC), the local University community of the Albert
Einstein College of Medicine in the Bronx, NY, as well as community-based locations using
flyers posted along building and office entry points. For recruitment into my qualitative substudy I used a two-stage sampling approach in order to work within the confines of the parent
study sample, while still allowing for exploration of emergent findings as is characteristic to a
theoretical sampling approach used in grounded theory studies.187 For a complete list of parent
study inclusion and exclusion criteria, please refer to Appendix C. The recruitment criteria most
relevant to this study were:
•

Age: 18-45 years old

•

Sex: Female

•

Health status: In general good health, including not having an active STI and being
HIV uninfected via blood test at screening.

•

Reproductive factors controlled: Have a regular 28-day cycle, to ensure women did
not menstruate normally during the 14 days of ring wear, thereby isolating any
potential bleeding as not being due to menstruation; menses regulated prior to ring
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insertion via three months of oral contraceptive pills; could not be pregnant (tested
via urine test at screening); were not breastfeeding or trying to get pregnant.
•

Behavior: Agreed to abstain from any oral, anal or vaginal sex during the course of
the trial until 7 days following ring removal; agreed to refrain from inserting any nonstudy vaginal products or objects into the vagina, including but not limited to
contraceptives, douches, lubricants, sex toys and tampons until the end of the study.

•

Location: Lived within reasonable proximity to the study site in the Bronx, NY, to
improve retention at each of the clinical and qualitative behavioral visits.

Sample Selection
I used multiple sampling strategies based on type of data to be collected (interviews, card
sorting and focus groups), progressing stages of data collection, and overall logistical
considerations as described below.
Interviews and Card Sorts
Sampling Stage 1 – Stratification
One of the key questions in this research is to understand potential differences in
women’s acceptability of an MPT IVR based on the acceptability of the investigational drug
TDF. Specifically, I wanted to know if women’s acceptability of an MPT ring was different if
the TDF drug was present. To address this goal, I used a segmented (ring vs. placebo) purposeful
sampling approach throughout the sampling process aided by the parent study research
coordinator to maintain my masking to participants’ study arm.217 This stratification is important
to be able to identify potentially different patterns in the data based on the presence of drug. With
five participants being the rule of thumb for minimum number of participants per cell for
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comparison in a segmented sample, I invited the first 10 participants (5 Experimental, 5 Control)
who enrolled in the parent study to also participate in my qualitative sub-study.218
Sampling Stage 2 – Theoretical saturation and theoretical sampling:
As with other qualitative methods, grounded theory aims to reach theoretical saturation,
meaning that no new themes are emerging from the data and findings are becoming redundant.219
One of the key features, however, that distinguishes grounded theory from other methods of
qualitative analysis is the process of theoretical sampling, which is a cyclical (i.e., iterative)
approach to sampling and preliminary analysis whereby the researcher selects subsequent
participants such that they can further explicate a phenomenon until “no new properties emerge”
and theoretical saturation of the developed themes has been achieved. 186 In this approach to
sampling, “the analyst jointly collects, codes and analyses [the] data and decides what data to
collect next and where to find them, in order to develop [the] theory as it emerges.” (Glaser and
Strauss, p. 45)182
Following enrollment of the first 10 participants, I had not reached theoretical saturation
on developing themes either within the segmented groups or across the sample as a whole, so I
continued to recruit participants. For selection of the 11th and subsequent participants, I
continued to recruit participants from the parent study pool, comparing themes emerging from
the new participants to the previous participants until I was confident saturation had occurred.187
Following interviews with the first 13 participants, the emergence of new themes slowed,
signifying that I was nearing theoretical saturation of findings. The 14th participant brought no
new findings, yet the 15th participant expressed idiosynchratic discomfort with and strong
disapproval of the ring. She was the first, and youngest, participant to report such disfavor, and
thus I began to explore this issue as a potentially emergent finding.
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Inherent to this grounded theory process of theoretical sampling is abductive reasoning,
an approach to making sense of puzzling or odd findings. Abductive reasoning allows and
pushes researchers to go beyond inductive reasoning to develop hypotheses, based on insights,
connections and grappling with data to see what fits the newly emergent theory and what does
not. 182 In this case, after reaching saturation on nearly all themes with 15 participants, I began to
recruit only younger participants to further pursue a specific emergent issue, i.e., if and how
young age may be related to product acceptability. Not only was the sampling narrowed in
response to early findings, but also based on new evidence from the microbicide field
demonstrating that young women had significantly lower rates of product adherence. In an aim
to shed light on this seeming phenomenon of lower acceptability, adherence or potential
effectiveness among young women, 129,130,138,164,165 I continued to enroll only the younger women
who entered into the parent study (age 18-21) resulting in a total of 18 women in the in-depth
interview (IDI)/card sort study sample.iv
The parent study was necessarily double-masked to reduce potential bias; participants
were masked to their randomized experimental condition (treatment or control), and I (in the
roles of both data collector and analyst) was masked to experimental condition of the interviewee
until all data were collected. However, it was essential that a nearly even distribution of women
in both experimental conditions were recruited into my study to allow for this comparison in my
analysis. To achieve this, I conferred with parent study staff about the aggregate distribution of

iv

Theoretical sampling was based solely on emergent findings from the interview data (not the
card sort data), due to the rapid turnaround of participant recruitment and time limits on
intermediate data analysis.
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participants randomized to treatment vs. control following the 10th, 15th, and 18th participant in
the IDIs. There were no refusals.
Focus Groups
For focus group recruitment, each of the 30 women who participated in the parent study,
regardless of participation in the IDIs/card sort, were invited to participate in a focus group. For
women who were interviewed, the focus group invitation was extended following completion of
both interviews and card sort data collection points. For women who were not interviewed, a
focus group invitation was extended following completion of the final clinical visit. I conducted
three focus groups, with 5 to 8 women in each group. The first two focus groups only included
women I had previously interviewed, and the third focus group only included only women who
had not been interviewed.
The sampling plan for the focus groups was crafted based on Morgan’s (1997)
consideration for segmentation to manage a group’s composition by strategically choosing
participant characteristics to be homogenous within a single group.220 The goal of segmentation
and homogeneity of participants is meant to improve group dynamics via the overall free-flow of
dialogue and information exchange. Homogeneity of participant profiles typically includes
background characteristics such as age, race, gender or social class.220–222 I incorporated
grounded theory principles to identify participant characteristics that could potentially impact
group dynamics in a negative way. To do this, I developed criteria for homogenous focus groups
based on emergent findings about potentially clashing participant characteristics from the
interviews. At the time of recruitment for each of the focus groups, the two main characteristics
that emerged as having potential to harm group dynamics was age (younger vs. older) and
education level (PhD students studying infectious disease vs. others). I hypothesized that age or
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education or both of these factors could negatively impact the group dynamic and findings,
whereby younger and less educated women might feel uncomfortable sharing experiences or
beliefs alongside older, more experienced or highly educated women. I also was concerned of the
complement, that older, more experienced, or highly educated women might be disrespectful or
overshadow their counterparts. I therefore considered constructing one focus group of PhD level
students only vs. others and one group of younger women only vs. others. Logistically, this was
not possible in order to hold focus groups of 4 or more participants. Therefore, groups were
formed as soon as enough parent trial participants were available to participate in a focus group,
without segmenting the groups by demographic homogeneity factors of age or education.
Data Collection
Phases of data collection
I collected three forms of data with women in my study: two sequential In-depth
Interviews (IDIs); a card sort exercise; and focus groups. All women approached to participate
in the interviews accepted invitation and enrolled. Nearly all participants (17/18) completed both
interviews; only one was unable to complete a second interview nor her card sort because of a
restless infant (Table I). Focus group recruitment happened on a rolling basis, according to
parent trial enrolment and the subsequent acceptance of focus group invitation by 8 women, to
ensure a minimum of 5 women per group. Each of the 30 women from the parent trial were
eventually invited to participate in one of three focus group discussions, and 18 women attended,
of whom 13 also participated in IDIs. There were no active refusals for focus group participation,
with the remaining 12 women unable to attend a group because of scheduling, or unknown
reasons due to no-shows or non-response. All IDIs were conducted in a private office in a
university setting. The focus groups were held in a conference room in a university setting.
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Figure II describes my study in relation to the goals of the clinically-based parent study,
which required 9 total visits and aimed at 100% retention for each participant at each data point.
The first data collection point for this sub-study was ‘Interview 1,’ occurring following
menstruation and on the same day as ‘Visit 6’ of the parent study, one week after ring insertion
(‘Visit 3’ of the parent study). ‘Interview 2’ took place approximately two weeks after interview
1, one week following ring removal, and prior to the next menstruation. A card sort activity
immediately followed Interview 2, in the same location as the interview. The two-week time lag
between Interviews 1 and 2 allowed me to identify and document in the interviews any changes
in women’s experiences with the ring during use, removal and following removal. Once
participants had completed the parent study (completing two weeks of IVR wear, IVR removal,
final interview and card sort) and were eligible for a focus group, I conducted three focus groups
each with 5-8 women.
In-depth Interviews
In-depth interviews are an appropriate data collection method for learning about new
areas of inquiry.223,224 Because of the minimal existing knowledge on MPT acceptability (with
the exception of male and female condoms), IDIs are well suited as a data collection technique to
gain a deeper understanding of a potential user’s context, perspectives, needs and questions
about MPTs that could impact eventual use and/or help shape the approach to new MPT
development.82,225 As discussed in Section 1, microbicide trials have suffered because of product
acceptability issues and subsequent non-adherence.129,130,132 Judging from those trials, it is
possible that the development of new technologies would benefit from an earlier and deeper
understanding of user preferences and acceptability based on product type and characteristics,
risk perception and relationship status, among others. By inviting discussion and feedback from
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participants regarding their experiences, IDIs offer prospective insight into user experiences
measuring previous, current and changing product experiences and perceptions of use. In the
case of newly developing MPTs, IDIs can help generate understanding about MPT acceptability
factors. Further, IDIs provide a safe space for individuals to talk about topics considered to be
sensitive or private.226,227 For these reasons, IDIs were chosen for this relatively uncharted MPT
research on sensitive and/or stigmatized socio-behavioral topics such as sexuality, reproduction,
relationships and HIV.228
I developed semi-structured interview guides (for IDI 1 and 2) that included questions
and probes and was designed to be used flexibly, whereby the ordering of questions changed due
to participants’ responses, but with enough specificity to ensure pursuit of areas of importance to
my research questions across all respondents.223 I chose to use a semi-structured guide because it
is ideal in circumstances where there exists some previous breadth of knowledge, but
simultaneously allows the researcher to follow emergent topics important to the participant that
may not have been anticipated by the researcher. 229,230 The guides were designed (See Appendix
D) to allow for questions to be probed for depth, and for relevant topics to emerge from
participants other than those explicitly included in the guides.
IDIs 1 and 2 were designed to be sequential and complementary in order to build rapport
and meaning-making231 between participant and interviewer about topics that were potentially
uncomfortable or difficult. The two guides contain some similar questions to help ease
participants into deeper sharing at both data collection points. The IDI 2 guide was designed to
be tailored to each participant based on findings from the first interview so that depth of
responses could be flexibly explored for each woman individually. Topics covered in both guides
included experiences with the ring; expectations of an MPT ring with HIV prevention and
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contraceptive properties; concerns about wearing the ring for extended periods of time including
during menstruation; perception of partner acceptability, potential barriers to use and willingness
to use an MPT ring if it were available in the future.161,209,212,213 The first interview lasted
approximately 45-60 minutes, and the second 30-45 minutes to accommodate administration of
the card sort activity (see below). All transcripts were entered into Dedoose, an online qualitative
analytic package that facilitates the coding and data retrieval process.232
Focus Groups
The general purpose of the focus group as a data collection method is to capture data on a
researcher-defined topic via group interaction. Although the researcher defines the focus,
participant interaction is key to the process of data generation. 233 Used as part of a multi-method
approach (as was done in this study), focus groups can add depth, augment or clarify findings
from another method (e.g., IDIs or self-administered surveys), consequently allowing for
triangulation of data or capture unique perspectives only attainable through a combination of
data sources. 220,234
In this research, all parent-trial participants were invited to participate in a focus group
discussion. The purpose of the focus group was to further ascertain women’s experiences using
an IVR and perceptions of use for an MPT IVR; to explore unexpected findings from the
interviews and card sort activity; to allow participants to “share and compare”220 their own
experiences; and, to generate understanding about group-level norms and perspectives. Although
I defined the topics of interest for the focus group guide, participant interaction was essential for
data generation on those a priori topics as well as other emergent topics.233 I facilitated each of
the focus groups, accompanied by an assistant whom I trained to take notes on content and
process within each of the groups.235 Special attention in note-taking was paid to significant
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shifts in group dialogue based on interaction among group participants and with the facilitator.236
As facilitator, I was mindful of potential problems in group dynamics between younger and older
women, and those with less and more education, as I was not able to conduct separate focus
groups based on these characteristics. For example, if a PhD student dominated the conversation,
I would make equal time for a non-PhD student to respond. If no one volunteered or only offered
a minimized response, I would catalyze further participation by offering up alternative
perspectives that had arisen in the IDIs, if appropriate, such as “In the interviews I conducted,
some women mentioned another perspective. What do you think about [naming the
perspective]?”
The focus group guide addressed themes that emerged in the interviews and card sort,
with emphasis on social and relationship-level influences on acceptability such as HIV stigma,
relationship norms and social understanding of HIV risk, pregnancy desires and potential conflict
between the two (Appendix D). The focus group(s) were audiotaped, transcribed, and reviewed
by the facilitator for accuracy, and entered into Dedoose for analysis.
Card Sorts
The card sort technique has been used successfully to explore sensitive topics among
women such as post-partum concerns,237 violence or abortion,238 that may otherwise be
considered taboo to discuss in the research environment. I chose the card sort method to both
facilitate conversation about sensitive topics such as sexuality and reproductive health and to
collect ranked importance data. Using a closed card sort technique,239 I asked participants to sort
and then rank approximately 25 a priori statements (Appendix D) on physical cards about ring
acceptability that were selected from previous themes in the microbicide and family planning
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literature along with statements made by women in previous interviews. Individual cards were
conceptualized as part of seven different domains (Table II).
This approach encouraged discussion about topics that might not have emerged without
prompting in the IDIs or focus groups. First, women were asked to sort statement cards into one
of three piles: 1) reasons to use a vaginal ring, 2) reasons not to use a vaginal ring, and 3) does
not matter to me. During this sorting process, they were asked to ‘think aloud’ to provide
qualitative insight into the meaning they assigned to their preferences or choices. The comments
they made as they ‘thought aloud’ were captured on the recording and transcribed as part of the
second interview. Following this sort, they were then asked to rank all cards from piles 1 and 2
by level of importance. Some of the statements were purposefully neutral in direction, forcing
participants to engage with the concepts and vocalize their struggle to understand and
hierarchically categorize the statements in a meaningful way.239,240 The card sort activity was
piloted with 3 females of child-bearing age using hormonal birth control methods and
components were adjusted to improve clarity of instructions; to add the category ‘it doesn’t
matter to me’ into the first stage of the sort; and to add blank topic cards for participants to
generate their own areas of importance.
This card sorting approach aimed to both encourage discussion about topics that were
currently being discussed in the microbicide and family planning literatures, and to help
understand the ways women order or rank the relative importance of different factors
contributing to overall acceptability of an MPT. The card sort was administered immediately
following the second interview, in the same room, and lasted approximately 15-20 minutes.
Completed card sorts were photographed upon completion and transcribed into Excel for
organizational and analytic purposes.

45

Table I: Participant Data Points

Name
(Pseudonym)

Carly
Marina
Celia
Tracy
Adele
Nora
Laura
Angela
Rose
Sara
Kerry
Madison
Hillary
Maureen
Megan
Jenna
Ellen
Jamie
Rachelle
Kelsey
Natasha
Brianna
Jean

IDI
1

IDI
2

Card
Sort

FG
1

FG
2

FG
3

Any
IDI

Any
FG

x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x

x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x

x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x

x
x
x
x
x
x
-

x
x
x
x
x
x
x
-

x
x
x
x
x
-

x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x

x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
-
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Completed IDI
+ Card Sort +
FG
X
X
X
X
X
X
X
X
X
X
X
X
x

Day 1

Ring Insertion
*end of parent study

Day 7-13

Day 14

Days 14-35*

IDI 1

Ring
Removal

IDI2
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Menstruation

Menstruation

Figure II: Research Design
Days 45-90

Focus Group

Table II: Card Sort Statements and Their a priori Domains
(a priori) Domain

Card Statement
The ring will stay clean
Menses
The ring won’t get menstrual blood on it
My period would still come once a month
My physical comfort during sex
Sexual Experience
My Partner’s physical comfort during sex
Wetness during sex
Sex would be better
My sex drive or being turned on might change
Discharge during sex*
Side Effects
Side effects from the ring
Type of Hormone/Birth control in the ring
Ring characteristics
Higher cost compared to my regular contraceptive method
Material that the ring is made out of
Having sex without thinking about getting HIV
Disease prevention
Feeling safe during sex
The ring will prevent STIs/STDs other than HIV*
Putting my finger inside my vagina to put the ring in and take it out
Ring Exchange
Being able to put the ring in and out of my body
I can take the ring out for short periods of time
Having sex without thinking about getting pregnant
Fertility
The ring will NOT prevent pregnancy
The Ring will prevent pregnancy
Will not affect me getting pregnant in the future
My partner supports my choice to use this ring
Relationship Factors NOT needing to tell a partner it prevents HIV transmission
Not needing to tell my partner it prevents pregnancy
My partner trusts that I am faithful
*Cards generated by participants
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Data Analysis
Grounded Theory, integration and triangulation
Grounded theory analytic methods have been used by others exploring acceptability of
sexual and reproductive health products (e.g., contraception and PrEP). Specifically, analysis of
acceptability data on contraceptive vaginal rings,197 contraceptive IUDs,189,241 general
contraceptives,190,191,242

male

condoms,193,198

female

condoms,192

rectal

and

vaginal

microbicides,137,196,198–200 and oral PrEP.194 Practically speaking, grounded theory analysis is
conducted by moving "back and forth between empirical data and emerging analysis”; 183 it is a
constant comparison approach to analyzing qualitative data throughout the research process from
data collection through to theory development.186,243 A grounded theory approach to data
analysis is well suited to the exploration of acceptability of MPTs, as it is a new area of research
where little is known.186
In addition to the grounded theory approach to data analysis, I followed an integrated
methodological approach to this research that began from the conceptualization of the study
using three different types of data; was enacted throughout the implementation of the research in
which data collection was influenced by ongoing emergent findings; and concluded with the
integrated analysis of the stories understood through these different forms of data. Some
generally identify this approach as methodological triangulation, but it has been more explicitly
defined by Moran-Ellis et al. as methodological ‘integration’, which “involves the generation of
a tangible relationship among methods, data and/or perspectives, retaining the integrity of each,
through a set of actions clearly specified by the research team, and that allows them to ‘know
more’ about their research topic.”216 I therefore followed this integrated approach within
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grounded theory to further explore, compare and ‘know more’ about the complexity of the social
phenomena informing acceptability of an MPT ring.
The term ‘triangulation’ originated in the quantitative paradigm, where there is a desire to
measure a single concept or construct with different questions or items so a researcher can feel
confident in the validity of the findings when the measurements converge: the greater the
convergence, the greater the confidence in the captured measurement.244–246 Small (2011)
alternately refers to this as ‘confirmation’, to “ensure that…findings do not depend on the
particular kind of data collected” (p.63).247 This validation approach to triangulation, which can
include both convergence and divergence of findings across measurements, I am labeling in
Section 3.4 as a comparability analysis. As applied to this research, I compared ring
acceptability themes according to the data collection approaches that were used to elicit them:
interviews, card sorts and focus groups.
Conceptually, however, triangulation need not be limited to concept validation. In the
qualitative paradigm, and certainly in mixed methods research, there are different ways that
researchers have come to apply triangulation--and more specifically, ‘integration’216 -- including
consideration of complementary findings across different data sources. Denzin and Lincoln
(1994) task qualitative researchers with using “a wide range of interconnected methods, hoping
always to get a better fix on the subject matter at hand.”248 They further specify:
“…the use of multiple methods or triangulation, reflects an attempt to secure an in-depth
understanding of the phenomena in question. Objective reality can never be captured.
Triangulation is not a tool or strategy for validation, but an alternative to validation [emphasis
added]. The combination of multiple methods, empirical strands, perspectives and observers in a
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single study is best understood then as a strategy that adds rigor, breadth and depth to any
investigation” (p.5). 248
Therefore, I conducted a complementarity analysis to triangulate the data in order to more
robustly synthesize thematic findings across different types of qualitative data to better
understand a complex social phenomenon: MPT ring acceptability and likely use.249,250

In-Depth interviews
IDI analysis was conducted in four phases. The first phase included coding the dataset for
themes specific to acceptability of the TDF-only vaginal ring because of early demands of the
parent trial. This first round of coding helped to identify, divide and ultimately compare key
themes that were specific to the TDF ring, the MPT ring and those that were applicable to both.
In this phase, I approached the interview data using grounded theory’s constant comparative
method of analysis, whereby one categorized segment is compared to previous segments in the
same or different categories to help refine, combine and/or distinguish one concept from the
next.182 The coding process consisted of initial coding to group basic categories of data, focused
coding to determine higher level analytic groupings of codes as they compare to initial codes,
and theoretical coding to assemble a story to integrate themes or constructs emergent from the
focused coding phase.231 I concluded the coding process with the development of theoretical
codes, which were assembled to extract the story line present in the data.243
During the second phase of IDI analysis, I began by writing case profile memos for each
participant, drawing on data from IDI 1, IDI 2 and the card sort that included key components of
my research questions (MPT acceptability components, method-specific issues to IDIs) as well
as important quotes or data segments to maintain closeness to the data. Concurrently, I re-read
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transcripts, alongside their first-round codes and iteratively identified new, irrelevant or different
codes to be added, removed or adjusted (respectively) to a second-round codebook.
In the third analysis phase, I re-coded the IDI data using the revised codebook consisting
of more honed, higher-level themes. (Appendix E) During the second-round coding process, as
new themes unfolded, I wrote analytic memos to document insights as well as perplexing issues
needing resolution. These memos created a foundation for conceptualizing and reconceptualizing findings from the data based on what I learned during data collection, coding,
constant comparison, and early stages of theory development.182 Memos such as the ‘duality of
menses as both dirty and cleansing’ and the ‘importance of male partner’s health’ clearly
pertained to my initial research questions and helped expand my understanding of MPT
acceptability overall. These and other thematic memos provided a medium for connecting
emergent themes, categories and concepts, eventually laying a foundation for developing a new
theoretical framework grounded in the data.182,186
In the fourth phase of analysis, I segmented the coded IDI data by the following a priori
or emergent participant characteristics of interest: experimental condition (a priori), race(a
priori), age(a priori), relationship status(emergent), prior NuvaRing use(emergent) and tampon
use in the past month(emergent).
Focus Groups
Grounded theory analysis techniques are well suited to focus group data because of their
methodological foundation in symbolic interactionism. This is a theoretical perspective which
embraces the notion that meanings are “social products formed through the activities of people
interacting”.182,251 Focus groups capitalize on this perspective by creating a space to facilitate
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interpersonal interactions, and thus, meaning-making of reality is emergently co-produced by
focus group participants.
Scholars have recently acknowledged the need to pay more attention to interactions
within focus groups.236,252–255 Typically though, the stated purposes of these analyses are distinct
from one another: either for “purposes that are oriented to substantive content” to explain what
data participants are creating or for purposes “that relate to the conversational dynamics” to
explain how participants create those data.256 In an attempt to integrate these two analytic
purposes to address my overall research questions, I used a multi-dimensional process to analyze
both the thematic content and the interactions between participants in order to identify the
potential for synergistic findings.
The first dimension of the analysis consisted of a debriefing session between the
facilitator and assistant which took place immediately following each focus group. The
debriefings were designed to capture nuances that might otherwise be lost over time and space as
I moved further from the data collection environment.235 During these debriefing sessions, we
noted issues related to group composition, rapport between the research team and participants
and other contextual factors that may have been influential on the data produced. Further, we
reviewed assistant notes and discussed facilitator insights interactively for each topic of focus
group discussion, with attention to both thematic content and process. Final summaries from
these debriefings were then dictated into a tape-recording device, reviewed and transcribed.
The second dimension of the analysis included deeper exploration of thematic content
generated within and across focus groups using similar techniques of constant comparison as
used in the IDI analysis described above. For these analyses, which occurred sequentially
following the second round of IDI coding, I first applied the IDI codebook to the focus group
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data, noting similarities and differences within thematic findings, across the three focus groups,
and across the IDI and focus group data collection methods. Analytic memos were concurrently
developed to identify and discuss these thematic similarities and differences between individual
focus groups’ data and between the focus group data and IDI data.
A third dimension of the focus group analysis included studying specific interactions
between focus group participants. Morgan and Hoffman (2018) offer a concrete approach to
coding focus group interactions called the “Co-Production of Interaction.”257 This is an approach
that builds on and attempts to incorporate 1) techniques used in conversation analysis, which
focuses on micro-dynamics of participant interactions and ‘turn-taking’;258 and 2) the concept of
the co-creation of meaning, which relies on interactions to co-produce knowledge in ways that
are most meaningful to participants.254 The co-production of interaction suggests a particular
coding system that is based on typical interactive processes where participants share and
compare experiences, perspectives, and specific life moments with one another in their dialogue.
Thinking of the co-production of interaction as a framework for facilitating the integration of
content and process of focus group data, I coded the focus group interaction data using relevant
codes from its affiliated coding system. (Appendix E for Focus Group Interaction Codes)
Specific moments of interaction that I coded for included 1) nonverbal behavior captured in
observational field notes taken at the time of the focus group,259 and 2) key conversational
interactions (continuing topics, changing topics and interpersonal connections) between
speakers257. Therefore, in addition to thematic coding of the focus group data, I also coded the
data for these specific moments of interaction to explore how participants described their own
experiences and acceptability factors in relation to one another.
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Card Sorts
Card sort data were analyzed in three different ways. First, I identified common clusters
of cards across participants to understand potential factors or themes within the acceptability
construct. I grouped these cards into ‘clusters’ based partly on emergent themes found in the IDIs
and focus groups and partly on themes or items found only in the card sorts. I used a process of
constant comparison to identify similarities and differences between the presence of card sort
‘clusters’ and previous themes developed in the IDIs and focus groups.
Second, I examined patterns in the way women ranked the cards to determine relative
importance of factors for MPT use and non-use. During this process, I paid special attention to
patterns hypothesized yet not systematically studied during the IDIs and focus groups. The
patterns I specifically queried included the most important and least important reasons for use
and non-use; the ranking of factors related to partners vs. self vs. relationship priorities; and the
relative importance women paid to contraceptive vs. HIV preventive properties of the ring. The
rank-ordered results were then comparatively analyzed for differences by experimental
condition, age and relationship status to explore potential typologies of respondents.
To more closely analyze individual and then aggregate patterns in the card sort activity, I
color coded each individual’s card sort by a priori domains. Color coding included each of the
cards within the a priori domains. For example, the cards entitled ‘the ring will stay clean’, the
ring won’t get menstrual blood on it’, and ‘my period will still come once a month’ were all
coded in pink representing the ‘Menses’ domain. After each individual card sort was color coded
by domain, I first evaluated patterns in the clusters within and across the sorts. To ensure that I
was visually identifying clusters correctly according to color-coding, I also entered all data into
SPSS to query and verify emergent patterns across all cases.
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Data Reporting
In Chapter 3, most results are reported in narrative form, using verbatim excerpts of raw
data to illustrate key findings. Exceptions include the use of [bracketed text imputed by the
researcher], that replaces colloquial or difficult to interpret text and “…” in cases where data
were not sequential. In the few cases where qualitative data have been summarized in
quantitative form, I parenthetically report a numerator and denominator. In these cases it can be
inferred that all participants were asked the same question and provided a response.

Human Subjects Protections
The study was approved by the Albert Einstein College of Medicine Institutional Review
Board (10/2/2013, protocol: 2013-329) and then subsequently was granted “exempt” status by
the CUNY Human Research Protection Program for purposes of dissertation research
(11/03/2017, protocol: 2017-1225) (Appendix B). Written informed consent was obtained from
all individual participants included in the study. Qualitative data were collected confidentially
between the participant and this researcher and were de-identified prior to sharing with clinical
research staff. Participants were assigned pseudonyms and quoted text identifies the data
collection type (and sequence, if applicable), participant name, and age in years (i.e, . “IDI1,
Nora” is from Nora’s first interview; “FG3, Jamie” is from Jamie in Focus Group 3).
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SECTION 3: STUDY FINDINGS
The following Section of study findings presents a new model that describes acceptability
and likely use of an MPT vaginal ring for prevention of pregnancy and HIV along with a detailed
description of methodological factors that helped to produce this model. This Section is divided
into four sub-sections. Participant characteristics are presented first (Section 3.1), for those who
provided interview, card sort, and/or focus group data. Section 3.2 then presents the overview of
the model (Figure III). This overview is then followed by a detailed description of the conceptual
components of the model and the relationships among those components (Section 3.3).
Throughout the presentation of findings, thematic contributions based on data collection method
are identified and discussed as they influenced model development. Following this detailed
description of the model, there is a summative discussion of how the different data collection
methods uniquely contributed to production of thematic findings and associations (Section 3.4).
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Section 3.1: Participant Characteristics
Of the 18 participants who participated in the in-depth interviews, 8 were in the TDF arm
and 10 in the placebo arm; the card sort included 17 of the 18 women from the IDIs (8 TDF, 9
placebo), missing one because of her restless child; and across the 3 focus groups there were 18
women (9 TDF, 9 placebo), of whom 13 had participated in an IDI (Table I). There was no
evidence of participant unblinding. The IDIs and FGDs had similar racial and ethnic makeup;
respectively, 44% and 39% were white; 22% and 22% were Black; 17% and 28% were Hispanic.
The median age of participants was similar in the IDIs and FGDs (30.2 vs. 31 years,
respectively), but the median number of years of education was slightly higher in the IDIs (15.5
years) vs FGDs (14 years). In both the IDIs and FGDs, 67% were in a current relationship; and
almost all participants were sexually active in the past two months (Table I). Approximately half
of the IDI participants (10/18) and FGD participants (8/18) had used tampons during their most
recent menses prior to ring insertion. None of the IDI participants considered themselves at risk
for HIV on a dichotomous quantitative measure used in the parent study (“Do you think you are
at risk for HIV?”) (Table III).148
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Table III: Participant Characteristics of IDI and FG Participants

Characteristic
Age (years) a
Education (years completed)
Race
Black/African American
White
Asian
‘Other’ b
>1 race
Hispanic ethnicity
Tampon use: past month
Prior tampon use: ever used
Prior NuvaRing use: ever used
Sexually active past 2 months
Relationship status (at first IDI) C
Married
Partner, not married
No partner
Perceived risk for HIV
Randomized to TDF (vs. placebo)

IDIs: Median (range) or n
(%)
29.6 (19.4-39.4)
16 (12-22)

FGs: Median (range) or n
(%)
32.3 (25.2-45.4)
14 (13-22)

4 (22%)
8 (44%)
2 (11%)
2 (11%)
2 (11%)
3 (17%)
10 (56%)
16 (89%)
3 (17%)
17 (94%)

4 (22%)
7 (39%)
2 (11%)
1 (6%)
4 (22%)
5 (28%)
8 (44%)
16 (89%)
2 (11%)
18 (100%)

2 (11%)
10 (56%)
6 (33%)
0 (0%)
8 (44%)

3 (17%)
9 (50%)
6 (33%)
0 (0%)
9 (50%)

a

Sixteen years is equivalent to a 4-year college degree.
‘Other’ includes those who declined to answer or who responded ‘yes’ to the following racial categories: American Indian,
Alaska Native, or Native Hawaiian/Pacific Islander.
C
Relationship status does not infer cohabitation status. Participants did not systematically report on whether or not they
lived with a current partner, married or not.
b
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Table IV: Participant Profiles

Name

Age
(yrs)

Educ
(yrs)

Race

Hisp.

Tampon
Tampon
Nuva
Sex:
Rel.
BMI Group
d
use: last
use: ever ring use: last 60 Status
b,c
month
ever
days
Carly
31.0
18
A
x
x
x
M
28.3
E
Marina
31.9
18
W
x
x
x
NP
24.6
E
Celia
26.4
14
B
x
P
22.8
E
Tracy
27.3
22
A
x
x
x
NP
21.3
P
Adele
27.0
20
W
x
x
x
P
23.2
P
Nora
39.4
14
W
x
x
M
27.4
E
Laura
25.4
16
W
x
x
x
x
NP
23.9
P
Angela
36.0
14
O
x
x
x
NP
28.6
P
Rose
37.1
14
W
x
x
x
P
37.3
E
Sara
33.4
16
>1
x
x
P
26.8
E
Kerry
24.9
16
W
x
x
x
x
P
22.4
E
Madison
29.4
14
W
x
x
x
x
NP
23.5
P
Hillary
33.3
16
>1
x
x
x
NP
25.4
P
Maureen
34.9
15
B
x
x
P
28.3
P
Megan
21.1
13
B
x
P
21.8
P
Jenna
35.7
20
B
x
x
P
24.1
P
Ellen
19.6
12
W
x
x
P
20.2
E
Jamie
25.2
15
B
x
P
26.1
P
Rachelle
37.9
14
>1
x
x
x
x
P
22.5
P
Kelsey
35.3
13
>1
x
x
x
P
26.3
E
Natasha
25.7
13
B
x
x
x
M
30.3
E
Brianna
45.4
14
B
x
x
P
39.3
E
Jean
19.4
12
O
x
x
x
x
P
31.7
P
a
Race categories were collapsed to include A=Asian; B=Black; W=White; O=Other; and >1=more than 1 reported racial
category.
b
Relationship status does not imply cohabitation status. Participants did not systematically report on whether or not they
lived with a current partner, married or not.
c
M=Married; NP=No Partner; P=Partner, not married.
d
Group categories included those randomized to the (E)xperimental vs. (P)lacebo conditions.
a
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Section 3.2: Overview of the grounded theory model - Dynamic Considerations for
Acceptability and Likely Use of an MPT Ring
The main goal of a grounded theory study is theory generation.182 This dissertation
research aimed to understand multiple facets of women’s experience with and perceptions of an
MPT vaginal ring. The understanding generated from these findings informed a new conceptual
model for general MPT acceptability and use. Toward that end, throughout the research process I
used grounded theory techniques, as others in the sexual and reproductive health field have
done,189–196 to question and expand on existing models in order to produce a new theory to
understand MPT IVR acceptability among women (Figure III). Initially, my research questions
and study design were guided by Woodsong et al’s framework of microbicide acceptability,
which identifies multiple attributes of microbicide acceptability (e.g., product, relationship and
sexual encounter attributes) and nests these attributes completely within socio-cultural norms and
individual and partner preferences.208 This framework was helpful to guide study design, data
collection and early analytic thinking about iterative findings. This study expanded on this
microbicide acceptability framework to include issues of fertility and contraception that are
germane to an MPT, as well as to clarify pathways between emergent themes and higher order
constructs.
As this new model of MPT acceptability matured, it was clear that women defined MPT
acceptability as distinct from, but intertwined with, likely product use. This empirical finding
was supported by an existing conceptual framework that distinguished the potential role of
product acceptability from product adherence, as it related to microbicides.154 This model by
Mensch et al. proposed “a revised definition of acceptability that clearly and operationally
separates product acceptability from product adherence, and the factors that may influence these
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two constructs”. The Mensch model added a necessary guiding framework to my own
developing model, in that it acknowledged both a clear distinction between acceptability and
likely use in the presence of product choices and alternatives, as well as an association between
the two.154,205 Hence, the Woodsong and Mensch frameworks together helped to guide and
generally frame the ideas about product acceptability for HIV prevention, but were missing key
pieces about pregnancy prevention (with respect to MPTs) and were also missing the detailed
connective tissue that could demonstrate associations, directionality and subsequent intervention
points.
Developing a grounded theory involves multiple steps, achieved through a non-linear
process that can be sequential, overlapping and circular.186 I used the constant comparative
method to iteratively evaluate and incorporate relevant components from both of the guiding
models alongside emergent findings from this study into the developing conceptual model. The
resultant “Dynamic Considerations for Acceptability and Likely Use of an MPT Vaginal Ring”
model, therefore, reflects incorporation of components from both guiding frameworks
(Woodsong et al and Mensch et al) as well as empirical findings from primary data collection
and analysis of MPT ring acceptability.
The new model has several parts:
The Priority Triad: First is an interrelated triad, called the ‘Priority Triad’, prioritizing
oneself, partner or relationship. The Priority Triad emerged as the core process for women as
they evaluate the acceptability and potential use of an MPT ring. As the analysis of the interview,
card sort and focus group data will show in detail, the components of the Priority Triad are
dynamically (re)prioritized, (re)shifted and (re)balanced as part of the contextual considerations
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that women make toward potential ring acceptability and use. The Priority Triad drives the
complete narrative of acceptability and likely use of an MPT ring.
Rationale for Need: The rationale for need of an MPT ring refers to a woman’s
evaluation whether she needs a product to prevent pregnancy and/or HIV. This is typically based
on her fertility desires and/or HIV risk perception. For women who establish that there is a
rationale for her need for an MPT, the model demonstrates bi-directional relationships between
The Priority Triad and Episodic Considerations (below). However, when women determine there
is no rationale for needing an MPT, regardless of how acceptable a product may be, acceptability
attributes are largely irrelevant to likely MPT use.
Episodic considerations: Episodic considerations capture various attributes of an MPT
vaginal ring that women temporally consider, per life episode, as part of their overall assessment
of product acceptability and use. The distinction between Episodic Considerations and the
Priority Triad is a critical part of the model. A product may be deemed acceptable to a woman in
terms of its attributes, but commitment to use an MPT is driven by things that change, like their
relationships. For example, if a woman’s partnership status changes from being in a committed
relationship to being single, ring acceptability and likely use may change. An example of an
Episodic Consideration might include device interference during sex, which acts as a deterrent to
acceptability and further use.
Product Use Preferences: Lastly, the category for ‘product use preferences’ highlights
women’s agency in her choice of prevention method. While this study explored MPT ring
acceptability, a woman may prefer attributes or experiences associated with alternative products,
such as a barrier method, or to use no method at all.
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Together, the Priority Triad and Episodic Considerations make up what is generally
referred to as “acceptability”. These considerations for acceptability can be jointly connected to
expected product use when a woman has an identified rationale for needing an MPT above all
other prevention methods.
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Section 3.3: Detailed Model Description - Dynamic Considerations for Acceptability and
Likely Use of an MPT Ring
Introduction
In this section, I describe the components of and associations within the model,
“Dynamic Considerations for Acceptability and Likely Use of an MPT Ring,” referred to as ‘the
Model’ moving forward. There are three major components described in the model: The Priority
Triad, The Rationale for Need and Episodic Considerations. The remaining two components
(Product Use Preferences and Expected MPT Use) are necessarily integrated into the other three
and are therefore not discussed separately. The Model components are presented in the order that
best crafts a coherent narrative but does not align with the sequence in which they are presented
in the visual model.
EPISODIC CONSIDERATIONS
In this study, ‘episodic considerations’ includes three types of attributes that can shape
acceptability and expected use of MPT rings: product attributes; use attributes; and sexual
encounter attributes. These attribute types sometimes overlap and are interconnected to one
another in women’s descriptions.
Product Attributes
‘Product attributes’ refer to considerations that are specific to the product such as size,
material or dosing regimen. Although ‘appearance’ of the ring has been included here in other
research on ring acceptability

154,160,260,261

in this study it was discussed by women relative to

other themes (e.g., menstruation) and thus it is classified elsewhere.
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Size and Material
In other trials of microbicide and vaginal ring perceptibility and use, product attributes
such as circumference and thickness, texture and pliability have been examined in-depth as these
dimensions were considered critical to efficacy and user behaviors.160,260,261 In my study, by
contrast, women were not shown the ring prior to the focus groups. If they were interested in
relative size or shape prior to insertion, the parent study medical practitioners would show them
photos of a NuvaRing, which was similar in size to the TDF ring they would wear as part of the
trial. This approach appeared to assuage women’s fears or concerns; they all continued to
participate in the trial and have a ring inserted. In the focus groups, women were shown a sample
ring that they could handle, which was identical to the placebo ring worn by participants in the
trial. The placebo ring differed from the TDF ring by the amount and type of white powder
(TDF, experimental) or granules (salt, placebo) inside the ring’s reservoir.148 Using a show of
hands, nearly all of the women (16/18) reported seeing the ring for the first time during the focus
group. The dialog that ensued about participants’ real-time reactions to the look and feel of the
ring, reflected surprise to the size and hardness of a sample ring.
Angela:

What size is that?

Tracy: I would say it’s about two inches.
Adele: It looks a little intimidatingly larger than I thought it was. (FG 1)

To ensure masking, women were not able to see or touch the ring during this trial or
subsequent data collection, which included restrictions placed on self-insertion and removal.148
Because of these restrictions, exposure to the look and feel of a ring was limited to a brief
exercise during the focus group where women were shown a sample placebo ring. Still, women
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in the focus groups had strong reactions to their first visual and tactile experience of the ring.
They connected their expectations of the ring (its appearance, size and material) to their actual
personal experiences of comfort or, more specifically, the absence of discomfort. “I didn’t know
it was there” (Jamie, FG 3). Their expectations were incongruous with the actual look and feel of
the ring; women were surprised at how hard and large the ring actually was compared to what
they had imagined. They had assumed that if they could not feel it then it must have been more
diminutive.
The ‘material’ that the ring was made from did not seem to affect women in the way that
has been described in other perceptibility research about product attributes.260 In other research,
‘material’ was evaluated more for the feel and flexibility of the ring’s material to the touch or
inside the body. In this study, however, women did not identify preferences or distaste for the
ring ‘material’ as it would relate to their personal experience with the ring through touch and
feel, but instead spoke solely about their partner’s potential perceptibility and acceptability of the
ring. Women perceived their partners might object to a material that felt “unnatural” or that
could potentially cause physical problems such as “rash” or “allergic reaction.” This finding was
seen most clearly in the card sort findings; as women talked about and sorted the card “Material
that the ring is made out of,” most of their narrative centered on partner health rather than their
direct exposure to the ring’s material.

Dosing Regimen:
A key decision in IVR development is how long the ring should be left inside the vagina
before being exchanged for a replacement. Each participant was asked about the ideal length of
time to leave the ring inside her body before exchanging it, without providing contextual cues
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about the possibility that replacement could involve a clinic visit or be self-administered. Women
had clear and strong opinions but disagreed about how long a ring should remain in place before
exchanging it. Most of the women participating in the IDIs (11/18) thought that monthly
exchanges were ideal, while a smaller sub-group (5/18) preferred the ring to stay in for a longer
duration, ranging from 3-12 months. One participant had no preference and the other wanted
weekly or biweekly exchange.
Monthly ring exchange
While most women preferred a monthly ring exchange their reasons for this choice
differed. For most monthly timing was familiar and fit with their monthly menstrual cycle. These
women already calendared their cycle by a 28-day pack of oral contraceptives, so a monthly
interval was easily tied to starting and stopping birth control medication. This familiar cycle
would help them to remember that the ring should be changed and a new one inserted.
I think a month is appropriate because it’s easy to track, like four weeks long or
however long and then every month you would just be able to get a new ring from
wherever you get it from. (Kerry, IDI 1)
Other women preferred a one-month interval because they did not want the ring inside
their body for too long. Some worried that they might forget the ring was inside:
You don't feel it so it's going to be hard to remember to take it out or change it …
Because I think if it's longer, we'd probably forget about it. (Madison, IDI 1)
Some had preferences for a shorter duration of wear due to fear that the ring -- either the
ring itself or a drug inside the ring -- might deteriorate the longer it was left inside the body:
Because you’re putting a foreign object inside of your body and I think, you
know, there might be effects on it, wear and tear on the material. Because it’s
man-made material, whatever it is. (Nora, IDI 1)
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In focus group 1, the women played with some ideas about what monthly ring exchange
might entail. As part of a conversation about potentially removing the ring during a week of
menses, or foregoing menstruation altogether, the group began to talk about their feelings about
monthly menstruation. One reason many women liked monthly menstruation was that it acted as
an indicator that they were not pregnant. In the absence of monthly menstruation, there was
concern that women would be unaware of a pregnancy. Adele describes worrying about
effectiveness of the MPT for reliable pregnancy prevention.
If I were wearing it for three months straight, I would have a probably
psychological concern about whether it’s still efficacious. So there’s no way to
test them? What if something went wrong and I’m no longer protected? The next
checkpoint for that will only be in a few months. (Adele, FG 1)

This description captured women’s expressed anxiety about leaving the ring inside for an
extended period of time. The desire to bleed was a marker of trust that the ring would still be
working as intended to prevent pregnancy. For women like Adele, who wanted monthly
menstruation, a 3-month window without bleeding seemed like a long time to wait to find out
about accidental pregnancy.
For those who preferred to wear the ring for longer than one month, two separate but
related themes emerged: they preferred a provider to insert the ring because they felt
uncomfortable with self-insertion; consequently, longer wear was more convenient. In
comparison to the women who preferred a monthly exchange, none of these women questioned
ring effectiveness or durability. Instead, they cited current life circumstances; four were graduate
students who preferred the convenience of a ring that they could ‘forget about’ for anywhere
between 3-12 months.
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In the IDIs, two women explained that although convenience was still paramount, their
desire for longer duration was more closely tied to reducing the frequency with which they
would need to make a doctor visit. These two women were strongly against self-insertion
because they did not feel comfortable inserting anything into their vaginas, yet they were still
willing to use a ring if a medical provider would insert it for them. Celia was one of the two
women who stated in the IDIs that they rejected the idea of self-insertion due to reluctance to
touch her own body. She attributes her hesitation over self-insertion to familial and cultural
beliefs that stigmatize menstruation and the female body more generally. However, Celia was
open to the idea of a medical provider inserting it for her.
I wouldn't want to [insert] it for myself ….it would be like a fishing expedition
literally. And to me, I probably wouldn’t go far enough.… I’d probably just go
half-way and I’ll put it in there and it would just fall out after a while. (Celia IDIs
1 and 2)

Drug Combination: Doubling drugs
In the focus groups, the facilitator gave women a list of instructions for using an MPT
ring, to generate conversation about areas of agreement, disagreement and overall acceptability
of dosing regimen possibilities (Appendix D: Focus Group Guide). During this exercise women
expressed many concerns about the potential effects of combining two drugs inside one ring,
with a few raising the questions about whether using two drugs in combination would result in
their losing effectiveness, by in some way “cancelling each other out.” Since this hypothetical
MPT ring was not the one developed, tested or worn, women had not been given any instructions
or assurances about the potential mechanisms of action or interaction as might be the case for
women wearing an actual MPT ring. However, the descriptions women gave during the focus
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group exercise are suggestive of potential users’ acceptability prior to use, outside the context of
a clinical trial.
In both the IDIs and FGs, women were particularly interested in how they would be able
to stay protected from both HIV and pregnancy concurrently, and ultimately what would be
indicators of effectiveness. Being able to trust efficacy of an HIV preventive ring has been found
to be an important factor in product choice.262 For an MPT, this finding is escalated, such that
women questioned not only efficacy of prevention of HIV singly, but also prevention of
pregnancy. Specifically, however, women were uneasy with a possibility that their protection
from pregnancy might be jeopardized by the presence of the TDF.
While there was some discussion in the IDIs about the potential of multiple drugs
working against one another or potentially causing problems because of a possible drug
interaction, the discussions in the focus groups approached the matter of two drugs in
combination from a slightly different angle. The impact on effectiveness of the “double drugs”
themselves was questioned; does the presence of both drugs “cancel each other out”?. Further,
women in the focus groups questioned how having the two drugs was necessary for dual
protection, but the combination of the two drugs seemed like it would be incompatible with
women’s preferences for removal during menses. When these group participants were asked to
evaluate criteria for MPT ring use, they could not reconcile how a ring could provide trusted
continual protection against both HIV and pregnancy if the ring was removed at any time,
especially for a week duration while menstrual blood flowed out of the body. These data
precipitated from the exercise where women reflected on the instructions for using an MPT
Vaginal Ring; one section discussed ‘wearing the ring during menses’. A vocal majority in each
of the focus groups established that ring removal during menstruation was a leading feature that
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they wanted. Following this, they were confused about how they would be protected from
contracting HIV during menstruation, assuming they would remove the ring from their bodies
during that time.
[You wouldn’t get pregnant during menses]---not with the pregnancy ring, my
one thing is if you took out the HIV ring for your period, for those people that did
have sex while on their period, I would just be scared that they may---there may
be some kind of misconception that [they’re] still protected but [they] need to take
it out during their period and then they put themselves at risk by possibly taking it
out and then you know, participating in [sexual activity]. (Laura, FG1)
Laura is one of the 3 women who had self-inserted, used and removed a NuvaRing in the
past, so may have been primed to conceptualize an MPT ring as one that would be removed
during a week of menstruation. However, the other women in the group nodded in agreement at
this statement.

Use Attributes
‘Use attributes’ refers to experiences associated with ring use such as comfort, side
effects or even secondary benefits. ‘Use attributes’ generally differ from the forthcoming
category of ‘sexual encounter attributes’ in terms of the type of experiences women are
describing. In this section, I describe attributes of the ring that mainly are discussed in the
context of daily wear, rather than during sex. It bears noting that women themselves did not
always explicitly distinguish between these two categories (use attribute vs. sexual encounter
attribute), and therefore some of the themes within these categories appear to overlap. Therefore,
I am presenting these categories as separate but also connected with dotted lines in the visual
model.
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Comfort in Use
During the IDIs, I systematically asked all women about bodily comfort with the ring,
and there was near unanimous reporting (17/18) that they felt no discomfort while wearing the
ring. Although not asked systematically in the FGDs, there were no spontaneous reports of
discomfort among the FGD participants. The overwhelming sentiment was surprise that “[I]
didn’t even notice it was there” (Carly 2, 30). However this comfort had a downside. Seven of
the 18 women in the IDIs reported checking on the ring to make sure it was still in place, despite
being told not to insert anything inside the vagina, because they expressed concern that it may
have fallen out or become lost during the course of the study.
Megan was the only participant who reported discomfort with the ring and consistent
trouble with the ring staying in place throughout both weeks of wear.
I mean it just like slides down…. And I like can't do anything about it, so I’m
trying to cramp up like try to use my muscles to make it go back up…. And it
makes me feel uncomfortable when I got to [have a bowel movement], to like use
a piece of tissue to try to hold the ring up and go to the bathroom…. Sometimes I
lay down, you can feel the rubber. It’s like bent, so you can like feel it poking me.
(Megan, IDI 1)
It was common for women to compare the IVR to other vaginal devices they had
experienced personally or had heard about before, such as tampons or NuvaRing. “I wasn’t able
to see how big it was [prior to insertion], but I don’t think it’s that big cause you don’t feel it.
Like you know when you wear a tampon.” (Angela, IDI 1) Prior to ring insertion, however,
participant expectations were different: participants who had never used a vaginal ring prior to
the study anticipated that the ring would be noticeable during daily activities and could easily fall
out at any time. Marina compared her expectations of the ring to her previous experiences with
cotton tampons and the Instead menstrual cup.
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I know with tampons, they're cotton or whatever and so it kinda sticks in there, I
guess. Maybe it's because I had such a hard time with that Instead thing and I felt
like it wasn't staying in place, I guess I just felt like wearing something plastic in
there for a long time, it would be more likely to move around than something
cotton. (Marina, IDI 2)

In the IDIs it was clear that women interpreted ideas about comfort as having to do more
with activities of daily living rather than during a sexual act. However, the card sort allowed for
exploration of a priori topics, including further hypothesizing about comfort specifically during
sex. In the card sort context, ‘comfort’ was a use attribute that was seen as equally relevant for
the woman and man during sex. In nearly all cases, the participants grouped together the cards
for ‘my partner’s comfort during sex’ and ‘my own comfort during sex’ adjacent to one another
(typically with ‘my own comfort during sex’ being prioritized directly ahead of ‘my partner’s
comfort during sex’ card) (See Figure IV). Nearly all women (14/17) who participated in the
card sort grouped these two cards next to one another in terms of level of importance for use.
This adjacent grouping of cards regarding own and partner’s comfort during sex demonstrated
the linked importance of mutual comfort during sex with ring use. In nearly every case (12/14),
however, women elevated their own comfort during sex above that of their partner’s. (Figure
IV).
In the focus groups, participant expectations prior to ring wear were articulated early in
the sessions. The facilitator’s first prompt (following an icebreaker exercise) was “Tell me what
it was like for you to use the vaginal ring.” This opening statement was designed to invite the
discussion of the full range of participants’ lived experiences with wearing the ring during the
trial. In each of three focus groups, responses to this question included combinations of mostly
negative expectations associated with ring wear prior to insertion alongside actual experiences of
comfort wearing the ring. In the following passage, Hillary described a thought process that
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others in the group identified with, as was indicated by other participants nodding their heads up
and down along with implicit statements of agreement in the dialogue which followed. Such
indications of assent and concurrence have been identified by Morgan as a special feature of
focus groups such that the data are dynamically co-created among group participants. 257 Hillary
described her anticipated feelings of physical discomfort (which she equates to the discomfort
she feels with tampons) alongside her established ideological discomfort of wearing a product
inside her vagina.
I don’t really like to have anything in there, like I said so, just the idea of it, it
makes me feel uncomfortable, like I’m not going to be comfortable under my own
skin, so I was actually surprised when I didn’t feel anything… I swear I wasn’t
going to be able to sit properly or anything but I realize that it was all in my head.
And I know I had other friends that had the NuvaRing before and they said, no,
it’s comfortable, you don’t feel it. But you know, it’s something that I still
couldn’t---you know, get my head wrapped around until I actually experienced it
myself. (Hillary, FG 2)
The three trial participants who had used NuvaRing prior to the study reported no
negative expectations of the physical sensation or comfort of a vaginal ring (including sensation
for their sexual partners), yet their concerns over using an HIV preventive drug and related
implications were similar to the concerns of those who had never used NuvaRing.
Overall concern for the TDF drug was low for a few different reasons. First, women
explained that the short duration of wear during the trial was unlikely to impact their health.
Second, as part of the consent process to enroll in the parent study, women were made aware that
the Food and Drug Administration had already approved a form of TDF for use as oral PrEP
(marketed to the public as ‘Truvada’). That a similar formulation of the study drug was available
on the open market allayed fears about drug safety. However, a few of the women mentioned
that a longer exposure probably would have impeded their interest in using the drug inside their
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bodies. Even though the drug was available as Truvada, and therefore ruled ‘safe’ by a governing
body, there was some skepticism over the perpetuity of this safety rating:
I guess, you know, how they used to use mercury in fillings, not that there’s
mercury in this but you know, they learn things as time goes on, right?... In my
mind this is how it works—that they knew mercury was toxic for a long time but
they put such a small amount in the fillings and thought that it doesn’t leak out,
that they weren’t worried about it. But as science gets more sophisticated or we
start to understand things about biology and chemistry more you can learn things
that contradict what you previously thought. (Marina, IDI 1)
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Figure IV: Rose’s Card Sort Activity: Ranking Her Own and Her Partner’s Comfort
During Sex
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Side Effects and Secondary Benefits
The only side effect spontaneously mentioned by women in the IDIs was increased
wetness or discharge, reported by 7 in the TDF group and 3 in the placebo group, but only 2
reported distress from the amount or presence of wetness or discharge.
In the card sort, the exercise was designed to encourage women to think about all
possible types of side effects and to reflect on their meanings to them, personally. One card was
entitled “side effects” that women were instructed to sort into reasons to use or not use a ring.
This card was most often placed in a participant-generated pile “it depends,” meaning the
decision to use or not to use would depend on the specific type of side effects: whether they were
perceived to be beneficial or detrimental to the woman, her partner or to their relationship in
some way. Laura described how some side effects would be worrisome or difficult, but
anticipated other side effects might not bother her or even could provide benefits:
It would depend on the side effects…And not all side effects are bad. I mean,
maybe a side effect is I’m wetter. I have increased libido. So those are side
effects that I would be like, “Yeah, I’m totally okay with those side effects.” If
decreased libido, dryness…which can always be overcome but I guess the side
effect is the risk-benefit factor for me and not knowing which side effect it would
be I don’t know whether I would choose the ring or not choose the ring. (Laura,
Card Sort)

Side effects were critical to all the women, but it was difficult for them to classify how
these theoretical side effects would impact their acceptability, and even in the card sort it was
difficult for women to rank the card relative to other factors. Women often explained that this
was because there could be a range of side effects, some of which might be more or less difficult
to manage. Those would need to each be evaluated in the context of all other factors.
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Some of the side effects that women identified as potential barriers were also considered
a possible secondary benefit depending on the circumstances. These secondary benefits included
features akin to some of the benefits women were already receiving from their contraceptive
methods. Women named benefits like being protected against ovarian cancer, clearing up acne,
and regulating menstrual cramps that would make a ring more acceptable to women. Both side
effects and secondary benefits were discussed in the context of the interviews and card sort but
were not a topic of discussion in the focus groups.
Impact on future fertility
All of the women in this trial were trying to avoid pregnancy to some degree and were
taking oral contraceptives as a prevention mechanism. They were all of childbearing age, but at
different stages of reproduction. A few were clear that they had completed childbearing, but most
were either considering an additional child or imagined that they would have a first child at some
point in the future. For the women who had not yet completed childbearing, they reported strong
sentiments that acceptability of an MPT ring would be contingent upon their fertility not being
impacted in any way. Additionally, women wanted assurance that upon discontinuation, their
return to fertility would not be delayed.
I want to finish school in a year and you’re thinking about having a baby after or,
you know, start your job for that first year, you want to---you and your partner
decide that you want to get pregnant, what’s going to be the, you know, the long
term effects of getting pregnant? Their biological clock is ticking… is it going to
be a year, two years, three years before I can conceive? (Maureen, FGD 2)

While some participants spoke about fertility and return to fertility in the context of the
interviews and focus groups, most of the data supporting this theme was generated during the
card sort in response to two different cards: ‘side effects’ and ‘Will not affect getting pregnant in
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the future.’ In the card sort, because there were pre-determined card topics that women were
asked to reflect upon, all of the women were asked to think through the different ways that
specific side effects and possible future pregnancy might impact their decision to use a ring.
Because of these cards, women were able to comment on this attribute even if they had not
organically brought this up in the context of the interviews. Women highly valued a ring that did
not interfere with future fertility. This was evidenced in the card sort where 10 of the 17 women
ranked the card “will not affect me getting pregnant in the future” within their top 4 reasons to
use a ring. Hillary describes her rationale for ranking this attribute as the single-most important
reason for her.
Yeah, that would be a reason to use it because right now I don’t want to have
children right now, but in the future, I’m open to [pregnancy] so I would want to
have something that’s not going to be affecting me negatively and in a way that I
won’t be able to have children. (Hillary, Card Sort)

Menstruation:
Menstruation was discussed as a key episodic consideration affecting ring acceptability.
Different from other episodic considerations for acceptability, menstruation considerations were
not limited to a single set of ring acceptability attributes (product attributes, use attributes or
sexual encounter attributes), but rather it crossed all three of these attribute categories. I am
arbitrarily presenting the theme of ’menstruation’ as part of the ‘use attributes’ section of this
dissertation, but it could be equally discussed within the ‘product attributes’ or ‘sexual
experience attributes’ section as well. Menstruation emerged as a factor toward acceptability in
two main ways: as it was related to keeping the body ‘clean’ which precluded wearing a ring
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during menstruation, as well as desires to menstruate at different intervals if wearing a ring. The
two factors were highly intertwined in women’s descriptions.
Participants did not menstruate during the two weeks of ring use but were asked about
what they anticipated it might be like to menstruate with a ring in place every month. In the IDIs,
nearly half of the participants (8/18) expressed no concerns about wearing the ring during
menstruation, while the remaining 10 women did report worries that would prevent them from
using an IVR during menstruation. The card sort data echoed this clear divide within the sample
of those women for whom menstruation considerations generally “did not matter” vs. those for
whom menstruation factors limited their acceptability of a ring.
In both the IDIs and FGs, about half of the participants said that because they would not
wear the ring during menstruation it was a deal-breaker in terms of acceptability and use; the
other half cared very little to not at all. However, in the card sort, these concerns fell to lower
priority levels than they were seemingly expressed in the IDIs or FGDs. For example, we can see
Rose’s card sort where she ranked the cards “The ring will stay clean” and “The ring won’t get
menstrual blood on it” as having lower importance in her likelihood to use a ring (See Figure
IV). Among the other women participating in the card sort, these two menstruation cards tended
to get clustered together (potentially identifying a sub-theme connecting menstruation and
cleanliness) and were ranked certainly near the bottom of all reasons to use a ring for nearly all
of the women. In other words, menstruation was a factor in ring acceptability, yet when
considering it in relation to other potential factors, menstruation held less importance than when
women discussed it relatively independent from other factors as they did in the IDIs or FGD.
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Ridding the body of menstrual blood: the need to be ‘cleaned out’
The most common reason cited for not wanting a ring during menses was that menstrual
blood was perceived as ‘dirty’ and could cause ‘infections’ if its exit from the vagina was
obstructed by a ring in the vaginal canal. Women perceived their bodies as being naturally
programmed to expel menstrual blood monthly as both a typical and natural process that should
not be interfered with. They described the process of menstruation as a cleansing ritual which
supported the body’s natural way of ‘flushing out toxins’ and ridding itself of any unnecessary
‘waste.’
Women did not like the possibility of the ring would change appearance in the presence
of menstrual blood. When interviewed about this, Rose and Megan discussed the reasons for
their disgust, as it being ultimately tied to hygiene and maintaining good health.
“So everything is like coming out of your body the ring should come out too. It
would be really nasty to have something that’s had menstrual blood all over it and
then…yeah. I would feel like dirty and stuff like that.” (Megan, IDI 1)

“[The ring] would absorb [blood], and if it's too much it would cause an infection
or something. You shouldn't really have something, you know, blood stuck up in
there.” (Rose, IDI 1)

Therefore, these women explained that having a device inside the vagina while the body
was trying to rid itself of unhealthy or unnecessary material would potentially cause health
problems such as infection if the blood was somehow ‘caught’, ‘stuck on’ or ‘stained’ the ring.
In the middle of a discussion about this topic in focus group 1, Nora blurted out the word
“skevatz”, a derivation of an Italian word for ‘disgusting’, to capture the conversation in one
word. In the focus groups and IDIs, menstrual blood stains on the surface of the ring were
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described as unacceptable to many women. Previous ring trials, where women were instructed to
leave it inside the vagina during menstruation, found that women removed their rings during
menstruation to clean their vaginas.152,153
Aligning intervals of menstruation with ring exchange:
During each of the focus groups, I introduced the topic of desired frequency of
menstruation. Within each of the three focus groups, there were two distinct groups of women
that formed: one group that wanted to menstruate monthly, and the other group that wanted to
menstruate over differing intervals ranging anywhere from three months to never menstruating.
This breakdown was fairly similar in the IDIs as well. For those who preferred less frequent
menses, they typically pointed to reducing the logistical burden and “mess” involved in
menstruation. They liked the idea that an MPT ring might be designed to elongate the interval
between menses to be longer than one month. For women who preferred monthly bleeding, there
was a wide range of reasons given including verification of not being pregnant, cleaning the
body of “waste” regularly and maintaining a schedule that could be anticipated.
In FG1 for example, Adele, Angela and Marina formed one group who were vocal
opponents of monthly menses. In contrast, Rose and Nora formed a group in which they were
proponents of it. Rose and Nora refined their positions about why they preferred monthly menses
including “not feeling normal,” a desire for “feeling refreshed,” and it being “natural for all that
discharge to come out,” as they exchanged reasons for frequency preferences with Adele, Angela
and Marina. In the following exchange, Angela and Rose engage in a dialogue that highlighted
their divergent attitudes about the desired time interval between menses.

84

#1: Angela: I would prefer that way to only have your period four times a year
because I don’t like periods. I hate them. I hate them with a passion.

#2: Rose:
I would prefer to get it every month because I’ve been on a pill that
I got it every three months and I didn’t like it.

#3: Adele:

Was there a major thing that you didn’t like about it?

#4: Rose:
I just didn’t like it. It didn’t feel normal, maybe the hormones
maybe in the pills in everything, different type of hormones that made me not get
it for three months. I was still spotting in between so it’s not like you don’t get it,
so what’s the point then?

It is important to understand here how these data were produced or ‘co-produced’, so we
can identify the benefit of the focus group method toward these findings.

257

This coding

approach compares each subsequent participant statement to the previous, to identify a range of
possible directions where the conversation might flow. Applying Morgan’s co-production of
interaction coding scheme here, we can see how this conversation between Angela and Rose
(and facilitated by Adele) opened deeper exploration of how menstruation is clearly connected to
desired intervals for product exchange.
At first (#1), Angela firmly states her distaste for menstruating without much explanation
(although she does explain later that she “hates” menstruating because of restrictions on her daily
living and sexual activities), justifying her desire to menstruate less frequently, “four times a
year.” Rose’s response to Angela (#2) then differentiates Rose’s perspective about monthly
menstruation from that of Angela’s, both expanding on what Angela first established but also
comparing it to her own experience of having used a contraceptive pill that was designed for her
to menstruate every three months instead of every fourth week. In Rose’s response, she explicitly
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differentiates her own attitude towards menses from Angela’s. Following Rose’s response, Adele
then prods Rose (#3) to give more detail about Rose’s experience with this 3-month interval.
Rose complies (#4) and expands upon her own previous statement (#3): Rose first mentions (#4)
hormones made her feel not ‘normal’ and then connects back to Angela’s expressed distaste,
adding that she was also breakthrough bleeding during the months when she was not supposed to
be bleeding.
In the focus group forum, Rose is able to clarify her reasons for wanting monthly menses
through the narrative that she develops to respond to Angela, who had a conflicting viewpoint to
hers originally. Rose supported (#4) her position with evidence from her own lived experience.
Further, in an effort to support her own stance Rose circled back to implicitly agree with Angela
(#1) about breakthrough bleeding as a deal-breaker reason for not wanting an MPT with longer
than monthly menses intervals. Breakthrough bleeding was not something that Angela had
experienced, but it was also not favorable to her. Rose’s determination to explain why she felt
differently from Angela about desired intervals, exposed another component of acceptability that
had not emerged previously from Rose on her own. Thus, Rose’s ultimate point about disliking
breakthrough bleeding was produced in response to Angela’s perspectives and would not have
emerged on its own. This interaction between participants therefore encouraged new and more
detailed data to emerge that might not have in the context of an individual card sort or IDI.

Limiting foreign objects in the vagina
There was some concern that the presence of a ring might cause additional distress during
the menstrual cycle in which women were already experiencing discomfort, such as menstrual
cramps, bloating or restrictions on daily activities or sexual activity. In focus group 3,
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participants discussed their worries over the potential for a ring worn during menses and how
they might not want to take the chance of worsening their menstrual symptoms. Brianna captures
this concern.
I’m feeling all the menstrual cramps that I never knew existed so if it’s going to
make me feel uncomfortable even more during that time –I would probably don’t
want to go through any more uncomfortableness. (Brianna, FG3)
Menstruating with a ring also posed some ideological challenges for women who used
tampons. “Crowding” the vagina by using a tampon and a ring simultaneously was a deterrent
for use during menses, described by one focus group participant as “a double whammy”. In a
recent study of a PrEP-only vaginal ring, participating women experienced displacement and
expulsion of a vaginal ring with tampon use during menstruation.262 In this study, women
worried about this exact thing, questioning if tampon insertion would somehow move or displace
the ring or vice versa, causing discomfort or expulsion of either product. For the tampon users in
this study, this consideration was prominent.
Just it shifting if you put a tampon in there - it might shift. You know, too many
things up in there. (Rose, IDI 1)
One respondent questioned the impact of menstrual product use on effectiveness of the
drugs inside the ring to prevent HIV or pregnancy. Specifically, she noted that since tampons are
intended to soak up blood, there was potential for the tampon to soak up drugs emitted from the
ring, limiting its intended function.
If I were to get my period I would want to use a tampon, and I would be
concerned about putting the tampon in with the ring for fear of the tampon
absorbing whatever the ring is giving off. (Laura, IDI 1)
In the focus group discussions, women went into more depth about concern of using the
ring alongside tampons and other vaginal products. While most of the women disagreed that
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tampons could ‘soak up the drug’, there was some concern that other vaginal products might
interfere with expected effectiveness of the drugs inside the ring. Natasha said:
I’m a product user, too. I’ll use douches and there’s other you know, different
items I guess with my husband. You know is that safe? Can I use that during the
ring? You know different types of jellies. Will it make the product ineffective?
(FG 3)
In addition to questioning a possible reduction in drug effectiveness due to vaginal
product use, the use of tampons made the women especially uneasy, even comparing it to
potential side effects from tampons alone. These concerns came mainly from the women who did
not regularly use tampons.
There’s certain side effects to using the tampon. You have the toxic shock
syndrome and there’s already that worry that if you know, don’t use a tampon
properly or keep it in there too long. It might be overwhelming. (Natasha, FG 3)
A few of the women in the focus groups agreed with one another (Natasha and Kelsey)
about a negative impact of leaving a tampon inside for too long and extended that concern to
leaving a ring inside the body for a long time period. In 2 of the 3 focus groups, participants
discussed the possibility of getting toxic shock syndrome (TSS) as a deterrent to their own
tampon use during menstruation. They equated the possibility of getting TSS from a tampon with
the possibility of getting TSS from a ring and were therefore disinterested in using a ring during
menstruation for fear of TSS.
The card sort activity was the only method that generated no data about ‘crowding’ in the
vagina. As the developer of the card sort, I did not recognize this as an important dimension of
the broader ‘menstruation’ domain until the card sort data collection had been completed; it was
only during focus group data collection and retrospective analysis of the IDI data that the
crowding dimension became clear. Additionally, it is important to call attention to the fact that
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participants also did not develop a card to represent the crowding dimension spontaneously
during the sort. The absence of this card suggestion may be related to crowding being a more
distal theme for participants, and one that might not occur to women in the absence of the
sensory experience related to actual product use and physical crowding; this should be studied in
subsequent studies of acceptability of an MPT ring specifically if designed to be worn alongside
other intravaginal menstrual products.
Abstinence precludes the need for protection
Some participants preferred not to engage in vaginal sex during menses because they saw
it as being “dirty” or “messy.” It has been noted in other research about menstruation and sexual
intercourse that women’s abstinence during menstruation is a deeply entrenched cultural and
social expectation in some communities, such that women can be branded as “unclean” and
physically or spiritually hazardous.263,264 In this study, women only discussed this theme in the
interviews, not in the FGs or card sort). Angela rationalizes this cultural expectation as justified
because nothing (including a penis) should obstruct the outward flow of menstrual blood.
It doesn’t sit right with me to be bleeding and have sexual intercourse. I wasn’t
taught to do that or raised to do that and I just think that’s when all our bacteria
is… that’s when all the bacteria that we have carry in us is being discharged. So
why would I want it to cause like a back-up or something?
(Angela, IDI 1)
Women who practiced abstinence during menstruation said they had no need to wear the
ring during menses because they would be at no/very low risk for getting pregnant or contracting
HIV through sexual transmission.
I don't like to have sex during my cycle. So why would I have it on anyway? It's
just supposed to prevent HIV that's when you normally have it on when you're
about to have intercourse so during my cycle I don't have intercourse for sure. So
that's why I would take it off and then I put a new one in right after my cycle is
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done and then take off. So it would be every month I guess or every 28
days.(Hillary, IDI 1)
Some participants thus assumed that the protection conferred by the ring could be
episodic, not continual, and removal during menstruation would be an expected feature. This
theme of abstinence precluding the need for a prevention device was not solely limited to the
time during menses, but also extended to include abstinence in general.
Sexual Encounter Attributes
‘Sexual encounter attributes’ of a ring include aspects of sexual episodes that potentially
shape acceptability of the ring for the woman, her partner or their relationship. While these
attributes were originally conceptualized only in terms of the ways the ring might negatively
‘interfere’ physically with the sexual encounter, instead a more positive outcome ‘sexual
pleasure’ emerged as a clear theme for women within each of the three types of data collected. In
general, sexual experience attributes were discussed with great emotion, but were limited. This
was potentially a function of the hypothetical nature of the inquiry, as women were asked to
refrain from sex during the course of the study.
Sexual pleasure
Sexual pleasure was discussed as a basic requirement for overall ring acceptability and
product use but was discussed in more abundance and depth during the card sort than in the other
data collection forums. Consistent with the trial requirements, all of the participants reported
refraining from vaginal, anal or oral sex during the study period. However, women were asked to
comment hypothetically on what they anticipated the experience of having vaginal sex with a
ring might be like. There was a clear connection for women relating sexual pleasure and physical
comfort. Most women assumed that they would not feel any discomfort or pain during sex from
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the ring, however their partner’s physical comfort was discussed as being just as important as
their own. But it was not just the avoidance of discomfort that concerned women, it was also the
ability to prioritize and enjoy sexual pleasure, both personally and together with a partner.
If my partner is not comfortable sex wouldn’t be pleasurable for both of us. Being
intimate, that’s something you share together.” (Carly, IDI 2)

I can’t be bothered. You know it’s going to be uncomfortable for him and
uncomfortable for me, and I just want to enjoy the sex. I just don’t want to have
to think about it. What if he doesn’t like it? And then it’s going to get
interrupted. (Natasha, FG 3)

Reciprocity during sex was a common theme; ultimately, sexual pleasure was
compromised for women if their male partners were distracted or uncomfortable. Sex was
described as being “good for both of us or it’s not good at all” (Laura, Card Sort). If reciprocity
of intimacy were interrupted, women were clear that they would not want to use the ring and
would remove the ring, even if only temporarily during the sex act (Figure IV).
Interference with (or facilitation of) sex
The introduction of a foreign object or substance into a sex act was previously noted as
one reason that women posited the ring might interfere with intimacy. While there were
questions about the potential for the ring to cause physical interference in a sex act, most of the
conversation regarding theoretical interference was related to secondary effects of ring use such
as increased wetness or discharge and were contextualized, respectively, as a facilitator of or
barrier to vaginal sex. More than half (10/18) of the women reported actual increased wetness
from ring use, which was generally viewed as a benefit for providing extra lubrication during sex
for women and their partners. “Extra wetness is never a bad thing…you just can’t go wrong with
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lubrication”. (Sara, IDI 2) A clear distinction was made, however, between wetness and
‘discharge’ in the card sort, so much so that when Laura was contemplating where to place a card
labelled “discharge during sex”, she talked through her thought process and eventually generated
a new card entitled “wetness during sex”. While wetness was described as a clear and familiar
substance that the body made naturally, discharge was considered to be unfavorable, as it would
disrupt the natural experience of sex and have a negative impact on intimacy.
It’s not necessarily always bad but when I think of discharge I don’t think of
normal wetness. I think of actual discharge and if I were to be having sex with
my boyfriend and he were to want to get me closer to coming I don’t want him to
go down there and say eat me out and have more vaginal discharge that then
makes it an unpleasant experience for him during sex. (Laura, Card Sort)

Carly went further to question how discharge could be potentially related to the drugs
used in the ring.
The ring is giving out something. It’s releasing something. If it’s going to be like
a different discharge, even if it’s going to mix, like with the semen and the vagina
discharge, like if there will be a smell, if there will be an odor, a different color. If
that’s going to turn the mood on or off while, you know, using the ring? (Carly,
IDI 2)

In FG 1, the opening conversation mirrored Carly’s concern about discharge she
perceived as due to the drug inside the ring. Two of the women talked about having extra
wetness and discharge and questioned if that was indicative of wearing an experimental ring that
“put out” the drug into their vaginas (as compared to the placebo group). In one set of exchanges,
Angela, Rose and Nora wondered aloud if their excessive wetness and discharge was due to the
TDF drug being released from the ring into the vagina. Marina countered that possibility by
suggesting that the discharge may have occurred from the presence of the ring device itself, but
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Angela, Rose and Nora instead settled together on the explanation of drug release as the cause.
This may have implications for how women believe they can decipher effectiveness of a device
in the future: if they experience discharge, then the drug must be present and working whereas
absence of discharge indicates lack of effectiveness (FG 2).v
In the card sort, ‘wetness during sex’ held value for most women as a component of their
sexual experience, yet they distinguished it from discharge. When women spoke about how
much discharge mattered to them, however, the distinction was less profound than indicated by
women in the FGDs or IDIs; women expected and were satisfied to experience wetness during
sex and would not be happy to experience ‘discharge’ during sex. When challenged to rank the
presence of wetness or discharge as reasons to use or not use, these two factors were
idiosyncratic across the group but neither card (wetness or discharge) rose to a high level of
importance to use or not use a ring.
The prioritization of sexual experience was one of the tightest cluster of cards in the card
sort, meaning that these cards in this category all hung together more closely than any of the
other a priori categories (See Table II). Further, this category of sexual encounter attributes
always ‘mattered’ to women to some degree, indicated by these cards always being chosen for
the second ranking exercise. In sum, women described that if the ring did not interfere with sex
and sexual pleasure, then that would be a reason to use it, and conversely, if it did interfere with
sex or sexual pleasure, then that would be a reason not to use it.

v

All researchers in the parent trial and this qualitative study were careful to maintain participant
masking throughout the trial and at all data collection points to discourage potentially false or
otherwise influential conjecture among participants.
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If you are sleeping with someone you’d be very conscious of that person feeling
the ring inside of you. Like there would be lots of oral sex and fingering tonight, I
do not want a ring inside me. That would be a reason to take it out for a short
period. (Adele, Card Sort)

However, it is important to note that these reasons were not ranked as top priorities to use
or avoid a ring. Rather, they tended to hang somewhere in the middle of the rankings of
importance for women. Potentially this reflects an idea that a device that is used for prevention
of pregnancy and HIV should not impact the sex act; but the middle-of-the-road prioritization of
sexual experience relative to other factors suggests that women would value effects of the device
on sex a moderate amount.
THE PRIORITY TRIAD: PRIORITIZING THE RELATIONSHIP, PARTNER OR SELF
I explored how relationship dynamics between partners could impact ring acceptability
and use. It was this factor that generated the construct of the Priority Triad. Acceptability and
likelihood of ring use depended on circumstances that were quite distinct from the episodic
considerations just discussed and reflected sometimes competing priorities: those of the
relationship, the partner and the woman herself.
All three types of data clearly demonstrated each of the three individual components
within the triad, but the focus group data were the first to ellucidate the connections between the
components of the Priority Triad. The emergence of a new concept around balancing priorities
led me to return and further investigate how it played out in the card sort and interview data.
Across the three data collection methods, women identified interconnections within this triad of
priorities such that what might impact her priorities could subsequently impact the health of a
partner or the relationship. The reverse was also true. The concepts hence became multidirectional and intertwined. The forthcoming sections describing the three components of the
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Triad are presented in 3 mutually exclusive sections both for clarity of presentation but also to
stay close to the way that women generally spoke about each, as distinct priorities, despite
acknowledgment of their overlap.
Prioritizing the Relationship
Relationship type and the complexities of ring disclosure
The use of devices such as an IVR does not require prior consent from partners, but
women’s decision-making process about device disclosure can be complicated.157 I asked women
to talk about if and how ring disclosure to a partner might transpire. Nearly all women said they
would talk to a partner about the ring prior to sex with the ring in place, and the ultimate decision
would involve what was “best for the relationship,” even if it only factored to a small degree in
the decision-making process. These decision-making conversations, however, were anticipated in
different ways.
In the interview context, ring disclosure was described as being deeply dependent on
relationship status and type. Hillary explained the nuances of disclosure based on the dynamism
associated with relationship status and type, specifically, of being in a long-term, serious
relationship vs. a new relationship.
The thing with my boyfriend, yeah I would tell him right away because we are
sexually active. If it’s just somebody that I’m dating, I just met, I don’t really just
jump in the sack with anybody that I wouldn’t tell them there’s [some]thing in my
vagina … Yeah, so it depends on where I am with [a partner]. (Hillary, IDI 2)
During the course of the study Hillary rekindled a relationship with a long-term
boyfriend, and shared the complicated but focused scenario of how trust, ring disclosure and
relationship status interacted. She explained that if she used the ring without having told him,
and he felt it during intercourse, she feared she would lose his trust because he would expect to
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have been involved with the decision to use it. However, Hillary went on to explain that in a new
relationship she might choose to conceal a ring at least initially, mainly because calling attention
to the presence of a ring would imply promiscuity and potentially ruin the spontaneity of sex
early in a relationship.
I wouldn’t mention. It’s kind of the same way of saying, ’Oh I have condoms in
my purse.’ It’s implying that, ‘Yeah, you’re a good candidate for me to get laid
with,’ and I don’t want to give that impression because it’s not something you
plan…and I don’t want to give out the idea that I am going to jump in the sack
with you right away. (Hillary, IDI 2)
However, not everyone would conceal the ring from a new partner. Angela described
how non-disclosure would preclude the possibility of transitioning into a more serious
relationship status at some point in the future.
You know, some people would be like, ‘Well, I don’t want to see you
again…why did you lie? Why didn’t you tell me you had something? What’s it
for? Do you have a disease?’ You know, all things could run through their mind.
(Angela, IDI 2)
Laura further explained how transitioning from a new relationship to a more established
one would warrant disclosure. Uncomfortable situations in a new relationship would be
exacerbated by concealing ring use, which would make it awkward to explain after sex had
occurred and more difficult to establish an open and trusting relationship moving forward.
Like if you’re on a first date and it’s already uncomfortable or like on a third date
and it’s uncomfortable already, you might be like “Oh, this is uncomfortable.”
What if he feels the ring? What if he finds out I have that ring? How is he going
to react? Like this is already uncomfortable as it is, I don’t want to make it more
uncomfortable. (Laura, IDI1)

In FG 1, Marina, Rose and Angela discussed how wearing a vaginal ring without
disclosing it to a long-term partner could cause trouble for a woman during sex. “She might be
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afraid of his reaction.”(Marina, FG1) When the facilitator asks them to clarify what type of ring
they were talking about, Adele went further to refine that different rings could provoke different
responses from a long-term partner:
I think any HIV ring will cause more conflict than a pregnancy ring. Even if the
pregnancy ring is actually a dual ring. . . Whereas an HIV ring, he’s like, “Either
you’ve been sleeping around and you’re worried about getting infected or you
think I’ve been sleeping around.” So either way I could see a potential partner
becoming more upset at an HIV ring. (Adele, FG 1)

In the card sort, I examined ranking patterns among the disclosure-specific cards in the
‘relationship’ category (“I would not need to tell my partner this ring prevents HIV”; “I would
not need to tell my partner this ring prevents pregnancy”) to determine the relative importance
that women placed on these relationship-communication considerations for overall acceptability,
as compared to other considerations or categories. While women expressed strong feelings about
covert use
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or ring disclosure within a relationship in the context of the interviews and focus

groups, they ranked these disclosure considerations as having relatively less importance when
reported in the card sort activity. Specifically, regarding ring disclosure within the relationship,
over half (9/17) of the women ranked the potential for non-disclosure as ‘not matter[ing]’ to their
decision-making process for using a ring.
Women also acknowledged that both the presence or lack of partner support would guide
her ring acceptability and use during their relationship. When examining the placement of the
card ‘my partner supports my choice to use this ring’, 13 out of 17 women stated that her partner
supporting her choice to use the ring would matter to her ring use decisions, potentially
indicating that women wanted their partners to be involved with the decision overall. “If he's in
support, it just makes it a little bit easier to use.” (Jenna, Card Sort)
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Partner communication
Women went further to explain that ring disclosure was viewed as just one element
within the larger experience of overall partner communication about sex and reproductive
decision-making that affected ring acceptability. Megan explains that wearing a ring to prevent
pregnancy should be considered a marker of necessary trust within a sexual partnership. She sees
pregnancy as a critical decision that should be part of a couple’s reproductive plan, and one that
requires communication to execute.
I would tell my partner it prevents pregnancy because if we’re not planning on
having a baby or the partner don’t want a baby, I would definitely tell him. Like
you're not ready to have kids, both of you all, you guys should talk about ‘oh this
protects you against getting pregnant.’ I mean it’s not a negative thing to tell
somebody. (Megan, IDI 2)

In the focus groups, participants acknowledged that committed or married couples should
absolutely discuss the possibility of getting pregnant as part of the future planning of the
relationship. However, the decision to use a ring with contraceptive properties would be
predicated on both partners’ comfort with overall communication about the topics of sex and
family planning in general, not just specific to ring use.
So if that lack of communication was there, [if] we never even spoke about birth
control or any of you know, anything concerning that, I would be either hesitant
to make a move or I wouldn’t make a move at all until the time is right, and I
guess up until that point we’d be using condoms. (Natasha, FG 3)
A couples’ lack of communication about sex and childbearing was discussed as a
potential indicator of poor prospects for the future of their relationship as well as a warning sign
of lack of fidelity within the relationship.

Some women believed that lack of partner

communication would justify use of an MPT ring to avoid the unknown and “undiscussed”
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issues of potential pregnancy or HIV risk. In the context of a relationship where the desire for
children or HIV risk/status were not discussed, these women believed ring disclosure was
optional but unlikely. Others expressed an alternative view: that lack of general partner
communication would preclude ring use. These women described situations where partners
would have sex regardless of communication or joint decision-making about using protection
against HIV or pregnancy.
In focus group 3, there was an exchange between Natasha, Brianna and Jamie, wherein
they described different ways that a couple’s communication could impact MPT acceptability
and use. Brianna contended that, in the face of poor communication with her partner, a woman
would proactively evaluate her own preferences for avoiding pregnancy and HIV. Brianna’s
rationale gave prominence to a woman prioritizing her own health, after carefully evaluating her
risk level within her relationship and within her community. Jamie and Natasha maintained a
competing perspective explaining how both partners within the relationship were responsible for
and expected to communicate about their desires and concerns regarding pregnancy and disease
prevention to jointly decide on an appropriate prevention device or not.
Like with me and my husband, I wouldn’t make a move concerning [an MPT
ring] if we didn’t discuss it and I get the approval and his opinion of it. We
agreed collectively that the pill was the best thing for us. . . So if we wanted to get
pregnant we would have to wait for it to wear off. (Natasha, FG 3)

Jamie describes communication as a function of a strong partnership and, in the absence
of communication, it would be difficult to make any decisions about ring use for contraception or
for HIV prevention. Further, it would also be difficult to effectively evaluate one’s own risk in
the absence of information communicated from a partner.
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That’s like going from zero to one hundred, not talking about sex and not communicating
to ‘hey, I would like to try this NuvaRing that dispenses HIV, preventative medication’. He’s
going to look at you like you’re crazy because we don’t have that open dialogue. There isn’t that
comfort of talking about sex, of talking about feelings. So to jump from that to ‘hey, I would
like to introduce this’, he’s going to look like ‘huh?’. (Jamie, FG 3)

Using a ring primarily for HIV prevention is inconsistent with assumptions of fidelity
A clear threat to ring use is the perception that using a ring might imply mistrust and
infidelity to a partner. In a long-term relationship, wearing a ring could be interpreted by a male
partner that the woman cannot be trusted to be faithful, and that the ring might even increase the
likelihood of her cheating and engaging in behavior that could transmit HIV.
If you were wearing a ring that prevents HIV and you have a partner, they may
think the worst situation which would be you are wearing an HIV ring because
you could potentially be sleeping with other people and you’re just trying to be
careful but that may make them feel insecure and question your motives of why
you’re wearing it. (Tracy, IDI 2)
Conversely, using a ring could imply that a woman did not trust her male partner’s
faithfulness.
I think my current boyfriend would question why am I using a ring to prevent
HIV and him knowing that he’s negative and he knows my status too. He’s like,
‘Well what’s the point of using it if we’re just going to be monogamous together?
It implies to me . . . that you might just want to fornicate and do your thing with
other people and have that as a preventative measure from you getting the disease.
So that would be a reason not to use it just because of what he might think about
it. (Hillary, IDI 2)
For women already in a serious relationship where fidelity was assumed, initiating use of
condoms or other disease-prevention devices like an MPT ring would challenge fundamental
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tenets of trust. This dynamic, whereby relationship trust precipitates discontinuation of disease
prevention behavior, is corroborated in literature on other methods such as male and female
condoms and, more recently, Truvada.104,265,266 Nora discussed her marriage, and how they are
open communicators. Yet still, as she noted above, it would be difficult for her to communicate a
justified rationale for wearing a device solely for the purpose of HIV prevention.
If all of a sudden I came home and said ‘Oh honey, this thing has HIV
[prophylaxis]…?’ He wouldn’t be angry but he would just be like ‘We’ve been
together for so many years. Why all of a sudden would there be a need to have
HIV protection?’ It might be strange to bring up in the middle of a relationship,
especially marriage. I don’t know. It might throw a red flag up. (Nora, IDI 2)

In the card sort, when women were asked to rank the importance of how their partner
might perceive her fidelity to him, this sentiment was ranked as less important relative to other
considerations. Looking specifically at the placement of the card ‘my partner might question if I
am faithful’, over half (10/17) of the women stated that this would be an irrelevant factor to
them. Of the remaining seven women who ranked this as a reason not to use the ring, three of
them ranked it as the least important reason not to use it.
Prioritizing the Partner
Protecting men’s health
Implicit in their participation in the ring trial, women understood that they were assuming
a certain level of risk to their own health by testing ring safety, and they were well informed by
study staff of risk to their own bodies associated with wearing an investigational drug device.
However, women expressed concerns that if they used the ring during sex, their male partners
would be exposed to a drug without their explicit consent. Women thought this would leave men
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vulnerable to harm in some way if they were unknowingly exposed or not fully informed about
risks. Health concerns for men included allergy, rash, infection, side effects, or more generally
how they would react to medication coming in contact with their penis.
I mean he would have a right to know that I’m using a product that kills the HIV
virus and what the effects are. I mean, you know, he may have a different medical
history. I mean obviously his medical history is different from mine. So
something that may not affect me, could affect him. (Nora IDI 1)
Health concerns for male partners were only limited to the TDF medication component in the
ring, as women did not express concern for exposure to contraceptive drugs.
Women also worried that even the possibility of negatively impacting a male partner’s
health would cause negative consequences for their relationship. Sara explains below that any
negative impact on her partner’s health would cause her distress both from her partner’s anger
and from her own sense of guilt for negatively impacting his health.
I know tenofovir is FDA approved but then you never know what people are
allergic to and what they’re not allergic to. I don’t want to be responsible for that
because I’ll never hear the end of it, trust me, never. If I were to have sex and he
had a break out down there or god forbid some type of reaction that maybe he
needed to be rushed to the hospital, no way. . . I would feel bad. (Sara, IDI 2)
By contrast, some women framed ring use as a way to preserve men’s health and wellbeing. Keeping oneself safe from contracting HIV or getting pregnant was a way for a woman to
ensure that her partner did not contract HIV from her or face an unplanned pregnancy either.
“Hey buddy, I’m protecting both of us here.” (Maureen, FG2)
Prioritizing the Self
Demonstrating agency to protect personal health
Seemingly in contrast to the strong narratives about joint decision-making around ring
use just described, this next section showcases women’s clear statements of self-determination to
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keep themselves free from HIV or pregnancy, even in the face of partner dissent. “Being in
charge of my own body” was a strongly held value echoed by women in all relationship types
and statuses.
I would tell him that he would have to live with it. Because if I really like the ring
and I feel safe with it and I want to use it, I'm going to use it. Because I feel like
it's about me. It's about our relationship. It's not really about him. It's about me. So
I should be able to make my own choices about myself. (Ellen, IDI 2)
Here, Tracy aims to reconcile the contrast between prioritizing women’s health over the
health or desires of a male partner.
I think at the end of the day it’s really the woman’s decision what she wants to
use to protect or not protect herself. So, I’m a firm believer that it’s up to the
woman. So I would think my partner would, can weigh in but I don’t think he
would have much of an influence unless he provided a better option. (Tracy, IDI
2)

Nora held multiple and sometimes competing perspectives about the relative importance
of her own vs. her partner’s considerations for acceptability and use of a ring. In the early part of
her second interview, Nora said of her partner’s health was a strong factor in ring disclosure and
use. Later in the interview, however, Nora described her own agency as being primary in terms
of acceptability and choice of using the ring. She asserted that as long as the ring would cause no
physical harm to her husband, a diabetic, her desires would ultimately win out.
I mean I feel like it’s my body and it’s too bad for you, to be honest with you.
You know, if I’m telling you and it doesn’t interact with anything that you’re
taking, unless it affected him in some way, if maybe he had an allergic reaction or
he had a bad reaction, then I would discontinue it but if there was no effect on him
and this worked for me, it’s my choice. (Nora, IDI 2)
Women prioritized their own health and agency over that of their partner’s or their
relationship, yet all women acknowledged they contextualized this prioritization within their
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experiences with their partner and their relationship. Throughout all three data types, women
expressed the presence of this Priority Triad; which priority was elevated at any given moment
varied over time and across women. Some women believed the decision to use a ring would
need be a mutual one, whereas others would inform their partners of their intentions to use the
ring, believing that ultimately the decision should be made by the woman.
The focus group data demonstrated a wider range of perspectives about the Priority Triad.
The focus group exchanges were rich with agreement, disagreement and back-and-forth
discussions about women’s considerations for ring use. In the following exchange, Angela and
Nora discuss ring disclosure to a partner, presenting their different perspectives on prioritizing
oneself or a partner. This excerpt also highlights Nora’s ambivalence about shifting
considerations for prioritizing her own agency or her partner’s health.

Angela:

Because it’s with me. He’s not carrying the drug.

Nora:
I feel like I would have to tell my partner because if there are drugs
inside of me it could affect his health.

Angela:
(FG 1)

Well, he ain’t telling me when he’s sleeping with someone else.

In Focus Group 3, the women discussed how trust within a relationship is an important
consideration for acceptability and use of a ring. Kelsey participated in an exchange with
Rachelle and Jamie, in which each of the three women eventually defined their own positions
about trust and ring use. The dialogue itself created a unique space for these women to define
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and clarify their own feelings about the interconnectedness of relationship trust, prioritization of
one’s own health, and acceptability and use of an MPT ring.
Kelsey: I personally, I’m in a relationship with one eye open, one eye closed.
[group laughter] So I don’t care what he thinks. Yes, I trust you but why not [use
a ring]? Let’s protect ourselves just in case. You know we are in the war.
Anything can happen. A couple of drinks extra. You know I know. You know if
I can protect myself I’m definitely going to do it because I trust myself and I don’t
really trust nobody else a hundred percent.

Rachelle:

Sure.

Jamie:
Man, I mean that – I disagree. I think – I mean I think either
you’re going to trust or not. It’s either black and white. It’s not no gray area with
trust, but I think that the way his reaction is and that’s what we’re speaking about,
depends on how the relationship is on a regular basis. (FG 3)

Women’s descriptions of how they prioritized their own agency did not exclude
considerations for their partners or their relationships. Rather, women described agency as the
ability to simultaneously evaluate the health and well-being of their partner and relationship,
while still granting herself the ultimate right to decide what would be best for herself. Having the
power to consider, evaluate and prioritize these considerations was an act of agency.

RATIONALE FOR NEEDING AN MPT
The ‘rationale for needing an MPT’ refers to whether an individual or couple believes
there is sufficient justification to use an MPT. This construct lies outside the typical realm of
product acceptability as defined by leading scholars.154,208 However, in this study it emerged as a
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critical pathway variable for understanding how components of acceptability connect to one
another, and how acceptability considerations can be completely circumvented in a woman’s
decision to use or not use an MPT ring. When individuals or couples have no rationale for
needing an MPT, acceptability is irrelevant in the decision to use a ring or not. The two main
factors that women and couples consider in determining a rationale for need was their HIV risk
perception and pregnancy intentions. In this group of women, 15 out of the 17 card sort
respondents rated that not having to think about getting pregnant or contracting HIV during sex
was one of their top five reasons for using a vaginal ring.
HIV Risk Perception
Although the focus of the interviews was to understand components of product
acceptability and potential for future use, one of the central issues that emerged was risk
perception for HIV. Thus, I explored women’s descriptions of their own and others’ risk for HIV
and its relationship to acceptability and potential use of the ring. 186
Community-level HIV risk perception is irrelevant to individual risk perception
Epidemiologically, actual risk for HIV is based on individual risk behavior, partner risk
behavior and HIV status, and high community viral load.267,268 The majority of the participants
lived in or near the South Bronx within a few miles of one another at the time of data collection
(2013-2014). During that time, the Bronx had the highest prevalence of HIV in all NYC
boroughs (1.9%-2.0% of the Bronx population), and the HIV prevalence of the South Bronx
specifically, ranged by neighborhood from 2.5%-2.7%.269 Despite this, women were confident
that they were not at risk for HIV. They attributed all of their confidence to their own low-risk
behavior, including abstinence. There was no discussion in the interviews acknowledging or
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questioning the high community-level risk that surrounded them. The only expression of the
concept was associated with naming “other women” at risk where HIV prevalence was assumed
to be high.
During each of the focus groups, one of the exercises included a scenario about risk
perception (Appendix D—focus group guide) of a fictitious young woman ‘Carla’ who lived in
the South Bronx neighborhood of New York City. The script stated that Carla also knew a few
people who had HIV; she only had one partner at a time; and was currently married for 3 years.
During the focus group discussions, participants generated multiple interpretations of Carla’s risk
for HIV (and pregnancy), with some focusing solely on the potential risk brought from her
relationship with her husband, and others on the awareness of and response to her communitylevel risk. Brianna and Jamie debated how Carla’s overall risk perception may or may not be
shaped by her awareness of the HIV prevalence in her community.
Brianna:
If she’s aware that people in the community is getting the virus
she’s aware. She’s educated to it. She’s open to it. If she’s oblivious, then I
could say ‘well, why would she even bother with the ring’ but if I’m aware of
something is happening in my neighborhood, I’m going to get protected unless
I’m you know, stupid.
Jamie:
Not necessarily because there are a lot of people who are aware of
the HIV numbers and they’re aware of the single mothers and the unwanted
pregnancies, and they still practice behaviors that could possibly get them into
that result. (FG 3)
In the focus groups, it was clear that women did not identify their own risk for HIV to be
greater because they were living in or near community with a high HIV prevalence. Further, only
a few (all of whom were receiving graduate-level training in infectious disease research)
identified community-level HIV prevalence as a potential influence on personal HIV risk and
even then only did so when prompted in the focus group discussion about the fictional character,
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Carla. In fact, women went as far as to explain that community level risk was not a relevant
factor of influence on any woman’s perceived risk and subsequent ring use.
While women could identify community-level risk for HIV in a given scenario, they still
calculated their own risk based solely on their own behaviors and expectations of their partner’s
behaviors, disregarding community prevalence completely. In FG 3, Jamie succinctly explains
how awareness of HIV prevalence (as well as rates of unintended pregnancy) in her community
would have no impact on her own risk perception. Interestingly, she does not distinguish
between risk for an infectious disease with risk for pregnancy.
I mean I could be in the community of people who have HIV and who have
unwanted pregnancies, doesn’t mean that it’s going to have an effect on me. It
doesn’t mean that I’m educated on the ramification. So it could be happening all
around me but in my own world, I don’t know the seriousness about it. So then if
I don’t know or understand, why am I going to go look for a ring to prevent it?
(Jamie, FG3)
Risk, Relationships and Ring Use
Women generally described HIV risk as a function of the partner relationship. Further,
they connected the potential use of a vaginal ring that included HIV prophylaxis as a function of
risk perception for HIV. All of the women, regardless of current partnership status related to
these equations.
Laura did not have a partner at the time of the first interview, although she perceived her
HIV risk to be low because of previous relationships and her typical partner “type”.
I feel like I’m at low risk, I guess. I’m also one to date someone and end up dating
them for a significant amount of time and I guess in that time I wouldn’t feel like
I would need the HIV preventative [drug], because I only have one sex partner
who I feel will always be faithful. (Laura, IDI 1)
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Laura equated a low level of risk with having a single, long-time partner whom she had
determined to be faithful. At the time of her first interview, she did not have a current partner but
at the second interview two weeks later, she had a new boyfriend and was anticipating the
relationship to turn sexual after the study ended within a few weeks. She explained that, in the
early stage of a new relationship, she insisted on condom use and testing. However, if her partner
tested negative, Laura considered her HIV risk to be low going forward and would no longer
indicate a need for condoms. Other women expressed similar confidence that they were at low
risk because their long-term, committed and trusting relationships indicated a disease-free
partnership.
I wouldn’t be interested in the HIV ring. Because I’m married and I do trust my
husband and I’m not sleeping with anyone else. (Nora, IDI 1)

I would not [use this ring] because I’ve been with my boyfriend for like six or
seven years so he…if I’m in a monogamous long-term relationship and we both at
least annually get tested for STDs there’s not a sufficient incentive. (Adele, IDI 1)
All three women (Laura, Nora and Adele) explained they were not inclined to use a ring
because they perceived their risk for HIV to be minimal. Even though Laura’s new relationship
warranted an initial period of questioning her partner’s HIV status, she expected this period to
transition quickly into one that relied on monogamy and trust, as Nora’s and Adele’s did. Adele
bolstered her confidence in her low-risk status with mutual annual testing for STDs. She was the
only study participant who reported any type of persistent testing behavior during a long-term
relationship.
Some women acknowledged that, although monogamy is expected, infidelity is still
possible in committed relationships. Those currently in committed relationships talked about
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infidelity as something that happened in other relationships, while those not in a committed
relationship accepted that infidelity could happen to anyone, including them.
It's like you can never trust anybody. I'm like, who knows if they could be
exposed at any point so it is always good to have [the ring] as an option… Last
month I found out that he went on a date with someone…So we took a break. I
kind of broke up with him…. I would have sex with him before [last month], no
protection, because I was thinking he's okay...It's going to take me a while to trust
him again but we'll see what happens. (Hillary, IDI 1)

Specifically regarding disease prevention considerations outlined in the card sort, (
‘Having sex without thinking about getting HIV’; ‘Feeling safe during sex’), women discussed
these considerations as relevant to both self and the relationship, and varying alongside
relationship type changes (ex. changing from non-monogamous to inferred monogamous
relationship types). Women in more serious relationships would face negative repercussions and
appear to be actively downgrading the priority of their relationships with their partners if women
prioritized this self-focused priority of using an HIV prophylactic ring.
Sexual abstinence was another reason for perceived low risk. Women who were not in a
relationship explained that they had no need for a ring to prevent sexual transmission of HIV or
pregnancy.
If I wasn’t, if I was planning on being abstinent for a period of time like I am
now, I probably wouldn’t wear it just because I’m not at risk. (Marina, IDI 2)
Unsurprisingly, Marina and other women not in current partnerships were the only
subgroup of women who articulated this idea of abstinence precluding the need for HIV
protection. Despite their lack of current partnerships, all of these women reported having sex in
the past 60 days. For these women, it appeared that it may be the combination of lack of
opportunity for sexual encounter and related abstinence expectancy contributing to their
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diminished interest in a longer-term use MPT ring. To them, it seemed “overboard” to commit to
using a ring that would have a deeper meaning (including HIV prophylaxis) than their current
contraceptive pill.
Using a ring without contraception is stigmatizing: It’s for “other” women
All of the women in this study recognized they were at risk for pregnancy (and were
contracepting to prevent it), however none of the women in this study described herself as being
at risk for HIV. When asked to think about who might be interested in using a ring that included
HIV prevention medication, participants were quick to identify women who they deemed to have
high HIV risk profiles and two related themes became clear: 1) women who are at risk and
would need the ring are “the other” – “not like me”; 2) these “others” engage in stigmatized
behavior, such as having multiple partners or engaging in sex work, don’t think through their
actions, or live in regions with high HIV prevalence.
I wouldn’t feel it was necessary…unless you’re someone who’s having sex,
promiscuous sex you know, with a lot of different partners, unprotected…I don’t
ever like expect to be a part of either of those groups of people. (Kerry, IDI 2)

I think prostitutes definitely because I can imagine that a lot of their customers
don’t want to use a condom, right? So for them that would, wearing something
like this would be great, I think. (Marina, IDI 1)
It was clear that participants recognized and also enacted stigma associated with what
they termed to be risky sexual behavior and, by extension, using a product specifically designed
to prevent HIV. In addition to the stigma they assigned to the TDF-only ring, they also
anticipated rebuke from sexual partners, creating “unnecessary problems” in the relationship
specifically around issues of fidelity as previously described.
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Rare, yet extreme risk: The case of rape
Participants identified only one circumstance that posed a faultless risk to themselves for
HIV acquisition, and that was rape. Unprompted, some of the women mentioned that the
potential for rape put women at risk for HIV and might warrant wearing this ring regardless of
the contraceptive properties. However, rape was talked about only as a remote possibility and not
a major factor in determining one’s risk for HIV. Rape was not mentioned as a risk factor for
pregnancy. On balance, the fear of rape alone did not warrant wearing a prophylactic device:
I mean people are raped and they could contract HIV but you’re not going to wear
or take a drug just in case you get raped. I mean because that would be crazy and
just very emotional. I mean you shouldn’t just assume that you’re going to be
raped, that’s like emotionally really depressing. (Kerry, IDI 1)
Fertility desires and intentions, not risk.
While all the women acknowledged they could become pregnant in the absence of their
regular contraceptive method, there was minimal explicit discussion of this awareness in either
the IDIs or FGDs. When women did speak about the act of becoming pregnant, they did not use
fatalistic or ‘risk’ language, as they did when they discussed the possibility of contracting HIV.
Instead, pregnancy was talked about as something they “wanted” now or in the future, or
something they were or were not yet “ready for.” This contrast in language use between HIV risk
and pregnancy desires was stark, likely reflecting women’s underlying distinction in the way
they thought about the possibility of pregnancy vs. the possibility of contracting HIV. While
women saw contracting HIV as a condemning outcome, the possibility of pregnancy effected a
range of more positive feelings.
Potentially the lack of discussion about pregnancy as a risk is also related to the fact that
these women were also current contraceptive users, so most had implicitly acknowledged
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unwillingness to become pregnant presently, demonstrated by their choice to use a contraceptive
method in the first place. Even in the card sort data, where women were explicitly directed to
address fertility desires as they related to ring use (“The ring will prevent pregnancy”; “The ring
will not prevent pregnancy”), there was little in-depth discussion regarding current
considerations about pregnancy desires or intentions. The little that women did discuss (even
when probed) about wanting pregnancy was related either to satisfy one’s own desires “my
biological clock won’t stop ticking” or in response to the changing fertility desires within the
relationship context, “until we want more [children]”.

MPTs offer a joint solution to multiple concerns
Women described the benefits of using a ring that could simultaneously prevent both
HIV and pregnancy. They overwhelmingly saw it as a solution to some of the tensions they
envisioned having with partners or internally as they weighed acceptability of various attributes
of an MPT ring. Specifically, women lauded the device for its efficiency and the ability to
subvert the stigma related to using an HIV-only prevention product by casting it as a health
promotion tool.
Efficiency of a dual-purpose device
The most commonly described and clearly articulated benefit of using an MPT ring was
the fact that the ring could prevent two undesirable outcomes at once: HIV and pregnancy.
Women used colloquial expressions about efficiency, to provide descriptions of this idea:
“tackling...two birds with one stone” or “getting a two-fer". Here, the idiomatic language used in
both the IDIs and focus groups to describe the efficiency of using an MPT for dual prevention
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potentially demonstrates women’s perceptions of the obviousness of this benefit. In the IDIs, I
probed women to further describe these idioms, and typically women would offer up another
idiom or a terse rephrasing of what they had first stated about why more was better, as if their
rationale was obvious and self-explanatory. Jenna was one of the few women in the IDIs to
explain what she meant by “two for one”:
That's just - it's like a two for one; you're handling your responsibilities in both
ways, it makes it easier because then also, some people might use a pill and then
also use condoms to be protected, but with the ring, it seems like we have both of
them. It makes things easier, an easier option. (Jenna, IDI 2)

This finding was highlighted in the focus groups. Specifically, there was a focus group
exercise where women were asked to compare the instructions for use first for the TDF-only ring
and then for an MPT ring. The instructions were the same, including: wearing the ring daily
(including during sex and menstruation); inserting and removing the ring yourself; and replacing
it monthly. In this context of comparison between the TDF-only vs. the MPT ring types, women
expressed clarity about the superior acceptability of an MPT ring attributed to its ability to also
prevent pregnancy: a desirable goal. Women explained that they were more likely to accept an
MPT ring over a TDF-ring because it conferred more protection, and more protection was
typically seen as better. Jamie describes how she would feel if the ring she was wearing in the
trial was an MPT ring instead of a TDF ring.
It would motivate me to continue on because now I know that not only is it going
to prevent me from getting HIV, but it’s also altering my life in a very serious
way by preventing pregnancy. I would still feel the same, but I would be more
motivated to follow the rules because now okay, you’re telling me that this can
also prevent me from getting pregnant and HIV. I’m getting more bang for my
buck. (Jamie, FG3)
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One important caveat to this sentiment, however, was that women would accept an MPT
only if the PrEP component caused “no extra burden” on top of what was already acceptable in
their current contraceptive. Women named “weight gain”, “discharge” and “problems getting
pregnant” as some of the reasons why an MPT ring would be unacceptable and get in the way of
them using it.
While women did like the idea of an MPT ring efficiently providing protection against
both HIV and pregnancy, the card sort data showed an uneven distribution of women’s desires
for preventing HIV or pregnancy during sex (“Having sex without thinking about contracting
HIV”, “Having sex without thinking about getting pregnant”) relative to one another.
Specifically, 11 women prioritized pregnancy prevention as a reason to use the ring; 5 prioritized
HIV prevention and 1 ranked them as equally important in a decision to use a ring. Despite this
ranked division of preferences, almost half of the women (7/17) placed the two cards adjacent to
one another, signaling the desirability of a ring that could prevent both outcomes nearly equally.
MPTs de-stigmatize using HIV prevention methods
Another reason that justified MPT use was the way it could de-stigmatize HIV prevention
behaviors, such as wearing a prophylactic device. In contrast to the clear stigma women assigned
to a TDF-only ring, when women discussed the possibility of an MPT ring, it was
overwhelmingly positive and focused on the way that adding a contraceptive component could
“mask” the HIV preventive function. In their explanations for preferring an MPT to a TDF-only
ring, women talked about MPT rings as a direct solution to the stigma they might face socially or
the questions of sexual infidelity that might be asked by their partners. “No one would be so
suspicious” that a woman was cheating or that she was participating in stigmatized sexual
behavior, if she were using a device designed for preventing pregnancy. Preventing pregnancy

115

was discussed as virtuous, “part of normal life” and empowering whereas preventing HIV was
laden with stigma because it implied that one was having “promiscuous sex” or practicing
infidelity.
Women also believed that their partners would find an MPT ring more acceptable overall
if it were framed as a vaginal ring with primary contraceptive benefits and secondary HIV
prevention benefits. Women liked this idea for themselves as well, thinking of it as a
contraceptive ring with an “added bonus”.
If it was just an HIV thing he might say, well, we just have sex with each other so
what is the need for that. Especially after being married for, for some people that
might raise flags out of, you know, left field you’re wearing contraceptive with
HIV. That’s a bit strange but if it was, “I want to try something new. I want to try
a ring. It’s a contraceptive birth control and HIV.” That’s a little bit different. I
think that most partners would be more accepting of that. (Nora, IDI 1)
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Section 3.4: Methodological Considerations
“A theory generated from just one kind of data never fits or works as well, as a
theory generated from diverse slices of data on the same category.”
-Glaser and Strauss, p. 68 182
Introduction
In Section 3.4, I explore how specific features of each data collection method informed
the overall development of the model, Dynamic Considerations for Acceptability and Likely Use
of an MPT Ring, and I identify specific features of each method that can inform future study
designs for similar products. For organizational purposes, Section 3.4 also includes most of the
discussion and implications regarding this methodological assessment. Many of these
acceptability findings have already been discussed in Section 3.3 of this dissertation. Differently,
in the forthcoming section, I further examine the thematic findings with regard to specific
features of each method that produced those data.
To satisfy Specific Aim 2 of my research, I triangulated my data by examining the
comparability and complementarity of the thematic findings from each of the three methods.
This required acknowledging the inherent features of each data collection method. I therefore
triangulated the data by exploring 1) the convergence and divergence of thematic findings; 2) the
complementarity of thematic findings; and 3) the complementarity of findings that were
generated as a result of special features of each of the methods used to deliver those findings. I
used a hybrid approach to triangulation of multiple methods, which combined a traditionally
quantitative approach as lain out by Campbell and Fiske (Comparability),244 with a traditionally
qualitative approach as defined by Denzin and Lincoln (Complementarity) for the overall
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purpose of integrating the findings from all three data collection methods with attention to
features specific to different methods.248
Comp arability
One reason why it is useful to determine the comparability of findings across multiple
qualitative methods is to increase confidence in the overall believability (i.e., trustworthiness) of
the thematic findings. Thus, when the data collected using any of the three methods overlapped, I
could be fairly confident that the narratives were coalescing and telling a robust story
irrespective of method type. It was also important to assess comparability in order to identify
areas that required further thinking to fit the developing theoretical model to the data, rather than
the other way around. As Flick explains:
“The aim of triangulation…should be less a matter of obtaining convergence in
the sense of confirmation of what has already been discovered. [Instead, T]he
triangulation of methods and perspectives is particularly useful for theorydevelopment, when it can elucidate divergent perspectives” (p. 181).270
Non-comparability of themes across methods, therefore, presented a ripe opportunity to
further investigate why one type of data produced one finding, and another data type produced a
different finding. I therefore explored the possibility that the methods themselves may have
produced different kinds of data possibly due to attributes inherent to the method.
The first step in evaluating the comparability of findings across method type was to
identify the depth of discussion about each of the themes identified in the theoretical model
(Table V). If the topic was not discussed at all in one of the data collection methods, it would
otherwise be difficult to compare agreement or disagreement on the themes with that method.
Therefore, I focused my comparability analysis of findings primarily on the methods where
thematic data were available to compare. For example, the theme ‘Partner Priorities: Health’ was
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only discussed in interviews and focus groups, but not in the card sort. Therefore, I could not
make any assertions about comparability of thematic findings across all three of the methods. For
methods that only produced ‘limited discussion’ (lacking depth of information) of the data,
(Table V) this is noted.
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Table V: Methodological Comparability: Presence (x), Limited Discussion (l) or Absence
(o) of Themes
Theme

Interviews

Card Sorts

Focus Groups

CONTEXTUAL CONSIDERATIONS (1a)
Relationship Priorities
Type/Length

x

l

x

Fidelity

x

x

x

Communication

x

x

x

Disclosure

x

x

x

Health

x

x

x

Agency

x

x

x

Health

x

o

x

‘Self’ priorities

Partner priorities
RATIONALE FOR NEED (1b)
HIV Risk Perception
Community Risk

l

o

x

Risk, Relationships & Use

x

x

x

Abstinence

x

o

o

Stigma

x

o

X

Rape

x

o

L

Efficiency

x

x

X

Destigmatization

x

o

X

Future Fertility

l

x

L

Joint Solution

Fertility Desires
EPISODIC CONSIDERATIONS (1c)
Product Attributes
Size

o

o

X

Material

l

l

X

Dosing

x

x

X

Double Drugs

x

o

X

Comfort

x

x

X

Benefits

x

x

L

Discreteness

x

x

X

Side Effects

x

x

L

Use Attributes
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Theme

Interviews

Card Sorts

Focus Groups

Pleasure

l

x

L

Interference or Facilitation

x

x

X

Ridding blood/cleaning out

x

x

X

Crowding the Vagina

x

o

X

Abstinence

x

o

O

Sexual Experience Attributes

Menstruation
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Complementarity
In contrast to assessing comparability of findings across methods, I also assessed the
complementarity of findings across methods. These complementary findings did not contradict
one another, rather they enhanced, deepened or created more nuance in the emergence of themes
or relationships within the model in all of their richness.248 Additionally, when we see
complementary findings where one method may have produced more insight than another
method, we can see that there may be some benefit to using a particular method for a specific
topic, theme or process. In Sections 3.2 and 3.3, I triangulated the complementary findings
within the discussion of the emergence of themes. In the following, I will highlight if and how
particular features of the data collection method uniquely added to understanding about MPT
acceptability.
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Table VI: Thematic Findings across Interviews, Card Sorts and Focus Groups vi
Interviews
Card Sorts
CONTEXTUAL CONSIDERATIONS (2a)
Relationship Priorities
Type/Length

Fidelity

Communication

• Longer/more serious
relationships expect
inclusion in use
decisions
• Shorter/less serious
relationships shift
acceptability and use
decisions to women
• Relationship transitions
are key moments for
shifting acceptability
priorities
• HIV-only prevention
implies mistrust and
infidelity for the woman
and the man

• Communication is
critical for family
planning
• Lack of communication
indicates a weak
relationship and permits
a shift in a woman’s
prevention priorities

vi

Fo Groups

• Limited discussion
• Regardless of
relationship
length/type,
women want
partner support of
ring

• Any length/type
relationship matters
for acceptability and
ring use decisions
• Relationship
transitions are key
moments for shifting
acceptability priorities

• HIV-only
prevention implies
mistrust and
infidelity for the
woman and the
man
• Questioning
fidelity was a low
priority for overall
ring acceptability
• Communication
was a low-ranking
priority for overall
ring acceptability

• HIV-only prevention
implies mistrust and
infidelity for the
woman and the man

• Communication is
critical for family
planning
• Lack of
communication
indicates a weak
relationship and
permits a shift in a
woman’s prevention
priorities
• MPT – related

As part of the analyses reported in this table, I used a segmented analysis approach and also
analyzed the data separately by experimental condition to identify any potential differences in
emergent themes or reported concerns related to ring acceptability. Aside from increased reports
of wetness or discharge from the TDF group, there were no other notable differences between the
two groups of women on any of the themes presented here, or other components in the model.
This is unsurprising as there were few side effects reported by women about the TDF itself, and
these women were already using a hormonal contraceptive. Therefore, the results reported in this
table are for the complete sample of women, not divided by experimental condition
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Interviews

Card Sorts

Disclosure

• Relationship stage
dictates disclosure
decisions
• Non-disclosure can
prevent relationship
growth
• Non-disclosure can
imply promiscuity,
infidelity or lack of trust

• Relationship stage
dictates disclosure
decisions
• Non-disclosure
can prevent
relationship
growth
• Non-disclosure
can imply
promiscuity
• Disclosure matters
little for overall
acceptability
• Partner support is
a high priority for
use

Health

• Recognized potential
challenge to prioritizing
self vs. partner health
• Self-health sometimes
trumps partner health
• Strong statements of
self-determination
• Agency is also important
for feeling good within a
relationship
• Agency=sexual pleasure

• Self-health trumps
partner health
• STI protection is
important

Fo Groups
communication would
be predicated on
comfort with general
communication about
sex
• Relationship stage
dictates disclosure
decisions
• Non-disclosure can
prevent relationship
growth
• Non-disclosure can
imply promiscuity,
infidelity or lack of
trust

‘Self’ priorities

Agency

• Self-health sometimes
trumps partner health
• sometimes partner or
relationship trumps
self-health
• Strong statements
• Reciprocity between
of selfself-determination,
determination
male partner desires
and relationship
• Agency is
factors
important for
feeling good
• Agency is important
within a
for feeling good
relationship
within a relationship
• Self trumps partner • Strong statements of
self-determination

Partner Priorities
Health

o
• Men’s exposure to TDF
(not contraceptive) could
be harmful
• Partner health is
sometimes a factor for
acceptability
• Recognized potential
challenge prioritizing
self vs. partner health
EPISODIC CONSIDERATIONS (2b)

• General partner health
is sometimes a factor
for acceptability
• Recognized potential
challenge prioritizing
self vs. partner health

Product Attributes
Size
o
Material • Relevant to partner
health (not to personal
health)
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o
• Relevant to partner
health (not to
personal health)

• Larger than expected
• Harder than expected

Interviews
Dosing • Monthly, aligning with
menstrual cycle and wish
for reliable effectiveness
• Non-monthly, wanted
convenience/fewer trips
to care provider
(assuming provider
insertion)
Double Drugs • Drug interactions with
two drugs
• Question effectiveness of
2 drugs in 1 ring
• No discussion of
relationship to menses

Card Sorts
• Monthly, aligning
with menstrual
cycle

Fo Groups
• Monthly, aligned with
menstrual cycle
• Menstrual marker of
no pregnancy
• Monthly, wanted
convenience

o

• Questioning ring
effectiveness of two
drugs in one ring
(drugs cancelling each
other out)
• Mechanism of action
unclear if ring removal
during menses.

• Absence of
discomfort
• Referencing sexual
activity
• Own comfort
relative to partner's
• Relative to
relationship
considerations
• Telling partners
was a low priority

• Absence of
discomfort
• Referencing activities
of daily living

Use Attributes
Comfort • Absence of discomfort
• Referencing activities of
daily living

Discreteness • Relative to relationship
considerations
• Covert use would
challenge relationship
trust
• Women would tell
partners
Side Effects/benefits • Wetness is ok/discharge
is not ok
• Difficult to identify
hypothetical side effects
other than common OCP
side effects
• Side effects can be
secondary benefits
Sexual Experience Attributes
Pleasure • Physical comfort
connected to pleasure
• Reciprocity as pleasure

Interference/facilitator • Interpreted as having a
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• General side
effects were
potential barriers
but also secondary
benefits
• Hypothetical side
effects included
common OCP side
effects
• Physical comfort
connected to
pleasure
• Reciprocity as
pleasure
• Women and men’s
comfort prioritized
jointly, with minor
prioritization of
women’s over
men’s
• Interpreted as

• Relative to
relationship
considerations
• Covert use would
challenge relationship
trust
• Women would tell
partners
• Limited discussion

• Physical comfort
connected to pleasure
• Reciprocity as
pleasure

• Interpreted as having

Interviews
secondary impact on
acceptability (wetness vs.
discharge) spoiling the
mood
• Wetness is a welcomed
facilitator of sex

Menstruation
Ridding blood/cleaning out • Most discussed ring use
during menstruation as a
deal-breaker (i.e. ring
would get ‘dirty’)
• Aligned with strategy for
monthly exchange of ring
• Minority wanted to flush
toxins from ring
Crowding the Vagina • Additional items in the
vagina during
menstruation adding
unnecessary burden (i.e.,
cramps, bloating)
• Concern about physical
crowding and presence of
multiple items displacing
one another
• Concern the tampon
soaks up medication

Card Sorts
having secondary
impact on
acceptability
(wetness vs.
discharge)
spoiling the mood
• Linked facilitator
and interference
with acceptability
• Sexual experience
is a relatively
moderate factor in
ring use decisionmaking
• Ranked as lower
importance than
other factors
• Alignment of
menstruation and
removal of the
ring so no blood
on the ring

o

Abstinence • Some women do not
o
have sex while
menstruating
• Strong beliefs that
menstrual flow acts as a
self-cleaning tool
• Belief that periodic
abstinence would warrant
periodic break in ring use
RATIONALE FOR NEED (2c)
HIV Risk Perception
Community risk • Limited discussion
o
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Fo Groups
a secondary impact on
acceptability (wetness
vs. discharge) spoiling
the mood

• Most discussed ring
use during
menstruation as a
deal-breaker (i.e. ring
would get ‘dirty’)
• Aligned with strategy
for monthly exchange
of ring
• None wanted to flush
toxins from ring
• Additional items in
the vagina during
menstruation add
unnecessary burden
(i.e., cramps, bloating)
• Did not question
tampon soaking up
drug, but did question
other products' impact
on ring effectiveness
(i.e., douches)
• Concern over illness
if ring left inside body
too long
o

• Identified community
viral risk for other
women
• Did not identify

Interviews

Card Sorts

Risk, Relationships & Use • All perceived low risk bc
of partner type or
relationship length
• Infidelity acknowledged,
only for other
relationships
• Use positively impacts
self-health
• Use negatively impacts
the relationship

Abstinence • Abstinence precludes
ring use (only discussed
among the unpartnered)
Stigma • Labeled ‘other women as
being at risk (not self)
Rape • Rare but extreme case
• Fear of rape does not
justify the ring

• All perceived low
risk bc of partner
type or relationship
length
• Infidelity
acknowledged,
only for other
relationships
• Use positively
impacts self-health
• Use negatively
impacts the
relationship
o

o

o

•
•
•
•

Fo Groups
community viral risk
for self despite highrisk community
All perceived low risk
bc of partner type or
relationship length
Infidelity
acknowledged, only
for other relationships
Use positively impacts
self-health
Use negatively
impacts the
relationship

o
• Labeled ‘other
women as being at
risk (not self)
• Limited discussion

Joint Solution
• Preventing two undesired
outcomes at once
• More prevention is better
• Acceptable, only if no
extra side effects

• Preventing two
undesired
outcomes at once
• More prevention is
better
• Acceptable, only if
Efficiency
no extra side
effects
• Diverse
preferences for
HIV vs. pregnancy
prevention goals
o
• Contraceptive component
masks stigma of using
HIV PrEP
Destigmatization/Bonus
• PrEP is therefore bonus
Prevention
prevention to
contraception
Fertility Desires
future fertility • No current desires for
pregnancy
• Desire quick return to
fertility
• No impact on fertility
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• Highly prioritized
fertility not being
impacted by MPT
use

• Preventing two
undesired outcomes at
once
• More prevention is
better
• Acceptable, only if no
extra side effects

• Contraceptive
component masks
stigma of using HIV
PrEP
• PrEP is therefore
bonus prevention to
contraception
• No current desires for
pregnancy
• Desire quick return to
fertility
• No impact on fertility

Triangulating Comparable and Complementary Findings
Comparability
The overwhelming majority of the thematic findings, when discussed, were comparable
across the three data types: focus group, interview and card sort data. In Table VI, individual
themes are identified and basic components of those themes are condensed into bullet points. To
summarize the findings, many of the thematic components are similar regardless of method,
despite some methods capturing differing depth of themes. Throughout the whole dataset there
was only one theme in which the data were NOT comparable across data collection methods. I
explore this finding in detail to determine if and how the methods themselves may have
contributed to the discrepancy.
This exception to the thematic comparability across methods was introduced during a few
of the participant interviews. Although mentioned by only two women (Angela and Megan), the
TDF drug itself was mentioned as a possible “toxin,” which the body should cleanse away with
menstrual blood. A few of the women in the IDIs expressed beliefs that the flow of blood from
menstruation would be a natural mechanism for the body to rid itself of the TDF. Of note, none
of the women remarked about a concern or a need to rid the body of a contraceptive/hormonal
drug emitted from the ring. This may have been related to the fact that these women were already
using a hormonal method of contraception, so they were potentially less fearful of the impact that
a hormonal contraceptive drug might have on their bodies.
I think that would be a smart idea if somebody had a ring in and their menstrual
time came to take it out. I don't know, I guess nobody wants a drug in their body.
They want to be clean, clean from the drug. Yeah, that’s for me. I would want to
be cleansed from that drug. Everything leaves your body anyway when you have
your menstrual. (Megan, IDI 1)
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This finding about ridding the body of the TDF in the ring was only expressed by two
women but made sense ideologically as part of women’s complex concerns regarding
menstruation and ring use. Sometimes in qualitative research it is as important to further
investigate results further from a minority or ‘negative case’ -- to compare and contextualize an
emergent finding in the interest of theory building.271 In this case, the grounded theory method of
data collection allowed me to explore this new line of inquiry based on emergent and credible
findings, even if coming from a small minority. When this somewhat surprising yet
understandable finding emerged in the interviews about wanting monthly menstrual blood flow
to wash out “toxins” from the drug, I therefore took the opportunity to question that finding
further in the forum of the focus groups.
In each of the focus groups, I therefore adjusted the focus group guides to ask participants
what they thought about this assertion. None of the participants in any of the focus groups
(including Angela and Megan who had originated the idea in the IDIs) endorsed the theme of
wanting their menstrual blood flow to expel potentially toxic drugs in the ring. In fact, the
general sentiment in the room for all of the groups was a moderate amount of incredulity that
women might feel this way, expressed mainly in facial expressions with raised eyebrows or brief
exclamations like “that’s crazy” and “that makes no sense.” Rhetorically, Maureen captured the
general sense of the groups’ reactions:
Why would you want it to leave your body if it’s to protect you, from pregnancy
or HIV or both. (Maureen, FG 2)
It is possible that the minority group of two women somehow changed their minds
between their interviews and focus group discussions. However, this possibility seemed too
simple. I therefore decided to further analyze the individual and group data using a case-based
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approach, to determine if there were additional factors to explain the discrepancy around this
theme across data methods. Angela’s data are thus presented here in condensed form.
In her first interview, Angela introduced the idea that she would want menstruation
monthly to help rid her body of the toxins that the ring was secreting. She contextualized her
belief as being grounded in the information that her mother discussed with her about
menstruation when she was younger.
[My mother] said that’s when our reproductive system is getting rid of whatever it
doesn’t need. And basically she said that’s when new cells are being created.... If
there’s a drug being dispersed when I have the ring, I also want that drug to also
get released with my menstrual as well. (Angela, IDI 1)

While Angela expressed this strongly and clearly in the interview context, in the focus
group she remained silent when I asked the group their thoughts about the general assertion and
group dialogue ensued. Following the group discussion she vocally changed course,
acknowledging that she had “doubts now.” This discord within her own data was a notable
phenomenon, so I explored it further within Angela’s IDI and FGD data to help understand if
this was idiosyncratic to her or if there was potentially more meaning involved with her change
of heart that could be explained by features of the methods that helped produce those different
responses.
To help understand this change in Angela’s response, it is important to contextualize
Angela’s statement within the focus group in which she participated. Her statement about having
doubts closely followed two lengthy statements from fellow focus group participants, Tracy and
Adele, both of whom were PhD students in a related field to this dissertation research. In
contrast, Angela did not have a college degree. In their lengthy responses to the question about
wanting menstruation to flush out drugs emitted from the ring, Tracy and Adele debated high-
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science and metabolic reasons for and against having monthly menstruation. Tracy and Adele
both heightened the level of academic language and their own derivative scientific hypotheses,
using complex and depersonalized statements throughout: “homeostatis”, “shedding of your
endometrium”, “based not on my own research, but on a couple studies that I read”, etc. This
was not the first time one of the PhD students spoke using this type of scientific or sophisticated
language during the group, but it was the first time that these students held the floor for such an
extended period of time (approximately 2-3 minutes, together). The other women in the room
quieted themselves during this period. Following this dialogue between Tracy and Adele, the
stage had been set such that the language of science and budding scientists had overtaken the
direction of the conversation about monthly menses, leaving little room for the non-scientists to
hold the floor or for discussions of the women’s lived experiences to be vocalized.
While this topic was not explicitly about menstrual blood shedding toxicity from the ring,
temporally it set the contextual stage in which Angela rescinded her original statement.
Surrounded by academic discussion and clinical jargon about how the body worked and
responded to external medications and hormones, Angela retracted her earlier statement of her
perceptions, deferring to the vocal and more academically poised participants in the group.
This ‘non-homogeneity’ in the focus group (i.e., PhD vs. high school education) has been
recognized as a methodological concern in focus groups in general,220 whereby there is a worry
that power dynamics can subvert ideas that might have thrived if otherwise in the presence of
focus group participants with similar characteristics. In this case, Adele and Tracy’s exchange
had shaped the tone and context of the focus group, likely impacting Angela’s stated
perspectives in subsequent moments. Perhaps Angela was intimidated or believed that her way of
thinking might not have as much purchase among these group members.
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Recalling data previously presented in the IDIs, Angela clearly had stated that she would
want a ring that would allow her to menstruate monthly, partly for the purpose of flushing out the
drug/toxin. But here, in the aftermath of a conversation dominated by two PhD students, Angela
changed her own perspectives about menses, deferring to the scientific voices in the room,
effectively retracting her earlier stated preference for ‘cleansing’ her body of the TDF “toxin”
with menstrual blood monthly. It therefore became unclear whether this sentiment regarding
menstrual flow and ridding the body of toxicity might have been held among other women who,
while not mentioning it in the interviews, might have done so in the focus group in the absence
of the dominant participants. The non-homogeneity of the focus groups created a context that
made it difficult to determine participants’ beliefs. The focus group environment potentially
limited women’s ability to express themselves, whereas the IDIs and card sort allowed a space
for individual expression with less self-censorship.
Complementarity
Nearly all of the acceptability themes were comparable across data collection methods
(Table VI), the majority of which were described in greater detail in earlier parts of Section 3 and
will not be repeated in detail here to minimize redundancy. Many of these complementary
findings emerged as a result of the combination of data collection methods employed and the
different types of data they produced, respectively. These methodological features, along with
examples of associated findings, are discussed through this lens in the following sections.
Complementary Card Sort Findings: Ranking importance of acceptability factors
Relative importance of acceptability factors
One of the unique features of the card sort method was its capacity to help women rank
the level of importance of individual factors of MPT ring acceptability, relative to other factors.
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As designed, the card sort elucidated relative value that women placed on acceptability factors
including the importance of fidelity, communication, discreteness, pleasure and menstruation
among other themes.
The rationale behind a two-step card sort was to provide multiple opportunities for
women to think through different aspects of ring acceptability. First being asked to generally
think about reasons why she would or would not choose to use a ring, or reasons that did not
matter, opened the dialogue and allowed women to triage factors that were not relevant to them.
During the second card sort step (i.e., ranking cards) they were then asked to think more
specifically about the level of importance each of those factors might have on their choice to use
or not use the ring. Methodologically, this sequential sorting approach, of first sorting cards into
general piles and then ranking the relevant cards, prompted women to explore questions they
may not have accessed on their own (e.g., during an interview) and then provided an opportunity
to dive deeper into individual topics, order topics by importance and potentially revise their
choices once the whole card set had been lain out. This two stage process has been successfully
used by others to help participants elucidate categories within constructs such as social support
240,272

This two-stage, iterative process is a special illustration of the reason why it was important

to capture both the card sort product (i.e., ordered piles) as well as the commentary that
participants provided tandem to their card sorting process.240,272
One example of the complementary findings added from the card sort was related to the
level of importance women placed on ‘ring disclosure’ as a factor of MPT acceptability and
likely future use. The basic narrative about women disclosing ring use to a male partner included
the following shared components across all three of the data types, and there were seemingly no
disagreements across the data types (Table VI):
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1. Relationship stage closely dictated the decisions women would make in their
decision to disclose ring use to a partner.
2. Non-disclosure could prevent further growth of a relationship.
3. Non-disclosure could also imply that a woman was sexually promiscuous, was
unfaithful to a current partner and/or was untrustworthy or untrusting of her
partner.
However, the card sort data provided complementary findings about ring disclosure that
were absent from the IDI or FGD data: card rankings showed that women weighed the
importance of ring disclosure lower than other acceptability factors, such as risk perception,
fidelity, and personal agency. In Megan’s card sort, during the first phase of sorting cards, she
first explained how she generally felt about the concept of disclosure within a relationship.
For me [disclosure]’s a good thing. HIV is like really bad to have. You can die
from HIV. So I would think that would be something positive to share with him or
whoever’s using this because it’s a positive thing. A lot of people are getting sick
from this. (Megan, Card Sort)

In the second phase of her card sort, however, she is asked to rank the disclosure factor in
terms of level of relative importance to other factors. Here, Megan explained that she cared more
about ability to prioritize her own health vis-a-vis ring use than she valued the need to disclose
use to a partner, ranking the disclosure cards lower in importance than other cards.
For me I would tell him. But if I was the type of person I would be like, “It’s
really none of your business as long as I’m protecting myself it’s none of your
business.” When it comes to the female body, I think a female has a right to do
whatever she wants. (Megan, Card Sort)
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In Megan’s case and others, the card sort data explained an additional feature of ring
disclosure that was only decipherable in the presence of the ranking of other acceptability
factors. When describing the theme of ring disclosure in depth, as she and others did in the first
phase of the card sort, the interviews and the focus groups, it appeared that this factor held great
meaning. Participants often used hyperbole and fatalistic language ‘You can die from HIV,’
which guided me to initially think that women weighed this factor highly. However, when asked
to examine this factor relative to others in the second phase of the card sort, Megan and others
generally ranked the action of ring disclosure to a partner at a lower level of importance than
they did regarding factors related to prioritizing the relationship or things that impacted fertility.

An inability to rank?
While it was convincing that the card sort did explain women’s ranked order of priorities
around specific acceptability factors, there was a significant minority of women who were not
able to complete the factor ranking as requested. Out of 17 women who completed the card sort,
there were 5 who expressed they could not rank all topics sequentially. This was manifested by
participants deciding to place some cards next to one another, to signify equal value for reasons
why or why not to use a ring. While it is possible that some women actually held multiple topics
at the same rank, it might also mean that participants had difficulty ranking some of the cards at
all because it did not make conceptual sense to them or they were unrankable. The cards were a
pre-determined set of hypothesized acceptability factors and all of them may not have resonated
for each woman. Therefore, asking participants to rank factors when they did not rank those
factors in real life decision-making might have been an impossible task. This is a finding in and
of itself.
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The field of cognitive psychology may help explain this cognitive process using the
concept of ‘mental models’, which is a person’s way of creating a small-scale version of reality
to aid in understanding it, regardless of its accuracy.273 When there is a mismatch between reality
and ‘modeled’ reality, it is noted in cognitive psychology as a barrier between researcher and
participant or designer and user.274 Further, this mismatch in mental models can also cause
participants to try to remedy inconsistencies by reworking their original mental model to fit a
new experience.275 The implications of this mental model reconciliation process during the card
sort could mean that women may have artificially ranked factors in the study context only
because they were asked to. They may in fact have had no way to rank some or all of these
factors because a hierarchy among factors simply didn’t cognitively exist for them. It is difficult
to know which women were able to rank the cards to accurately represent their mental model of
acceptability factors, and which women fabricated or “satisficed” their rankings at the time of the
card sort to accommodate the researcher and/or avoid inconsistencies.

Regardless, this is

certainly an area for future research to better understand the way women can or cannot order
factors of acceptability in a linear hierarchy.

Complementary Card Sort Findings: Addressing sources of response non-validity
There are several reasons why data on sexual behavior, sexual relationships, and beliefs
about sex and how one’s body works is difficult to collect with validity.
Addressing Social Desirability Bias
One is Social Desirability Bias (SDB), which is a common occurrence in research (both
qualitative and quantitative) on sexual behavior and acceptability of vaginal products.276 Women
are reluctant to admit to behavior that reflects poorly on them (e.g., risky sexual behavior, how
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they treat partners, cheating, nonadherence). In a Phase 2 trial of microbicide gel and condom
use in South Africa, researchers found that SDB was enacted as politeness, avoidance of
criticism/seeking praise and embarrassment, leading to misreporting of product adherence in
over three quarters of the sample.277 In another study participants named interviewer
characteristics, interview techniques and privacy of location as important contributors to giving
socially desirable responses to sensitive topics instead of their lived experiences.278 In this study,
the card sort method may have helped to ameliorate SDB by normalizing potentially stigmatizing
behaviors through the act of naming them on cards.
Addressing sensitive topics
Another source of response bias is related to discussing cultural norms about women’s
sexuality, a topic that is controversial and sensitive in American society. It is often difficult for
women to have open and frank conversations about sexuality and reproductive issues with other
women or with researchers especially if their reports are inconsistent with societal
expectations.279–281 Scholars have noted the social and cultural expectations placed on American
girls (especially as they compare to American boys), whereby girls are limited in learning about
sexual pleasure in educational structures or in experiencing it in their own relationships.282–284
These social expectations shape the sexual lives of girls and women such that they receive and
embody messages that sexuality and sexual pleasure should be subverted. In their study on the
way women talk or don’t about sex, Montemurro et al. explain the social norms that make it
difficult for women to discuss sexual pleasure with strangers, as well as the gendered limitations
they impose upon their limited talk about sexual pleasure in an effort to sanctify their sexual
relationships and protect their partner’s masculinity in his ability to give her pleasure.281
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In this context of gendered norms around remaining quiet and protectionist about
sexuality and sexual pleasure, we can begin to understand that response bias is not limited to the
data that are produced, but it can also be responsible for the omission of participant data, such as
appeared to be the case in this research regarding sexual pleasure.

285,286

Therefore, it is not

surprising that women were less likely to discuss sexual pleasure in the focus groups or
individual interviews but were able to use the card sort as a mechanism for sparking data
production vis a vis pre-constructed cards. Thus, sexual pleasure was discussed in greater depth
in the card sort, augmenting the minimal findings produced in the interviews and focus groups.
During the card sort, women were cued to discuss their perspectives on sexual
experiences from five specific cards in the sexual experience category (Table II):
1.
2.
3.
4.
5.

My physical comfort during sex
My Partner’s physical comfort during sex
Wetness during sex
Sex would be better
My sex drive or being turned on might change

The card sort, however, was able to facilitate discussion of sexual pleasure by presenting
the participants with cards that inquired about specific features of sexual experience. This created
a nonthreatening opportunity for women to address these features without judgment or fear. In
comparison to the IDIs, where women were limited in their descriptions or concerns about sexual
encounters unless prompted, and to the focus groups, where women jested about sexual pleasure
with brevity, the card sort elicited the richest data about sexual encounter attributes overall.
Women detailed components of partner intimacy and sexual pleasure in ways that only appeared
when probed specifically. For example, Marina responded to the card titled ‘Sex would be
better’.
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That would be a reason to use it. I feel like I kinda have a hard time and it's hard for me
to have an orgasm as it is. So if it made it easier in that way, that would be a good reason
to use it.
I conclude that this relative openness about sexuality in the card sort was due to the
nature of the data collection method.

Complementarity: Providing depth of understanding through the interviews:
Many of the concepts and themes in the Dynamic Considerations Model, which was
developed from an integrated analysis of all three of the data collection methods, have been
described earlier in Sections 3.1-3.3. However, the interview data collected from individuals at
two points in time uniquely add a level of depth and richness not present in the focus group or
card sort data.
In-depth interviews are well suited as a data collection technique to gain a deeper
understanding of a potential user’s context, perspectives, needs and questions about MPTs that
could impact eventual use, and/or could inform new MPT development.82,225 In this study,
participants spent approximately 2 hours with me discussing their user experiences with a ring;
contemporaneous perspectives on acceptability factors; and hypothesizing about the complexities
of potential future use. The interview context was designed as a safe space for women to discuss
these topics, any or all of which could be considered to be sensitive or private.226–228 While some
participants may not have felt comfortable one-on-one (e.g., preferring a card sort) with me,
others certainly did and generally developed rapport over the course of the 2 sessions. The
intimate setting of the interview context had few outside distractions, thus facilitated sessions of
close listening, tailored responses, and directed probing to encourage participant comfort with
sharing their rich experiences with me.223,287,288 I probed their responses for complete
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descriptions, and encouraged them to speak about connective thoughts that emerged for them in
the context of the interviews. When new or related topics emerged, the interview context allowed
a flexible space for deeper probing of emergent ideas and themes.
One example of the richness of emerging data shared in the interviews was in the broadreaching theme of menstruation. All of the women in this study had many experiences with
menstruation over their lifetime and could therefore speak in realistic detail about their previous
and projected experiences with menstruation in the context of an MPT ring. As previously noted
in Section 3.3, menstruation related to multiple themes. In fact, throughout the many stories that
women shared about their experiences, expectations and perceptions, menstruation was integral
to MPT acceptability including product attributes, use attributes and sexual experience attributes
of the ring. Women spoke with rich detail about the way menstruation would be likely or not to
influence their desires for ring exchange intervals. They described their desires to menstruate
with or without menstrual products and/or additional products (ring). Menstruation was also
discussed as a reason for abstinence and was connected to the lack of a rationale for needing a
ring. The depth with which women described themes and relationships among themes was
facilitated by the open-ended nature of inquiry and rapport developed with me in the context of
the interviews. The interview format provided the space for theme exploration and an
opportunity for me, as the data collector and analyst, to openly ask for clarification and rich
descriptions to interactively broaden and deepen my understanding of women’s thoughts and
experiences.
Complementarity: Clarifying and reconciling complex connections in the focus groups:
The Dynamic Considerations Model includes the Priority Triad: an active prioritization,
balancing and rebalancing of acceptability factors related to the woman herself, her partner and
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their relationship. Each of those factors (self, partner, relationship) were discussed in depth and
breadth throughout the interviews, card sorts and focus groups. However, it was only in the
context of the focus groups that the connections among factors were established.
In the focus groups, the dialogue among women highlighted the struggle of prioritizing
the health or agency of oneself or one’s partner. Some participants held firmly in their
convictions about prioritizing the health and agency of oneself or that of her partner, throughout
the course of the focus group. In contrast, other participants’ convictions about their priorities
shifted over the course of the focus group discussion, often changing in reaction to statements
made by other women in the group. In either case (holding firm or shifting convictions), the
focus group was a unique method in which women clarified their positions on how they balanced
or prioritized their partners, their relationships or themselves. It was through the facilitated
process of comparing and contrasting their own experiences with those of other women that
these participants could affirm their own beliefs or change them.
Recall the dialogue between Kelsey and Jamie in Focus Group 3. The two women reflect
on and converse about the connections between relationship trust and ring use from their own
perspectives, but also as informed by one another’s perspectives. Thus, the general pattern
observed in the focus groups, different from the IDIs and card sorts, was one of connections:
between participants (through dialogue) and subsequently between themes (analytically). The
overarching benefit from the focus group data was that they helped to connect the richly
described themes from the interviews and card sorts into a cohesive narrative: one that
participants grappled with in order to make sense of it to themselves, each other, and me as the
observer. The focus group findings that emerged were therefore a result of the interactions
among participants, the stories they presented, and the way they presented them. Participants
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connected or disconnected themselves to various acceptability narratives based on their
awareness of their own shifting contextual and episodic factors.
I argue that this rich discussion among focus group participants, and the resulting
clarification over their convictions about personal, partner and relationship priorities was only
possible because of the heterogeneity of participants based on relationship status and beliefs. The
women who were in newer relationships or no relationship initially gave more weight to personal
priorities in ring use, whereas women in longer term relationships tended to prioritize their
relationships or partners’ perspectives on acceptability. These differing perspectives shifted over
the course of the focus group, as women clarified their own positions about the meaning of the
Priority Triad within their own current contexts and through recalling previous relationships and
projecting new ones. However, all of this clarification and conjecture was made possible because
of the diversity of relationship statuses of the women in the room: heterogeneity of participants.
While there are clearly understood benefits to ensuring homogeneity, such as ensuring minority
participant voices are not subverted by majority voices, there are also benefits to heterogeneity
on some factors around attitudes and perceptions. As Morgan stated, “The goal is homogeneity
in background, not homogeneity in attitudes” (p. 46)289

Conclusion and Implications of Methodological Considerations:
I began Section 3.4 with a quote from the founders of grounded theory, Glaser and
Strauss, prompting us to acknowledge that a theory is always better informed by using multiple
forms of data to investigate various emergent findings. In Section 3.4, I evaluated the process by
which the data from the interviews, card sorts and focus groups were collected to explore
potential impact of those processes on the emergent grounded theory Model. That evaluation
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highlighted a few key points. First, the overwhelming majority of the data across the three
methods were comparable to one another. In the few cases of non-comparability, it was helpful
to understand the context in which the data were collected in order to investigate these negative
cases and to incorporate that understanding into appropriate conclusions. Second, each of the
methods provided a unique lens through which to understand thematic findings. Thus, there was
an additive benefit of integrating multiple methods in the analysis. Third, there is an overarching
benefit to integrating multiple methods (also applicable to mixed methods) in study design in the
early stages of understanding complex processes involving multiple levels of influence on a
phenomenon or behavior. In this case, the narrative of likely MPT use became richer and more
complete following the back and forth analysis inherent in using multiple methods to identify
associations between themes and constructs. The emergent model was therefore a combination of
conceptual findings with the evaluation of the process undertaken to identify those concepts.
It is clear that not all research settings will have the good fortune of a research design that
can include multiple forms of qualitative data. I am not suggesting that every study do this.
However, when researchers do undertake multiple or mixed methods designs (driven by research
questions, above all else), it behooves them to explore not only purely conceptual findings
produced from those methods, but also to contextualize those findings based on features of those
methods that helped to produce them. In this way, studies that attempt to generate understanding
of complex processes or constructs should not overlook the inherent benefits of evaluating data
collection context and production, as it will likely increase overall understanding of complex
social and behavioral phenomena.
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SECTION 4: DISCUSSION, LIMITATIONS AND CONCLUSIONS

The final section of this dissertation begins with a brief review of the study purpose
(Section 4.1). I then provide a summary of the analytic findings and my interpretations, including
a review of the grounded theory of MPT Ring Acceptability and Likely Use (Section 4.2). Next,
I provide a detailed description of the study’s strengths and limitations (Section 4.3). Finally, the
section concludes with implications for future clinical, programmatic and research
recommendations (Section 4.4).
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Section 4.1: Study Purpose
This dissertation sought to understand women’s acceptability of a vaginal ring used as an
MPT to prevent HIV and pregnancy. Several related priorities guided this research. First, global
efforts to reduce HIV and unintended pregnancy rely on the availability of sexual and
reproductive health products that are acceptable to potential users. Second, the current mix of
prevention methods available to women to protect against unintended pregnancy and HIV is
limited. Third, MPTs are innovative products (e.g. vaginal rings, diaphragms, injectables) that
simultaneously offer protection against both pregnancy and HIV.87 Despite their promise, MPTs
will only be effective in reducing unintended pregnancy and HIV incidence if women are willing
to use them. Therefore, it was clear that research to understand user acceptability of MPTs early
in the product development process was needed to inform device development and trial design,
and ultimately improve product uptake and adherence. Last, in order to promote rigorous studies
on acceptability, this research explored optimal use of individual or multi-method designs in
early stage MPT trials.
This study was one of only two Phase 1 trials148,163 of an IVR with HIV prevention
properties, that incorporated behavioral science in early phases of product development to
address the concern ‘if women won’t use it, why make it?’ Hence, rather than examining
participant behavior following product design, trial implementation and failure due to lack of
product acceptability and adherence, the bio-behavioral design used in this trial was intended to
prospectively inform the development of more acceptable and user-friendly products in the
future.129,130,132,290 The parent study was the first of its kind to enroll women to wear a TDFbased IVR for 2 consecutive weeks, enabling their reflections on acceptability of the ring under
study (parent trial), as well exploring acceptability of an MPT IVR (this dissertation research).
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This research, therefore, helps to answer some early questions about how to develop an MPT
ring from inception that women will accept and use properly that can inform research
methodology employed in subsequent trials.
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Section 4.2: Summary of Key Findings
In Section 3.2, I provided an overview of the theory that emerged from analysis of data
content and data production. This grounded theory is titled “Dynamic Considerations for
Acceptability and Likely Use of an MPT Vaginal Ring” and proposes specific pathways and
relationships among themes and constructs of MPT ring acceptability. This new model was
informed by two previous frameworks from the field of microbicides (Woodsong et al; Mensch
et al)154,208 as well as literature from the field of family planning, and empirical findings from my
current study. The theoretical model developed in this dissertation therefore integrates two
distinct fields of research and practice and provides a blueprint for further research to test the
model’s assertions in the newly developing field of MPT acceptability. Section 3.3 provided indepth descriptions of three key factors that helped to explain women’s overall perceptions of
acceptability and potential future use of an MPT vaginal ring.

1. The Priority Triad
The first key factor, The Priority Triad, explained how acceptability was influenced by
changing prioritization of her relationship, her partner and herself. This triad of contextual
considerations were described sometimes as competing, but also women described their active
attempts to achieve balance among them.
In other research on the dapivirine ring in the ASPIRE trial, women identified
relationship dynamics with male partners as a strong driver of their perceptions of the ring’s
acceptability and future use of the ring, with male attitudes toward the ring as being salient to
women’s decision-making behavior.291 An extensive body of work has demonstrated the concept
that male partners and relationship dynamics are influential on women’s decision-making for

147

method use in the microbicide field.143,153,291–296 In the field of family planning, there is a large
body of research and consensus among researchers that male partners and relationship dynamics
also play a strong role in women’s contraceptive acceptability, choices and use.297–299
Contraceptive research also demonstrates that joint decision-making within the couple typically
has a positive effect on contraceptive use outcomes.300–302 In this research, women were
conflicted about if or how to involve their partners in ring use decision-making. Many insisted
that the choice to use or not use the ring was solely theirs, regardless of the opinion of their
partner. At the same time, many expressed concerns for their partner -- they worried that partners
might experience side effects from TDF (but not hormonal contraception). Women’s claims that
they were in charge of the decision were contradicted by their prioritization of partner
preferences and health. Women attempted to reconcile some of this conflict by extolling personal
agency as not excluding partner or relationship considerations, but rather as having the ability to
ultimately make a balanced decision about what would be best for all involved, including herself
as one of three priority players.
Women discussed the possibility of joint decision-making around MPT use but were
fraught with concern that their male partners might assume they were cheating, if HIV
prevention was part of the decision-making process. This concern over an assumption of
infidelity is a key factor of women’s lack of disclosure to a partner as well as poor adherence in
other trials of PrEP products.303,304 Assumptions of infidelity can have multiple meanings for
women, some of which result in fear of or actual intimate partner violence (IPV) or the risk of
relationship dissolution.213,293,303–306
The ability to successfully balance these priorities was especially challenging at moments
of relationship transitions such as in early stages of relationship formation, during a breakup or
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reigniting a previous relationship. Women highlighted the importance of good communication
and a joint understanding about fertility goals (i.e. to prevent, delay or become pregnant), but did
not share the same ease of communication regarding the use of a product that clearly prevented
pregnancy and HIV.
A rationale for developing an MPT IVR is that it is a female-initiated method. Because it
is worn internally and is not used episodically, women would not need to negotiate or necessarily
disclose ring use to male partners, as they do with condoms and may need to do with vaginal
gels.156,157,174,307,308 Moreover, an MPT IVR is intended to be used for long periods to avoid
adherence problems associated with daily or coital use. Unfortunately, this product rationale was
contradicted by data from the women in this study, who did not want a long-term product, and
felt strongly that their ongoing partners should know they were using it, with mixed findings for
new partners. Women valued MPT disclosure but explained that it would hinge upon her ability
and interest in the difficult task of communicating with a partner about the decision to use one.
Women held different opinions about whether to disclose ring use to a new partner based on their
relationship status and partner type. Some believed their partners had the right to know that they
were being exposed to a drug that could cause side effects. Others believed that disclosing the
ring too early in the relationship might send the message that they were promiscuous. Women
were torn, because withholding it might become problematic later if the relationship matured into
a committed one and that information had been withheld.
Previous microbicide gel research showed that covert use was inconsistent with a serious
or monogamous relationship.

173–177

Recent data on the dapivirine ring in the African context

suggest that relationship dynamics are a central component to acceptability291 and further, male
partners being unaware of their female partners’ ring use was associated with increased social
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harms within the relationship in the bivariate models.293

However, in this research with

American women, there were mixed findings about the relative importance of ring disclosure
within a relationship.

Future research on the introduction of vaginal rings for HIV and

pregnancy prevention should explore how relationship dynamics can influence individual (for
both women and men) and couple-level decision making around ring use. Study design and
product distribution efforts should offer women the opportunity to involve men if women believe
it will be helpful for uptake and use. Including male partners in these efforts offers opportunities
to educate men about drug exposure, STI and contraceptive counseling and to support joint
decision-making and trust-building within the relationship. It also, encourages men to take
responsibility for pregnancy and HIV prevention within a partnership.

2. Episodic Considerations
The second key factor in The Dynamic Considerations Model explained how
acceptability is shaped by Episodic Considerations that are event-driven, being relatively short
in duration, such as a single sex act or a week of menstruation. The main episodic considerations
for acceptability that women described were related to attributes of the ring itself (Product
Attributes); attributes about use of the ring during daily activities (Use Attributes); attributes
about use of the ring during sexual encounters (Sexual Experience Attributes); as well as issues
around menstruation which were integral to all three attributes.
Product attributes, such as size and material, have been extensively investigated in other
vaginal product research.200,260,309 In this study, comfort was reported to be overwhelmingly
positive . Wetness was reported in a positive light, and discharge, although disapproved of
theoretically, was minimally reported. However, general expectations of discomfort prior to ring
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use were high among many and might impede interest in the device outside of the trial context.
Initial perceptions of vaginal rings have been noted as generally negative for many women prior
to use, with approval ratings increasing only after an adjustment period.310 However, while
concerns over discomfort have been shown to diminish over time with use, other concerns such
as side effects and impact on fertility remained.310–312 In the TRIO study of choices among
different placebo forms of MPTs (pills vs. injectables vs. ring), women liked all forms better
after adopting them for 1 month with the largest increase in ring acceptability compared to other
products despite no previous knowledge of vaginal rings.312 This indicates that rings may not be
an initially attractive device to women, but acceptability increases when women are made aware
of their existence and receive early counseling.
Part of the rationale women gave for not wanting to use a ring, despite no feelings of
active discomfort, was that they were hesitant to accept a foreign object inside their bodies. This
is a sentiment that has been expressed in acceptability research on Long Acting Reversible
Contraception (LARC) and vaginal rings for PrEP: manifested as disapproval of an object that
cannot be seen or easily removed and that is located in the epicenter of reproduction and
sexuality.49,294,313 For those women who accepted the idea of inserting or wearing an intravaginal
device (i.e., vaginal ring, tampon), they were still worried about harboring too many devices
inside their vaginas. The idea of wearing more than one intravaginal device simultaneously was
unacceptable to all of the women who offered commentary on this practice. Women in Malawi,
Zimbabwe, Uganda and South Africa also expressed concerns about ‘vaginal crowding’ and how
this would be a barrier to uptake and use of a device vis-a-vis the blockage of necessary outward
flow of menstrual blood.314 Although some evidence exists showing that tampon use alongside
NuvaRing does not reduce effectiveness of the drug,315 this concern of overcrowding still should
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be examined closely by product manufacturers if a ring like this is to be worn during menses, as
‘effectiveness’ is not always women’s top priority in method choice.316
The complexity of ring use around monthly menses was extensive. Women varied
idiosyncratically in their willingness to consider wearing the ring during menstruation, with the
sample split nearly in half of women reporting they would and would not be willing to wear a
ring during menses. The unwilling half voiced concerns about cleanliness, contamination, or the
desire to flush out toxins (including TDF) via the menstrual flow. Because of similarly-held
personal and cultural beliefs about menstruation, women may decide to clean152 and/or remove a
ring during or after menses, even if advised against it. This practice could leave women open to
HIV infection at least monthly. In an MPT where use is indicated for prevention of both HIV and
pregnancy, it is possible that women may overextend their understanding about the mechanisms
of prevention: favoring what they know about hormonal contraception and incorrectly applying it
to TDF or other forms of PrEP, which may require a longer duration or continual wear for
effectiveness. Future development of MPT rings should explore the option of ring removal
during a specified period of menses, to heed women’s objections over vaginal crowding for
purposes of both effectiveness and cultural beliefs around menstrual flow.317 Implementation
studies will then be needed to define the limits of practice (i.e., how long it can remain outside
the body; safe cleaning solutions, etc.).262

3. Rationale for Need
The third key factor for understanding MPT ring acceptability in The Dynamic
Considerations Model is women’s Rationale for Needing a device to prevent HIV and
pregnancy. This rationale reflects a woman’s evaluation of her need to actively prevent HIV or
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pregnancy, including perceptions of risk for both outcomes. None of the women in this study
believed herself to be at risk for HIV and explained that as the major reason they would be
unlikely to use the MPT ring themselves. The women in this study were all using oral
contraceptives (likely indicating some level of pregnancy risk aversion); research has
documented that pregnancy risk perception is artificially low due to some women assuming they
are infertile in the absence of a medical diagnosis.318–320 Perception of infertility is associated
with decreased contraceptive use. Women’s lower risk perception for HIV was explained as
being related to their relationship status.
Theoretical models of health behaviors such as Protection Motivation Theory,321 the
Health Belief Model,322 Social Cognitive Theory,323 Extended Parallel Process Model,324,325 and
the AIDS Risk Reduction Model210 all identify perceived risk as an important predictor of riskrelated behaviors. Motivation to use a product for HIV prevention depends directly on beliefs
about one’s personal risk for acquiring HIV.326,327 Although perceived risk alone is not sufficient
to motivate attitude or behavior change, it is necessary for change. In this study, risk perception
was a central organizing factor related to use, regardless of components of acceptability. For
example, a woman could believe the ring was comfortable, not problematic during sex or for her
partner, and overwhelmingly an acceptable product. However, if her relationship was serious or
long-term, her perception of (no) HIV risk would drive her decision to not use a ring, regardless
of how acceptable it might be. Pregnancy was not discussed in the same ‘risk’ language as HIV,
and potentially reflects women’s differential feelings about pregnancy vs. HIV as a potential
outcome of unprotected sex; whereby pregnancy may be a welcome surprise, HIV is an
unwelcome and incurable illness. Additionally, women may not be or perceive themselves to be
at risk for HIV, which may guide their disinterest in an MPT.
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Relative to other regions where HIV prevalence can be as high as 35% for women of
childbearing age, the women in this study lived in a relatively lower risk region.328 However,
relative to other areas in New York City and the United States overall, the prevalence of HIV in
the Bronx was comparatively high. Despite this relatively higher risk profile of their community,
they were almost entirely unconcerned about this. Perceived low risk for HIV will remain a
barrier to uptake of any HIV-preventive IVR, regardless of actual personal or population-based
HIV risk status.
This finding may be different in high prevalence regions in sub-Saharan Africa, however,
it is also possible that this unawareness or dismissiveness of risk based on community prevalence
is more universal.294,329 Women in this study mainly perceived their risk status to be low, yet, the
inverse relationship between perceived risk and relationship trust is one that permeates romantic
relationships globally.329,330 The Model therefore explains that lack of perceived risk, regardless
of actual risk, can completely circumvent the acceptability of an MPT and the likelihood of MPT
use.
Despite decreased perception of risk for HIV and pregnancy, women in this study did
herald an MPT ring as a positive prevention option for women more generally. They appreciated
the efficiency of a device that provided a joint solution to prevention of pregnancy and HIV.
They also talked in many indirect ways about an MPT ring being able to ward off internalized
and externalized experiences of stigma for using an HIV-only prevention product. HIV-related
stigma around sexual behaviors and identities has been deeply entrenched in many communities,
and this stigma has been a barrier to prevention and treatment efforts.331 HIV stigma has also
influenced ‘PrEP stigma’, in which negative meanings around the use of HIV prevention
medications are tied to negative feelings about PrEP users.332–334 For the women in this study,
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the avoidance of PrEP stigma may help explain why women would emphasize the contraceptive
component of an MPT so as to avoid being castigated as engaging in ‘risky’ sexual
behavior.333,334
Toward this end, women explained that when pregnancy prevention was made primary,
the stigma associated with HIV prevention efforts was minimized for MPT use.310,311,335, In the
context of the relationship, therefore, attempting to prevent pregnancy would make it more
acceptable to actively prevent HIV because it would merely be added to the basket of preventive
behaviors a couple could conjure to prevent negative outcomes and to support individual and
relationship health. When use of an MPT was framed as contraception with this added HIV
prevention bonus, women saw this behavior as being less stigmatized and more acceptable to
herself and to the couple overall. Therefore, women classified an MPT ring as a joint solution to
the problem of perceived risk for HIV and pregnancy without embodying a stigmatized identity.
Overall, women accepted an MPT ring if it had little additional impact on her body (e.g., menses
and fertility), her partner, their relationship or the sex act. Women envisioned MPTs as an
efficient solution to accomplishing two goals if they were already looking to do so.
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Section 4.3: Strengths and Limitations
This study was the first of its kind to explore factors of IVR MPT acceptability with
women who are using a candidate IVR that is similar in structure and includes a microbicide
drug or its placebo. This study was only possible, however, because it was incorporated into an
ongoing Phase 1 clinical trial of a TDF PrEP-only ring. Inherent to this parent/dissertation
design, however, came some limitations that I detail below.
Recruitment
Phase 1 clinical trials are designed to “evaluate [a drug’s] safety, determine a safe dosage
range, and identify side effects” and therefore rely on participant adherence to product use.336
Hence, eligibility requirements for the parent study sample necessarily skewed the sub-study
sample toward ‘adherent’ participants in order to ensure product use. These were the need to live
in geographic proximity to the study site, ability to maintain sexual abstinence, taking oral
contraceptives and willingness to forego vaginal product use for 3 consecutive weeks.
Recruitment of women with higher HIV risk profiles (e.g. sex workers or those who regularly
douche) was limited. Women in this study therefore had relatively low HIV risk compared to
those to whom MPTs will likely be most targeted (e.g., countries with high rates of unintended
pregnancy and HIV). It is true that the Bronx, NY does have a higher rate of HIV infection and
unintended pregnancy among women than other places in the United States. However, there is
still a relatively low prevalence and risk for contracting HIV compared to places where HIV is
high, such as countries in sub-Sharan Africa.
Theoretical sampling was difficult to implement with this small sample, and complete
saturation was not achieved on all emergent themes.187 Logistically, I was also not able to
analyze the data quickly enough to identify appropriate emergent themes to inform successive
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participant recruitment for the parent study. I attempted to speed up the process of emergent
theme identification by weekly with my research assistant and an expert in qualitative methods to
identify early patterns in the data and questions requiring further exploration with each
successive participant. However, this was a challenge as I had little control over the speed of
parent trial recruitment. I communicated regularly with the parent study team to request
recruitment of women with characteristics of emerging interest, but the limited pool of women
made this challenging.
Skewed Participant characteristics
Participants may have self-selected to be part of the research for a few different reasons,
which was not explicitly unpacked during data collection. For example, the sample included
multiple PhD students in related health sciences fields. Their motivations to participate may have
been altruistic, but also may have been guided by a desire for experience with the research
environment or the parent trial investigators. Their motivations remain unknown but may have
shaped the overarching narrative of the data such that positive beliefs about the development of a
biomedical product were disproportionately positive. In the ASPIRE microbicide vaginal ring
trial, a range of participation motivations were identified including women’s ethical
predispositions.294 The idea of ‘ethical intercorporality’ has been coined to represent this type of
altruism among participants, who care more about social and ethical motivations for the good of
their communities when choosing to participate in a trial.294,337 It is important that we recognize
there may be a range of motivations influencing different women in this trial and therefore their
perspectives on acceptability and likelihood of use may be more optimistic than for women who
chose not to participate.
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In addition to having a high adherence/low risk profile, women recruited for the parent
study were further bounded by a range of characteristics that may have impacted the findings.
These women used oral contraceptives over other methods; were at least somewhat accepting of
an HIV prophylactic drug, and; were willing to wear an intravaginal ring for two weeks. These
eligibility requirements therefore included women who already did not wish to become pregnant
and had taken active steps to prevent it; accepted wearing an intravaginal device, accepted userinitiated hormonal contraception and were willing to use an investigational HIV drug. In an
attempt to expand the window of experiences with and thoughts about MPT acceptability over
the life course, I used a narrative approach to data collection when possible to encourage women
to retrospectively discuss previous life experiences (e.g., during a time in their lives when they
used a different type of contraceptive) and to identify reasons why other women may or may not
accept an MPT IVR.
Limited discussion of fertility related issues
The TDF IVR used by the participants in the parent trial did not include any form of
contraception, so participants explored some issues theoretically (contraceptive and fertilityrelated) and others based on their experience in the parent trial (TDF or ring-related). Without a
contraceptive ingredient to the IVR, there was likely an underreporting of real or perceived
contraceptive-related side effects that would be expected in the presence of an actual MPT. This
limitation also may have made it difficult for women to even engage with deeper thinking or
considerations related to the acceptability of a product that additionally prevented pregnancy.
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Hypothetical discussions about sex, menstruation, and partner experiences
Women were instructed to abstain from sex with a male partner while the IVR was in
place, limiting the ability to comment on the lived experience of ring use during sex. Further, I
was unable to speak directly to male partners because of parent sample limitations. To address
these limitations, I asked women to theorize her own and her partner’s likely perceptions of and
experiences with the ring in the context of their relationship and during sex. However, the
hypothetical nature of the data collection made it impossible to evaluate women’s and men’s true
experiences during a sex act, menstruation or within the context of their relationship.
Without the perspective of men, it is difficult to fully explore how men would actually
feel about the product components and the potential impact on use. For example, women
expressed the need for agency within their relationships as distinct from but also connected to
their desires to prioritize their own health. Their male partners, on the other hand, were perceived
to have concerns about their own (male) health, but the parallel issue of male agency within the
relationship never emerged, and therefore was not included in this model. I am calling attention
to the fact that male agency (as but one example) may or may not be related to overall MPT
acceptability. However, we cannot surmise this because of the limitations in study design to
restrict sexual activity and limiting the sample to only women.

Questions and Challenges to Methodological Findings
All research methods have strengths and weaknesses. The following details some of these
methodological strengths and limitations that may have changed the way the data were produced
and, subsequently the conceptual findings of this study.
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Focus Groups
Only 3 focus groups were conducted because of the small pool of women to sample from.
The third FG generated different dynamics than the first two, such that women had a livelier
exchange and disagreements were civil yet abundant. I hypothesize that the different dynamics
were related to the fact that participants and facilitator in group 3 had never met before, and
therefore the dialogue was about a new topic to them that had some novelty in discussion.
Because of this, women likely were more motivated to talk about their life experiences
and participate in the study, including discussion with other participants. According to principles
of theoretical sampling, the logical next step would have been to continue recruiting women for
additional focus groups who had not yet been interviewed, to best understand their Priority
Triads. However, there were no available participants left to recruit for additional groups.
Saturation on the focus group process was not met, leaving room for speculation as to why focus
group 3 produced more complex interaction data than groups 1 and 2.
Ordering effects or Participant Fatigue?
There is also the question about the sequencing of data collection methods and potential
impact of such ordering. Unfortunately, we cannot compare different sequences so that
hypothesis remains untested. It may be that the cumulative burden of data collection may reduce
participant effort. Alternatively, beginning the data collection sequence with interviews vs. focus
groups may have artificially imposed a ‘reverse funnel effect’220 on data production whereby
participants established their narratives about ring acceptability from a more focused experience,
only to be allowed to expand their perspectives and discussion considerations when exposed to
others in the focus group format. It could also be that some data are less amenable to focus group
collection if they are stigmatizing or sensitive and more likely to be withheld in public. For the
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12 women who completed all four possible data collection points, happening in the same
sequence (2 IDIs followed by card sort and focus group), there remain questions about the
sequencing of data collection techniques and potential for ordering effects to impact the findings.
For these women, in particular, I was concerned about a potential maturation effect in which
questions from the interviews and topics discussed in the card sort would change the material
women discussed in the context of the focus group.338 It is unclear if this occurred, but definitely
I witnessed participant fatigue during the second IDI and card sort, where women cut short
exploration of topics they had “already told me about” in IDI 1. Sometimes they rushed through
the cards to quickly place or order them. I frequently reminded them to “say out loud for the
recording” their choices for card placement or ranking, in an effort to encourage them to refocus
via explaining their choices of card placement.
This participant fatigue may have disrupted deeper thinking about ranked order of
importance of acceptability factors during the card sort, or it may have made it more difficult to
change course once previous statements had been made in the IDIs. I found that there were some
themes and constructs that emerged during one method and not in another; during one method
and then differently in another; or in one method but then was refined in another. In each of these
cases, it would have been necessary to use a crossover design to accommodate a return to a
previous method of data collection for confirmation, to test emergent findings or to verify
interesting or peculiar findings.
Compared to focus groups 1 and 2, the women in focus group 3 engaged in more
spontaneous dialogue between themselves, without my intervention as facilitator. However,
topics that were newly discussed in all three of the FGs for all participants, such as reactions to
visualizing a ring or community level risk, generated similarly high levels of discussion across
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all three groups. It may be that increasing the sheer number of data collection episodes may have
pushed the participants in FGs 1 and 2 to the point of boredom due to repetition, such that they
may not have engaged fully or as enthusiastically to the research topics they spoke about in their
earlier data collection episodes.
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Section 4.4: Implications and Conclusions
Clinical and Public Health Programming Implications
Counseling from health care providers should include intermittent assessment of
women’s joint HIV risk status and family planning goals, acknowledging that relationships,
sexual activity and related priorities change over time and may require new strategies.
Relationship types and characteristics vary dramatically in level of commitment, trust, love,
monogamy, sero-discordance, intermittence and length. Women’s perception of need for an MPT
may shift alongside changes in their relationships and with specific partners, as well as their own
priorities.104 Healthcare providers should counsel women about the range of prevention products
that meet these changing needs. Providers can play a further role in promoting user acceptability
by offering initial insertion as has been done with the diaphragm and guiding women to
overcome fear associated with device insertion and removal, potentially through comparing and
contrasting to other vaginal products like contraceptive rings or tampons. 152,329,339
Providers can prospectively alert women to monitor their own changing “seasons of risk”
or moments where family planning needs change such as relationship status changes and sexual
practices during menstruation. This approach may be particularly effective for women in new
relationships, as an opportunity to more easily onboard a new method with a new partner that fits
their needs. In the case of MPTs, special attention will need to be paid to match women’s
likelihood of use relative to menstruation, individual sex acts and start-up timing so women are
aware of potential effectiveness issues.329,340
This study adds more evidence to the growing body of research justifying a variety of
prevention options available for women to choose from, so women can make informed and
appropriate decisions for themselves regarding their own sexual and reproductive lives. It is
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known that method choice and related satisfaction are associated with consistent use.105,341–345 It
is prudent for clinicians and public health professionals to recognize that women are stewards of
their own health, and to proactively prepare patients and communities for future decision-making
points and awareness of the option for MPTs. Providers have the responsibility to counsel
women (and potentially their partners) on a variety of prevention tools, to help them assess risk
and fertility questions, and subsequently support women to choose the best method for them to
meet their sexual and reproductive health needs as guided by their own contexts and priorities.
Recent efforts in contraceptive counseling have emphasized a patient-centered approach that
recognizes women as experts over their own lives, with clinicians acting as medical experts.346
Public health systems can collaboratively ensure that a range of products are available and
accessible to women and their partners.
The process of method decision-making is complicated and will require clinical and
public health practitioners to hone suitable approaches, so that women are equipped to make
these challenging decisions that often attend to multiple factors at once and change over time. A
recent study exploring women’s decision-making needs for choosing a contraceptive method
shows that women turn to family members and peers to discuss contraceptive decisional topics,
but often feel ‘decisional conflict’ in the clinical context with their providers, potentially
explaining suboptimal choice and subsequent use outcomes.343 MPT decision-making will also
prove to be complicated when they become available and, thus, deserves a proactive approach
where clinicians develop more fluency with appropriate decision-making tools that are patientand woman-centered. Some of these decisional tools are in development for contraceptive
methods, giving MPTs a body of information from which to start building its own toolkit for
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appropriate counseling approaches.347,348 Health systems will need to adopt appropriate standards
for clinical counseling based on a strong evidence base that is woman-centered.
Addressing women’s and couples’ pregnancy desires as well as perception of HIV risk
are each challenging tasks, in and of themselves.180,329,349 In terms of MPT acceptability and
likely use, however, they are both essential to address as a package for ensuring sexual and
reproductive health. Concerted effort should be given to interventions that do not undermine
women’s relationships with male partners but instead support women in their relationships, as
well as attending to their own desires. One recent study on PrEP uptake among women cautioned
“by strongly emphasizing risk as a rationale for PrEP use, we may inadvertently connect the
concept of mistrust with PrEP use, forcing individuals to choose between the logic of PrEP and
their strong feelings of trust.”(p. 3477) 350 Interventions may therefore benefit from emphasizing
community level risk, as perception of high community HIV prevalence has been associated with
increased HIV protective behaviors.351,352 Alternatively, MPTs can be discussed as a
contraceptive that has “bonus” benefits, to minimize concerns around stigma and infidelity.
Offering couples counseling on a suite of prevention products may also avoid harming
relationships, especially if messages are framed with the goal of addressing their family planning
needs primarily and risk prevention secondarily. According to the contracepting women in our
study, preventing pregnancy was an outcome they believed to be easier to communicate than
HIV prevention. Perhaps a focus on balancing the needs and concerns of women and men in the
context of their reproductive circumstances can help to create equitable prioritization of health
needs for both partners, while maintaining the integrity of the relationship.204,342,353 Additionally,
public health messaging can focus on insuring women maintain good health for their own sense
of well-being, their relationships and the sake of future pregnancies and children.180,354
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Implications for Future Research
MPT research and development efforts should follow a woman-centered research
paradigm in which potential MPT users are integrated at the early phases of product
conceptualization and study design so women will find value in them once available in the
marketplace. Incorporating user preferences in early phase clinical trials may shorten the product
development timeline, prevent costly large-scale clinical trials that fail due to participant nonadherence, and improve likelihood of product adoption once developed.129,131,181,355
For the development of future MPT trials, it will be important to integrate experts and
previous lessons learned from the siloed fields of family planning and HIV prevention. As one
team of advocates urged regarding MPTs: “Don't reinvent the wheel.”82 Future trials of MPT
IVRs and other delivery devices that include an actual contraceptive component should include
early behavioral design research to assess acceptability and likely use. Some of these trials are
currently underway.87
MPT device developers should consider concurrent development of a range of devices
and drug combinations that are responsive to women’s changing life contexts, relationships and
related preferences. At the moment, there are multiple products in different stages of
development, and all may be useful to develop, rather than settling on a single product. Some
PrEP studies are evaluating the possibility of differently timed products, that can be eventdriven, daily, monthly or longer intervals.294,356,357 Following this approach, future study designs
should consider recruiting women from a range of relationship statuses, including those who are
in-between, recently broken up or participating in more episodic sexual relationships, to
understand how these temporally different relationship characteristics may affect women’s
choices among MPT features and products.

166

With MPTs being a relatively nascent field of candidate products, it is essential that early
bench research also explicitly investigates the dose-response required to confer protection for
women against HIV and pregnancy during periods of removal of up to 1 week, during which
menstruation may occur, as these are episodic considerations impacting choice, use and
subsequent effectiveness. While we know more about efficacy of a contraceptive vaginal ring,
we know less about localized PrEP efficacy for women, and almost nothing about localized
efficacy against both pregnancy and HIV from an MPT.358 As it appears that many women
would want to remove a ring during a week of menstruation and potentially during sex,
developers will need to explore how to confer protection during these potential periods of
removal.
As new MPTs are conceptualized, it will be important to more pointedly address
women’s acceptability of an actual MPT ring with contraceptive properties in the geographic and
relationship contexts in which they will be used. Cross-over designs can be helpful so that
women can compare methods to one another, but acceptability of these products should be
evaluated with attention to ordering effects and changing relationships.312

Male partners’

perspectives are also a critical factor in support and uptake of products; thus, male participation
should be seriously considered in study designs.
Study designs do not necessarily need multiple methods to understand basic thematic
findings, however, there is an unparalleled richness that is inherent in complementary designs
that is unachievable otherwise. A grounded theory is strengthened by using more than one
method to explain it and findings can be elevated when the context of data collection and factors
inherent to the methods are also evaluated. While it may not always be logistically feasible to
include multiple methods, this study reminds us of the inherent strengths and challenges that
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exist within individual methods that can be leveraged to help answer different elements of our
research questions.
For any new device, behavioral intervention will need to be developed and tested to
ensure that perception of HIV risk is adequately addressed. These interventions include clinical
interventions for provider counseling but require more thoughtfulness about which messages are
appropriate for different populations and who will most effectively deliver those messages. It
will be important to understand the impact of a variety of approaches to emphasizing individual
vs. relationship vs. community level risk, on a variety of outcomes including relationship
dissolution, relationship conflict (including violence), method choice and use.
Lastly, ‘The Model’ produced here is both exciting and preliminary, based on empirical
data from this study and from lessons learned from other microbicide and contraceptive research.
It should be tested, augmented and clarified conceptually, as more MPTs are developed and
evaluated. This would include explicitly testing the proposed associations for directionality and
applicability in different populations. This study was conducted with US women. While the
findings might apply to women in other contexts, it will be important to determine this with
similarly or more rigorous mixed- or multi-method study designs.

Conclusion
Qualitative research can be a valuable addition to early phase clinical trials of biomedical
HIV prevention methods. By using naturalistic approaches guiding women to discuss their
perceptions, attitudes, and concerns, qualitative interviews create opportunities for women to
raise problems with product acceptability and use that might not occur to product developers.
The intent is not to generalize these themes to other populations, but instead to explore common
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threads in the universality of some of these findings. Focus groups allow women a forum to
clarify some of their previously unexplored preferences and ideas. Card sorts allow for the
discussion of otherwise stigmatized topics as well as the ability to rank factors of acceptability
and likely use. Interviews allowed for deep exploration of emergent theoretical data. Each data
collection added specific findings that were inherent to their method.
Themes around partner trust, low perceived risk, menstrual practices and beliefs and
stigma have been documented in other populations and deserve further exploration, so we can
understand how to develop acceptable MPT products globally.152,163,168,174,359 Beliefs around
tampon use, interference with drug absorption and distaste for overcrowding products inside
women’s vaginas are relatively new findings that warrant further study both qualitatively to
explore depth and meaning and quantitatively to discern how widely and how strongly held these
beliefs are within a population.
Taken together with findings from other ring trials,152,161,163 it seems that women’s
acceptability has less to do with the specific drug within a ring or even the ring itself. Instead,
women’s acceptability and expected use of any product or drug combination hinges on the
complex totality of her experience with using any MPT product that might challenge her
relationship, partner and individual health. In a critique of contraceptive acceptability
assessment, Heise (1997) makes a similar point that contraceptive acceptability is not “inherent
in a product or a method” but rather is informed by contextual factors.204 My data similarly
reflect this point related to MPT acceptability, suggesting that one way to address MPT ring
acceptability and expected use is to develop different rings to fit women’s relationships and
contexts over time and across separate episodes. The women in this study certainly indicated
their preference for an MPT ring over one that solely provided protection against HIV, since all
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these women were trying to avoid pregnancy, regardless of their awareness or acceptance of HIV
risk. Adding an MPT to the mix of available women’s prevention methods would address
vulnerability to both pregnancy and HIV during seasons of risk.329
Actual and perceived risk status fluctuate over time as a function of relationship
formations, maintenance, breakups and all phases in-between. Eventual health promotion will
need to address the dynamic nature of sexual relationships by using a combination of tailored
counseling approaches to women and their partners, broad public health messaging, and the
development of multiple forms of preventive devices to increase acceptability more broadly
among both women and men. Researchers should also not artificially disaggregate women’s
rationale for needing an MPT from the conceptualization of acceptability or use of these
prevention products, as they are inextricably linked. Future MPT trials should continue to
grapple with how to develop and market an array of products that will be acceptable to women at
different life cycles or stages.
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APPENDIX A: PREVALENCE MAPS 21

Figure 1: HIV prevalence among women aged 15 years and older by country or region.
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Figure 2: UNMC among women aged 15-49 years by country.
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Figure 3: Unintended pregnancy rate per 1000 women aged 15-49 years by subregion.
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Figure 4: HIV prevalence and UNMC among women.
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APPENDIX B: IRB Letter of Exemption

176

177

178

APPENDIX C: COMPLETE INCLUSION AND EXCLUSION CRITERIA FOR
PARTICIPANTS IN PARENT STUDY FOR TDF RING
Inclusion Criteria:
Women must meet all the following criteria to be eligible for inclusion in the Parent
Study:
•
•

•
•
•
•

•
•

•
•

•
•

Age 18-45 years (inclusive) at screening.
General good health (by volunteer history and per investigator discretion) without any
clinically significant systemic disease (including, but not limited to significant liver
disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or
bone disease, and diabetes).
Able and willing to provide written informed consent to be screened for and take part in the
study.
Able and willing to provide adequate locator information.
HIV-uninfected based on testing performed by study staff during screening procedures (per
applicable algorithm in Appendix II).
Using low dose combined (estrogen and progesterone-containing) oral contraceptive pills
dosed as follows: one tablet daily for days 1-21, then one inert tablet daily (or no tablets for
days 22-28). (Does not include extended-cycle, 24 and 28-day active pill regimens). Per
participant report must be using this contraceptive method with no change in the prior 3
months and intending to use same method for the duration of study participation.
Currently have a regular 28-day menstrual cycle on combined oral contraceptive pills.
Normal Pap test at screening or appropriately documented history of Pap test and completed
follow-up of any abnormal pap tests consistent with American Congress of Obstetricians and
Gynecologists (ACOG) practice guidelines #99 and #109. (Atypical cells of undetermined
significance (ASCUS) with no evidence of high risk HPV will be included)
Per participant report at Screening and Enrollment, agrees not to participate in other research
studies involving drugs, medical devices, or vaginal products for the duration of study
participation.
At Screening, participant states she is able and willing to refrain from inserting any nonstudy vaginal products or objects into the vagina, including but not limited to, spermicides,
female condoms, diaphragms, contraceptive vaginal rings, vaginal medications, menstrual
cups, cervical caps (or any other vaginal barrier method), douches, lubricants, vaginal drying
agents, sex toys (vibrators, dildos, etc.), and tampons for the 48 hours prior to Visit 2
throughout the duration of the study.
Able and willing to abstain from oral, vaginal and anal sex for 48 hours prior to Visit 2 until
the sixth day after Visit 2, 48 hours prior to TDF or placebo IVR insertion, the 14 days of
TDF or placebo IVR use, and for 7 days after the TDF IVR is removed.
Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy
colposcopy and genital tract sample collection.

Exclusion Criteria:
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Women must meet none of the following criteria prior to genital sampling at Parent Study
Visit 2. Participant report of any of the following at Screening:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

•

•
•

Known adverse reaction to polyurethane or to any components of the study product or allergy
to both silver nitrate and Monsel’s solution.
Hepatitis B infection (defined as positive hepatitis B surface antigen).
Chronic, recurrent, and/or acute vulvar or vaginal symptoms (pain, irritation, spotting, etc.).
Known bleeding disorder that could lead to prolonged or continuous bleeding with biopsy.
Intending to become pregnant during the period of study participation.
Currently breastfeeding or having breastfed an infant in the last two months, or planning to
breastfeed during the course of the study.
Menopause.
History of unexplained or unresolved intermenstrual bleeding in the 3 months prior to
screening.
History of gynecological procedures (including genital piercing) on the external genitalia,
vagina or cervix in the last 14 days.
Hysterectomy.
Use and/or anticipated use during the study period of an intravaginal or intrauterine device.
Systemic use in the last 2 weeks or anticipated use during the study period of any of the
following: corticosteroids, antibiotics, antifungals, antivirals, anticoagulants or
antiretrovirals.
Plans to relocate away from the study site area during the period of study participation.
Grade 1 or higher laboratory abnormality, per the August 2009 update of the Division of
AIDS, National Institute of Allergy and Infectious Disease (DAIDS) Table for Grading the
Severity of Adverse Events (AEs).
At Screening or Enrollment, is pregnant (based on urine pregnancy test).
In the last six months, diagnosed with or treated for any sexually transmitted infection (STI).
Note: Women with a history of genital herpes or condylomata who have been asymptomatic
for at least six months may be considered for eligibility. HSV 1 and 2 serologies will be
obtained in order to correlate with CVF antiviral activity. Participants with a positive HSV 2
IgG test, but without a clinical history of genital herpes will be included.
Reproductive tract infection (RTI) or pelvic inflammatory disease (PID) requiring treatment
per current CDC guidelines at Screening or Enrollment.
Note: Women diagnosed with symptomatic bacterial vaginosis (BV) as defined by Amsel’s
criteria will be excluded. Otherwise eligible women diagnosed with symptomatic
vulvovaginal candidiasis (VVC) or urinary tract infection (UTI) will be eligible if Visit 2
(Enrollment) is scheduled after all symptoms have resolved and at least two weeks after
completing treatment.
Positive test for Trichomonas vaginalis, Neisseria gonorrhea or Chlamydia trachomatis at
screening.
Reactive test for syphilis at screening.
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•

•
•

Note: Women with a history of syphilis that have been appropriately treated may be
considered for eligibility. Women with a history of syphilis diagnosis or treatment in the last
six months will be excluded.
At Screening or Enrollment, has a clinically apparent Grade 1 or higher pelvic exam finding
(observed by study clinician or designee) per the Division of AIDS Table for Grading the
Severity of Adult and Pediatric Adverse Events, Addendum 1, Female Genital Grading Table
for Use in Microbicide Studies.
Note: Cervical friability bleeding associated with speculum insertion and/or specimen
collection judged to be within the range of normal according to the clinical judgment of the
PL/designee is considered expected non-menstrual bleeding and is not exclusionary.
At Screening, has severe pelvic relaxation such that either the vaginal walls or the uterine
cervix descend beyond the vaginal introitus with Valsalva maneuver.
Has any condition that, in the investigator’s opinion, would preclude informed consent, make
study participation unsafe, complicate interpretation of study outcome data, or otherwise
interfere with achieving the study objectives
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APPENDIX D: DATA COLLECTION TOOLSvii

vii

These data collection tools were designed for joint use with both the parent study and this
dissertation sub-study. Items that apply solely to this sub-study are highlighted in grey.
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In-Depth Interview Guide #1
Introduction: Thank you for agreeing to talk with me today. I am here to get a deeper
understanding about your experiences with the ring. I would like to hear about ALL of your
experiences with the ring since it was inserted, regardless of what you have been instructed to do
or not to do by the other study staff. To help you try to feel more comfortable with talking to me
about your experiences, the other study staff has agreed to let me conduct this interview with you
confidentially. So that means I won’t share any of your identified data with the study staff. Do
you have any questions for me before we begin?
1) First, please tell me about the ring -- How is it going so far?
• PROBE for range: What else? Anything else? (Obtain a complete list of the participant’s
reactions/experiences)
• PROBE for depth: Go back to each thing mentioned and ask for in-depth description,
including how, when, how long.
• PROBE for emotional valence: For each thing mentioned, ask how the participant felt
about the event/problem.
2) Have you had any problems since the ring was put in?
• PROBE: What were the problem(s)? How often? How serious? How do you know the
problem was related to the ring?
•

3) Have you had any (other) concerns or worries about wearing the ring?
PROBE: Exact nature of the concern, why the concern happened, when it started,
whether the concern got stronger or more serious or less serious over time.

4) Before you had the ring inserted, what did you expect it might be like?
• PROBE: To have it inserted; To wear it every day; To impact your menstrual cycle.
• PROBE: How does your actual experience compare to what you thought might happen?
5) What do you like about wearing the ring?
• PROBE: Was this true the whole time you used it?
• PROBE: How much do you like the ring?
6) Tell me about when the ring was (inserted)?
• PROBE: Was the procedure easy or hard?
• PROBE: Did you take the ring out?
7) I know that study staff has asked that you not have sex while the ring is in. What has
that been like for you?
• PROBE: Partner issues with the ring?
• PROBE: Any problems during sex?
• PROBE: Use any vaginal products?
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8) I also know that study staff has asked that you not to remove the ring at any time
during the last week. What has that been like for you?
• PROBE: Has the ring been outside of your body for any time at all?
• PROBE: Did you think about checking on it?
• PROBE: If yes, why, how easy/hard it was, whether they told the doctor);
• PROBE: If no, what did you think it might be like to remove it? Why?
9) If you had a choice in designing this ring, do you have thoughts about what would be the
ideal length of time to leave it in your body before changing it out for a new one?
• PROBE: How often you would want to change it out?
• PROBE: What helped you decide that amount of time?
10) Some women might be more interested in using a ring like this than others. Can you
characterize who might be interested in using a ring like this one to prevent them from
contracting HIV? What about those who wouldn’t want to use it?
• PROBE: Any particular lifestyle or life circumstance?
• PROBE: Why might women want to use it?
• PROBE: Why wouldn't they want to use it?
11) If this ring is available for use in the future, would you want to use it?
• PROBE: Why or why not?
• PROBE: What would they have to change about the ring to increase your interest in using
it?
• PROBE: What else would you want to know about the ring to decide?
12) What if we invented a ring like this one, but it was a ring that prevented HIV and
pregnancy, what would you consider before using this type of ring?
• PROBE: What more would you want to know about it?
• PROBE: Under what circumstances would you want to use it?
• PROBE: Why would you not want to use it?
• PROBE: What concerns might you have?
• PROBE: Can you describe a woman who would be interested in using it?
13) Think about a sexual partner or relationship. What would HE would think about you
using a ring like this?
• PROBE: What might a partner think about you wearing a vaginal ring that is meant to
prevent you from getting HIV and from getting pregnant?
• PROBE: What problems might he have with you using this ring?
• PROBE: What might he like about you using this ring?
14) If you were to use a ring that prevented both HIV and pregnancy, it might mean that
you would not get your regular period every month. What is your reaction to that?
• PROBE: Why might you want/not want to get your period every month?
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15) If there were 3 types of rings available today: 1) a contraceptive-only ring like the
Nuva ring, 2) an HIV-only ring, and 3) a combination ring that did both, which one would
you choose?
• PROBE: Why did you choose this one over the other options?
• PROBE: Would you choose a ring over other methods?
• PROBE: How did you make that decision? Walk me through it.
• PROBE: What factors were you considering?
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In-Depth Interview Guide #2
Introduction: Thank you for coming back to talk with me about your experiences with the
ring. It’s great to see you again. I am just going to remind you once more, that everything you
tell me during this interview is confidential from the other study staff. Since our last interview,
did you have any further thoughts about what we talked about, or any questions for me?
1) So now the ring is out. How was the experience? Since the last time I saw you has
anything changed?
• PROBE for range: What else? Anything else? (Obtain a complete list of the participant’s
reactions/experiences).
• PROBE for depth: Go back to each thing mentioned and ask for in-depth description,
including how, when, how long.
• PROBE for emotional valence: For each thing mentioned, ask how the participant felt
about the event/problem.
2) Have you had any (other) concerns or worries about wearing the ring?
• PROBE: Exact nature of the concern, why the concern happened, when it started,
whether the concern got stronger or more serious or less serious over time.
3) Have you had any problems with the ring since last interview?
• PROBE: What were the problem(s)? How often? How serious? How do you know the
problem was related to the ring?
4) What did you like about wearing the ring?
• PROBE: Was this true the whole time you used it? How much do you like the ring?
5) Tell me about when the ring was removed?
• PROBE: Was the procedure easy or hard? Did you take the ring out ever by yourself?
• Do you have any thoughts about putting it in or taking it out yourself?
6) Did you have sex while the ring was in? Use any vaginal products?
• PROBE for problems with the ring, partner issues with the ring, did they tell the doctor
7) Was the ring outside your body at any time?
• PROBE: If yes, why, how easy/hard it was, whether they told the doctor);
• If no, did you want to remove it? Why?
8) In your opinion, will women want to use a ring like this one?
• PROBE: Which women would use it? Why might women want to use it? Why wouldn't
they want to use it?
9) What if we invented an HIV ring like this one, but it was a ring that also prevented
pregnancy, would you be interested in using it?

186

•

PROBE: Under what circumstances would you use it? Why would you not want to use it?
What kind of woman would want to use it? In what ways might your relationship or your
sex partner influence your use of this ring?

10) If you were to use a ring that prevented both HIV and pregnancy, it might mean that
you would not get your regular period every month. What is your reaction to that?
• PROBE: Is that a good thing or a bad thing?
11) If there were 3 types of rings available today: 1) a contraceptive-only ring like the
Nuva ring, 2) an HIV-only ring, and 3) a combination ring that did both, which one would
you choose?
• PROBE: Why did you choose this one over the other options? How did you make that
decision? What factors were you considering?
• PROBE: (query anything different from IDI1 to IDI2)
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Focus Group Guide
FOCUS GROUP GOALS:
•
•
•
•
•

To explore participant experiences with the TDF-only ring
To understand potential barriers and facilitators to using a TDF-only ring
To understand potential barriers and facilitators to using a “dual” (TDF+contraceptive)
ring
To solicit suggestions for improvement of a TDF-only ring
To solicit suggestions for improvement of an MPT ring
MODERATOR NOTE: Make sure to ask the questions in bold. Other questions are

important and should be probed if they do not come up in the discussion. Adhere to the time
guidelines.
INTRODUCTION
minutes

5

The introduction should be individualized as desired. However, the following should be
covered:
•
•
•
•
•

•

Thank you for being here.
As you all know, my name is Dana and I will be leading our discussion today. My job is to
make sure everyone has a chance to talk and that we cover all the questions that we want to
discuss.
This is ______________ who will be assisting me during the group by taking detailed notes
on what is said and writing the group’s responses on the board when necessary. The notes
will not identify any group members by name.
We are here today to talk about vaginal rings! I don’t know many groups that come together
for this purpose. We really want to understand key issues about HIV preventive vaginal
rings, so we can develop one that is appropriate for women to use.
The questions I ask you tonight have no right or wrong answers. We just want to hear what
you think and we want to try to hear from all of you. I have interviewed each of you twice,
and I can say that I’ve learned something new from each one of you. So I am confident that
every one of you will add value to this overall discussion.
Also, I have interviewed each of you twice, so I know that you are accustomed to just talking
directly to me. But while we are in this group, I hope you will take advantage of the things
that the OTHER women say and ask about. I encourage you to talk to one another, but just
one at a time. I may ask some clarifying questions or steer us back if we get off-topic, but
ultimately I want you to feel free to respond to what other people are saying.
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•
•
•

•
•
•
•

The discussion group is confidential. The group discussion will be audio recorded just to
insure accuracy but your answers will not be linked to you personally, so feel free to say
whatever is on your mind.
The group discussion will last about 60-75 minutes.
Before we begin the discussion, we would like to go over the group agreement. It’s important
to establish a group agreement to abide by in order for everyone to feel comfortable during
the discussion.
Group Agreement (The Group Agreement Visual will be posted in the room)
One mic (one person speaks at a time)
Cell phones and other gadgets should be turned off or placed on vibrate mode. Only
answer for emergency calls.
No side conversations (no private conversations among group members)
What is said in the group stays in the group
MODERATOR NOTE: Please review the “Group Agreement” visual. Ask the group if

they feel anything is missing from the list that would help the group run more smoothly tonight?
Write down any additional rules the “group” agrees should be added to the list.
•
•

We also ask that you speak up during the discussion so that we can all hear you.
Any questions? Now let’s begin.
ICE BREAKER

5 minutes

Q1. Let’s first go around and introduce ourselves. Please tell the group:
•
•
•

Your first name
The approximate date when you had the ring inserted, and
How many people (besides yourself and the study team) knew that you were using this
ring?
PARTICIPANT EXPERIENCES WITH THE RING
10
minutes

Q2. Some of you told me that you were interested to hear about the experiences of other
women in this study. So here is your chance! What was it like for you to use the vaginal
ring?
PROBE: Tell me about something that seemed ‘out of the ordinary’ even if it was just a
little out of the ordinary?
PROBE: How did this compare to what you thought the ring would be like?
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BARRIERS &FACILITATORS TO RING USE

20 minutes

Q3. Many of you talked to me about your curiosity about what the ring looked like. So
here is the moment you’ve all been waiting for. How does this compare to what you thought
it looked like?
MODERATOR NOTE: show the ring and pass it around to group participants
PROBE: size
PROBE: material
PROBE: texture/feel
Q4. If this ring is made available for women in the general public to use, there will be
some instructions for use. I want to know your opinions about the instructions that women
will be expected to follow for using this ring.
ASSISTANT MODERATOR NOTE: Tape up the visual titled ‘HIV RING Instructions’ to the
front wall/board etc.
A woman will be instructed to:
•
•
•
•

wear it every day including when she has her period
wear it during sex
remove it and replace it herself
replace it monthly.

PROBE: I want to hear your opinions about these instructions. What do you think about
these instructions?
MODERATOR NOTE: MINIMIZE probing this section. See what they come up with
spontaneously that could potentially demonstrate ranking importance of each issue. Then probe
for uncovered issues.
PROBE: Inserting it themselves each time and removing it themselves each time (there
won’t be a doctor to do this for them!)
PROBE: During their period?
PROBE: Wearing it every day?
PROBE: During sex?
PROBE: Monthly?
TDF RING DESIGN

10 minutes

Q5. If you could change something about any of these instructions, what would you
change?
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PROBE: What about the way the ring looks or feels. What would you want to be
different?
MPT RING DESIGN

10-15 minutes

ASSISTANT MODERATOR NOTE: Tape up the visual titled ‘InstructionsHIV+pregnancy RING’ to the front wall/board etc.
A woman will be instructed to:
• wear it every day including when she has her period
• wear it during sex
• remove it and replace it herself
• replace it monthly.
Q6. What about if we added a hormonal contraceptive to this ring, so that the ring
prevented HIV and pregnancy. What is your opinion about these same instructions now?
PROBE: What is different than when the instructions were for a ring that only prevents
HIV?
PROBE: Thinking about the instructions from before, is there anything that feels
different when the instructions were for a ring that only prevents HIV?
PROBE: Are they easier or harder to follow?
PROBE: What if you DIDN’T get a period with this ring
PROBE: We heard that some wanted to menstruate in order to FLUSH out any toxins
coming from the HIV drug. Thoughts?
Q7. If you could change something about any of these instructions, what would you
change for a ring that was for both preventing HIV and pregnancy?
PROBE: What about the way the ring looks or feels. What would you want to be
different?
Q8. What if we changed one of these instructions because you did NOT get a period
every month. How would you feel about not getting a period every month when you used
the ring?
(ASSISTANT MODERATOR NOTE: put up blue tape over the item that says ‘During
their period’ on the ‘hiv+pregnancy instructions’ list)
Scenario: MPT RISK PERCEPTION; SOCIAL AND RELATIONSHIP FACTORS
20 minutes
Q9. Do any of you remember the “choose your own adventure” book series? We are
going to do something like that here. I am going to tell you a scenario, and then give you 4
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possible endings. I want you to tell me which ending you think the story ends up with and
WHY!

MODERATOR READS (AND RE-READS): “Carla is 27 years old and lives in the
South Bronx. In her community, she knows a few people who have HIV. She has never had more
than 1 partner at a time, and she has been married for 3 years with no children yet. She has
always felt very uncomfortable talking to her husband about sex, and they have never talked
about having kids. Lately, he seems distant.”
Possible story endings:
1. She does not use a vaginal ring of any type.
2. She uses a vaginal ring that is designed to prevent HIV only.
3. She uses a vaginal ring that is designed to prevent pregnancy only.
4. She uses a vaginal ring that prevents HIV and Pregnancy.
(ASSISTANT MODERATOR NOTE: tape up the 4 ‘Story Endings’. Stand at the
board and take notes under each of the ‘story endings’).
PROBE: How does her relationship with her sexual partner play a role in the ending to
this story?
WRAP-UP

2-3 minutes

MODERATOR NOTE: The wrap-up should be individualized as desired. However,
the bullets should be covered in general.
•

Thank you so much for participating in our discussion group today. You gave us a lot of
valuable feedback.
• I would like to remind you that what was said in this group should stay in this group. It is ok
if you want to talk to each other, but for everyone’s privacy, please don’t share outside of the
group.
Q.10. Does anyone have any questions or anything else they’d like to share?
•

Well, we are done with tonight’s discussion group. Again, thank you so much for coming.
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Card Sort
INTRODUCTION:
“Here is a stack of cards. Each card has a reason on it that a woman might give for
choosing to use the vaginal ring or for choosing not to use the vaginal ring. Please read each
card and put them in one of three piles. One pile is reasons why you personally would use the
ring. The other is reasons you personally would not use the ring. And then there is a third pile
for reasons that don’t matter to you one way or another in your decision-making process.”
INTERVIEWER INSTRUCTION: Interviewer asks women as they sort each card why
they put the reason in each pile.
“Now I’d like you to take the pile of cards that are reasons why you personally would use
the ring. Please put them in order of importance to you. The card on the top will be the thing that
is most important to you, and the one on the bottom will be the thing you think is the least
important reason to use this ring. Please do the same with the other pile, with the one at the top
being the thing that is most important reason why you would NOT use this ring and the reason at
the bottom would be the least important reason NOT to use this ring.”
(NOTE: This list will be modified and expanded over the course of the project.)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Having sex without thinking about getting HIV
Being able to put the ring in and out of my body
My physical comfort during sex
Lower cost compared to my regular contraceptive method
o what is your current method/methods previous
Having sex without thinking about getting pregnant
The ring will stay clean
o how might it get dirty?
I can take the ring out for short periods of time
o Like during sex?
o While you menstruate?
Feeling safe during sex
My Partner’s physical comfort during sex
The Ring will prevent pregnancy
Will not affect me getting pregnant in the future
Sex would be better
o better how-easier, safer, more spontaneous
My sex drive or being turned on might change
Side effects from the ring
Discharge during sex
o What about Discharge NOT during sex?
The ring will NOT prevent pregnancy
My partner supports my choice to use this ring
Not needing to tell my partner it prevents pregnancy
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•
•
•
•
•
•
•
•

The ring won’t get menstrual blood on it
My partner’s trust that I am faithful
NOT needing to tell a partner it prevents HIV transmission
Putting my finger inside my vagina to put the ring in and take it out
My period would still come once a month
Type of Hormone/Birth control in the ring
Wetness during sex
Material that the ring is made out of

INTERVIEWER INSTRUCTION: While the participant is considering placement of
each card, interviewer will probe about how participant interprets each topic and ask participant
to “think-aloud” to explain their decision-making process. Participants will also have blank cards
so they can add new factors or modify existing ones.
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APPENDIX E: DATA CODEBOOKS
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Thematic Codes for Interviews and Focus Groups (in alphabetical order);
•
•
•
•
•
•

•
•

•

•
•

•

•

Abstinence: Descriptions of reasons for abstinence or sequelae of abstinence. Can be double
coded with menstruation or HIV risk perception (among others) when abstinence is given as
a reason for non-use of a ring.
Added Bonus: How women view the ring as having HIV prevention as an extra benefit
(secondary) to contraceptive action (primary). Also include reverse cases (where
contraceptive action is secondary to HIV prevention).
Comfort in Use: The physical sensation and feeling associated with ring use
Double drugs: Discussion about combining two drugs or potential effects when two drugs
are combined.
Female Controlled: Descriptions of how women were or were not in control of ring use,
including initiation and removal.
Feminist narrative: General statements about how women should be in control of their own
bodies, make their own decisions, be independent, prioritize their own needs first, make
choice independent of their partners, etc. this could include statements both about just the
TDF or MPT device.
HIV Risk Perception: Descriptions of being at risk (or not) for HIV. Can pertain to oneself
or others’ risk perceptions.
Menstrual inevitability: women’s statements about the intersection between the act of
menstruation and personal control/lack thereof over menses. This is sometimes described as
menstruation being something that is controllable via MPT use, creating autonomy for
women.
Menstruation will interfere with Ring Use
o Limiting Foreign Objects in the Vagina
o Being Clean: How menstruation is described as making one’s body dirty or not. Can
include how menstruation is an act of ‘cleaning out’ dirt/waste/toxins in the body.
MPT Options: Having a choice in methods (contraceptive, or MPT); includes types and
differences in hormonal methods, dosages, benefits and off-label uses.
Partner acceptability of an MPT ring: What partners think or feel about an MPT ring,
including partner concerns for participant or future fertility.
o Covert Use: Captures descriptions of use that are not discosed to a partner.
o Infidelity: Issues raised within the partnership about trust and potential infidelity
o Men’s health: Women’s perceptions of and impact on men’s health.
o Sensation during sex and sexual pleasure/Sexual acceptability: How the ring may
impact a sex act or pleasure etc.
Pregnancy:
o Pregnancy risk/Pregnancy Risk Perception
o Pregnancy Intentions
o Pregnancy prevention behavior/contraceptive use
PrEP in the shadows: Contraception is described here as holding the limelight, and HIV
prevention taking the backseat. Discussions of being able to use a contraceptive because it
hides the fact they are using any form of PrEP. HIV drug component can be hidden or
subsumed behind the contraceptive component. This can include mentions of destigmatizing
HIV via contraceptive frontloading etc.
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•

•
•

Side Effects/Benefits: It is assumed that most of the side effects/benefits talked about will
be hypothetical. This code will include side effects (negative connotation) and benefits
(positive connotation). This is limited to how woman may feel in or about her own body.
o Partner: How a partner may feel about side effects or benefits
o Fertility: includes benefits/concerns about getting pregnant now or in the future
Timing and Duration of Use:
o Monthly Ring Exchange
o Longer than Monthly Duration
Vaginal crowding: Discussion of concern around having multiple items in the vagina
(including rings, tampons, penis, drugs etc).

Additional Focus Group Interaction Codes:
•
•
•

•

Questions and Answers
o Between moderator and participants
o Among Participants
Continuation of Topic Connections
o Implicit (maintains same topic without saying so)
o Explicit (maintains same topic with an overt statement)
Change in Topic (explicit or implicit)
o Introduction of new topic-shifts the content of discussion
o Expansion-shares new aspects of existing topic
o Differentiation-compares different aspects of topics
Interpersonal Connections (always explicit?)
o Agreement-reinforcing another participant’s statements
o Disagreement-disputing another participant’s statements
o Support-sympathizing with another participant’s statements
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